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Chapter 1
Ubiquitin conjugation
A defining feature of eukaryotic life is regulation of molecular processes. In many cases 
these regulatory effects are mediated through post-translational modifications (PTMs). 
One of these PTMs is ubiquitination. Ubiquitin is a small 76 aa protein that is highly con-
served in eukaryotes differing only by three amino acids between yeast and humans. The 
molecular structure of ubiquitin is compact and features a globular β-grasp fold followed 
by an extended C-terminal tail ending with a Gly-Gly motif. 
During the process of ubiquitination the C-terminal Gly76 residue of ubiquitin is covalently 
attached to the ε-amino group of a lysine residue on target proteins forming a stable 
isopeptide bond. The modification is reversible and can be cleaved off by deubiquitinating 
enzymes (DUBs)1,2. This seemingly simple PTM has far reaching ramifications in cells. It 
can mediate signal transduction, change the stability of target proteins, their enzymatic 
activity, their subcellular localization and can even serve as a seed for the assembly of 
new macromolecular complexes. Examples of ubiquitination and their effects are mono-
ubiquitination of PCNA as a signal for DNA damage, ubiquitination of the DUB ATXN3 
increases its rate, and the assembly of the BRCA-A complex to sites of DNA damage as a 
result of ubiquitination events3–5. The ubiquitin mark is pervasive in cells, and has been 
observed in systems ranging from the cell cycle and gene regulation to DNA repair and 
endocytosis5–8.
Mechanistically ubiquitin conjugation proceeds via a three-step enzymatic cascade that 
has been extensively studied in the past decades (Figure 1)9. Because the C-terminal Gly76 
of ubiquitin is unreactive as such, it first requires activation by E1 activating enzymes 
Uba1 or Uba6 through adenylation of the C-terminus at the expense of one ATP molecule. 
Subsequently the reactive ubiquitin-adenylate moiety is transferred to the active site cys-
teine of the E1 resulting in an E1-ubiquitin thioester intermediate. In the second major 
step, one of several dozens of E2 ubiquitin conjugating enzymes binds the E1 after which 
ubiquitin is transferred to the active site cysteine of the E2 in a transthioesterification 
reaction forming a E2-ubiquitin thioester. 
Ubiquitin E3 ligases catalyze the transfer of ubiquitin from E2-ubiquitin thioesters to the 
target protein via three divergent mechanisms. The RING/U-box class of E3 ligases al-
losterically promotes ubiquitin transfer from E2’s to targets. This class of proteins were 
long thought to merely function as scaffolds that bridge the E2-ubiquitin thioester and 
target. In recent years it has becomes clear however that they are active catalysts that bind 
the E2-ubiquitin thioester and stabilize a reactive conformation to allow efficient attack 
by the lysine residue on the target protein10–14. In the HECT class of E3 ligases, ubiquitin is 
first transferred to the active site cysteine of the HECT enzyme in another transthioester-
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ification reaction before being ligated to the target protein15. The RBR class of E3 ligases 
employ a hybrid RING/HECT mechanism to ubiquitinate targets16–18. 
Thousands of different target proteins are ubiquitinated. In mono-ubiquitination a single 
ubiquitin is attached to a target, while in polyubiquitination, multiple mono-ubiquitins 
or polymeric ubiquitin chains are conjugated to targets (Figure 2). Polyubiquitin chains 
arise when ubiquitin itself is ubiquitinated. This occurs on one of the seven lysines or on 
the N-terminal amino group of ubiquitin. In this way, eight different linkages of ubiquitin 
chains can be formed. Recent research indicates that “mixed” chains, consisting of different 
linkage types in the same polymer, can also be generated19. All chain types form distinct 
structures and are associated with specific cellular processes. Most famously, proteins 
modified with ubiquitin chains linked through lysine 48 (K48 chains) destine them for 
proteasomal destruction while K63 and ‘linear’ Met1 linked chains have potent signaling 
functions20,21. Mixed K48/K11 chains enhance proteasomal degradation of some targets19. 
The formation of polyubiquitin chains makes ubiquitination more versatile but also more 
complex than for example phosphorylation since different signals can be generated with 
the same molecule. To be able to decode these ubiquitin signals, cells use a multitude of 
ubiquitin binding domains that can specifically bind different ubiquitin-conjugates and 
thus “read” the signal (Figure 2). Among them are ubiquitin binding-in-ABIN-and-NEMO 
domains (UBAN), ubiquitin interacting motifs (UIM), ubiquitin associated domains (UBA) 
and some zinc fingers22. They generally bind free ubiquitin with low affinity but have high-
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Figure 1 | The ubiquitin system. Ubiquitin conjugation to a target protein is an ATP dependent three-step 
process requiring an E1 activating enzyme, E2 conjugating enzyme and E3 ligase. Deubiquitinating enzymes 
(DUBs) reverse the modification.
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er affinities for polyubiquitin chains through avidity effects. These domains can be very 
specific and discriminate between different chain types22. 
Polyubiquitin chains are of great importance in ubiquitin biology as they are responsible 
for the assembly and localization of important complexes. The DNA double strand 
break response for example depends on K63 polyubiquitin chains and binding domain 
recognizing them20. Similarly NF-κB completely depends on “reading” of linear Met1-
linked polyubiquitin23.
Ubiquitin deconjugation
Ubiquitin signals can be dampened or completely reversed by DUBs (Figure 1) enabling 
these isopeptidases to control all aspects of the ubiquitin-system. Being able to 
deubiquitinate proteins is useful for cells as it allows for rapid response to challenges and 
allows recycling of proteins instead of resynthesizing unmodified proteins. The importance 
of proper DUB function is evident from the high incidence of DUB deregulation in various 
neurological diseases and cancers2,24. Also, in certain infectious diseases, pathogens 
hijack host DUBs or encode their own DUBs to disable host defense systems and promote 
infection25. Because of these roles, DUBs are currently pursued as potential drug targets.
The human genome encodes around 100 DUBs and based on the structure of their 
catalytic domains DUBs are subdivided in five families: the ubiquitin C-terminal hydrolase 
(UCH), ubiquitin specific protease (USP), ovarian tumor protease (OTU), Machado-Joseph 
disease (MJD) and jab1/mov34/mpn (JAMM) families1,2 (Figure 3). While the first four are 
cysteine proteases the JAMM family members are metallo-isopeptidases that depend on 
Zinc ions for catalysis. 
The JAMM domain DUBs are structurally related to JAB domains found in bacteria, 
which are hypothesized to function as deconjugating enzymes for ancient ubiquitin-like 
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Figure 2 | Ubiquitin signals and readers. Ubiquitin can be conjugated non-ubiquitin proteins (magenta) or 
to itself giving rise to different polyubiquitin chain types. These different chains represent distinct signals. 
Several ubiquitin binding domains (brown) can specifically “read” the different ubiquitin signals.
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pathways26. A common characteristic of the cysteine dependent DUBs is that all of these 
bear structural resemblance to papain-like proteases and are hence thought to share their 
catalytic mechanism with papain-like enzymes. 
Chemically, all DUBs are hydrolases that utilize a water molecule in conjunction with 
an active site to break the isopeptide bond between ubiquitin and the target. The actual 
catalytic mechanism is different between metallo and cysteine dependent DUBs. In case 
of the UCH class, the enzymes that are the focus of this thesis, the reaction is initiated by 
deprotonation of the active site cysteine (Figure 4). This is achieved by a histidine general 
base that is coordinated by an asparagine or aspartic acid and gives rise to cysteine 
thiolate. This increases the reactivity of the cysteine for a nucleophilic attack on the 
carbonyl carbon of the scissile bond resulting in a tetrahedral oxyanion transition state. 
The negative charge of the transition state is stabilized by an “oxyanion hole” that facilitates 
the collapse of the transition state releasing the formerly ubiquitinated substrate as the 
leaving group. At this point the DUB is still covalently linked to ubiquitin and a second 
nucleophilic attack is required by a water molecule to regenerate the enzyme as well as 
free ubiquitin (Figure 4). 
The general functions of DUBs are diverse1,2. An important one is ubiquitin processing. 
Since ubiquitin is produced as a head to tail polyprotein DUBs are required to hydrolyze 
polyubiquitin into free ubiquitin ready for use in cells. DUBs are also necessary for ubiqui-
tin recycling of K48 polyubiquitin chains that were attached to proteins that are degraded 
by the proteasome. Similarly, DUBs can liberate ubiquitin from the numerous of small 
polyamines in cells that can be adventitiously conjugated to ubiquitin. Aside from these 
UCH | Ubiquitin C-terminal Hydrolase 
OTU | Ovarian Tumor protease 
USP | Ubiquitin Speciﬁc Protease 
MJD | Machado Joseph Disease protease JAMM | Jab1/Mov34/Mpn protease 
Figure 3 | The deubiquitinating enzymes (DUBs). Representatives (blue) for each DUB family bound to 
ubiquitin (gold) are depicted. We distinguish five sub families of DUBs: UCH, USP, MJD, OTU and JAMM. The 
first four are cysteine proteases while the JAMM family has metallo-protease activity.
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general house-keeping roles DUBs have more specific functions by controlling ubiquitina-
tion events in almost all cellular pathways including endosomal sorting, DNA repair, gene 
regulation, RNA processing and the cell cycle. 
Regulation of DUBs
Most DUBs are multi-domain proteins that in addition to the catalytic domain contain 
a large variety of other domains. In vitro studies comparing the activity of CD’s to full 
length DUBs have uncovered that these additional domains can sometimes allosterically 
modulate the catalytic activity of the CD27–31. In most cases, these domains activate the CD. 
Besides this type of intramolecular regulation, the catalytic activity of DUBs is also often 
directly governed by external proteins. Regulation does not always necessarily directly 
impinge on catalysis but may also guide DUBs to the correct cellular compartments or 
substrates. This can also be achieved by either intramolecular domains or external factors.
Because DUBs are generally considered to be relatively unspecific enzymes their tight 
regulation may be regarded as a safeguard mechanism for the cell that protects it 
from aberrant deubiquitination. As such, the DUB regulators are powerful accessory 
components of the ubiquitin-system. In chapter 2, different layers of DUB regulation are 
discussed in depth. A clear understanding of these mechanisms can assist in identifying 
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Figure 4 | Proposed reaction mechanism of cysteine protease DUBs. The hydrolysis of an isopeptide bond 
between ubiquitin (gold) and a target lysine (magenta) requires a catalytic triad consisting of a cysteine, his-
tidine and aspartic acid or asparagine (blue). The reaction is initiated by the abstraction of an hydrogen from 
the cysteine by the histidine general base (1) increasing the nucleophilicity of the cysteine. After the nucle-
ophilic attack of the cysteine on the scissile bond (red line), a tetrahedral intermediate forms featuring an 
oxyanion (2,3) that soon collapses to give rise to a acyl-enzyme intermediate (4) while releasing the formerly 
ubiquitinated substrate. The enzyme is regenerated by nucleophilic attack of a water molecule (4,5,6).
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crucial elements of DUB activity and in the development of targeted therapy.
The central theme in this thesis is to understand the molecular mechanisms that underlie 
these regulatory processes, particularly in the UCH family of DUBs. 
UCH-L5
UCH-L5 (UCH37) is a member of the UCH family of DUBs. The protein is 329 aa and con-
sists of an N-terminal catalytic UCH domain followed by an extended helical domain called 
the ULD32. UCH-L5 knock-out is embryonically lethal in mice and its function is perturbed 
in a number of different human cancers such as esophageal and hepatocellular carcino-
mas33–36.
UCH-L5 functions in several cellular systems. In TGF-β signaling it has been reported to 
deubiquitinate TGF-β receptor type I through association with SMAD737. In addition to 
this, UCH-L5 is part of two very different large molecular assemblies, the proteasome and 
the INO80 chromatin remodeling complex where its activity is tightly regulated38–41.
In the proteasome, UCH-L5 is a non-essential component that resides in the 19S regulato-
ry particle and associates with the RPN13 subunit. This interaction activates UCH-L5 on 
minimal substrates42,43 and is thought to be important for K48 polyubiquitin hydrolysis 
by UCH-L5. This activity is proposed to rescue some poorly ubiquitinated substrates from 
proteasomal degradation44. RPN13 consists of an N-terminal Pru domain that is responsi-
ble for polyubiquitin binding while its C-terminal domain binds UCH-L545,46.
In animals UCH-L5 is present in an animal-specific sub-module of the INO80 chromatin 
remodeling complex along with YY1 and INO80G (NFRKB)38. However, in this complex, 
UCH-L5 is inhibited by association with an N-terminal fragment of the INO80G subunit. 
This complex has an important role in the DNA damage response (DDR) by regulating 
DNA end resection47. The inhibition of UCH-L5, when it is bound to INO80G, stands in stark 
contrast to the activation of UCH-L5 in the proteasome. INO80G itself has furthermore 
been identified as an important determinant for stem cell identity47–49.
BAP1
BRCA-1 associated protein 1 (BAP1) is a 729 aa UCH enzyme that was originally identi-
fied as a BRCA-1 interactor in a yeast-2-hybrid screen50. It is closely related to UCH-L5. 
Together with the N-terminal UCH domain, BAP1 and UCH-L5 also share the ULD domain 
that is located at the C-terminus of BAP1. BAP1 however also contains an approximately 
350 aa insert relative to UCH-L5 situated between the CD and ULD domains. This insert is 
predicted to be disordered and bears no sequence resemblance to annotated conserved 
domains. 
14
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In recent years, BAP1 has risen to prominence due to its frequent disruption in several 
cancers such as renal, pleural mesothelioma’s and uveal cancers51–57. In many of these can-
cers BAP1 strongly correlates with poor survival. Moreover families have been described 
with germline BAP1 mutations where affected members are predisposed to a variety of 
cancers that are described collectively as the BAP1 cancer syndrome58. BAP1 is a tumor 
suppressor but little is currently known about the molecular carcinogenesis of BAP1 de-
regulation. 
Several studies in the past years have started to shed some light on BAP1’s tumor sup-
pressor activity. In these studies, BAP1 has emerged as a pivotal regulator of chromatin 
associated processes including DNA repair, DNA replication and gene expression. In these 
processes BAP1 is often present in large multi-protein complexes with proteins such as 
ASXL1, ASXL2, KDMB1B, HCF-1, YY1, MBD5, MBD6, OGT and FOXK254,59–63.
A recent DNA repair screen identified BAP1 as one of a select subset of DUBs that both lo-
calizes to DNA damage sites and gives DNA repair defects if perturbed47. Although BAP1’s 
role in this pathway has not been clearly resolved, another study indicates that BAP1 is 
necessary for the assembly of RAD51 and BRCA1 at damage foci64. BAP1 knock-out led 
to a variety of defects including increased frequency of chromosomal breaks after DNA 
damage64.
In addition to DNA repair BAP1 also has roles in DNA replication. For instance, BAP1 pre-
vents proteasomal degradation of Ino80, a key chromatin remodeler required for the pro-
gression of DNA replication65. The importance of this function is highlighted by the low 
Ino80 protein levels in BAP1 defective mesothelioma cells65. Similar to Ino80, BAP1 also 
stabilizes the transcriptional regulator HCF-1 by deubiquitinating it through the forma-
tion of a ternary complex that also includes the transcription factor YY1. This complex 
increases the expression of COX7C, an essential mitochondrial protein59,62. As HCF-1 is 
known as an important factor controlling cell cycle progression, BAP1 may also contribute 
to this process66. 
BAP1 also functions in Polycomb gene repression. In Drosophila, BAP1 associates with 
the Polycomb group protein ASX (ASXL1 in humans) to form the evolutionarily conserved 
Polycomb Repressive DUB63. In this complex, ASX activates BAP1 to deubiquitinate mono-
ubiquitinated H2A at lysine 119, an epigenetic mark for gene repression. Paradoxically, 
both the generation of K119 mono-ubiquitination, by the E3 ligase RING1B/BMI1, and 
removal of this repressive mark by BAP1 are required for the repression of genes. 
In general, to what extent the different BAP1 functions are intertwined is unclear. In some 
cases though, there may be functional connections. For instance the recruitment of BAP1 
15
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to certain genomic loci by transcription factor FOXK2 locally stimulates H2A deubiquiti-
nation suggesting that ASXL1 is also involved60. Similarly deubiquitination of HCF-1 by 
BAP1 has been suggested to occur in a multi-protein complex also including activator 
ASXL1 or ASXL2 and OGT54.
Common ancestry of UCH-L5 and BAP1 regulators
The UCH-L5 and BAP1 regulators, RPN13, INO80G and ASXL1 are large and diverse pro-
teins consisting of different domains. A common feature between them is, however, that 
all three contain a conserved stretch of about 150 residues. This stretch was identified 
through sensitive sequence analysis approaches and was subsequently named DEUbiq-
uitinase ADaptor domain (DEUBAD)67. Before this discovery, it was experimentally shown 
that fragments that include the DEUBAD domains of INO80G and RPN13 bind UCH-L5’s 
ULD38–41, but it was not yet noticed that they were related. Since BAP1 also contains a ULD 
and regulator ASXL1 a DEUBAD domain, it was proposed that the general role of these do-
mains was to bind ULD domains of their cognate DUB and thereby regulate their activity67. 
In chapter 3 and 4 we show that this prediction was correct.
Relevance of DUB regulation 
Because the ubiquitin system is crucial for normal cellular physiology and often deregu-
lated in disease, it has held a promise as a potentially “druggable” system. But unlike the 
phosphorylation system where some successes have been achieved, the ubiquitin system 
has proven a difficult target. Targeting the conjugation machinery especially presents 
some practical difficulties. There are ony two E1 enzymes and these are vital for normal 
physiology potentially making E1 inhibitors highly toxic for healthy cells. E2’s and E3’s are 
more numerous but lack distinct active site clefts that are in general more amendable for 
the development of small molecule inhibitors. Because of these reasons, focus has shifted 
to DUBs. DUBs contain defined active site clefts but despite this the development of in-
hibitors is progressing slowly. Currently, only one high affinity compound is known that 
specifically inhibits USP1 but sofar none are available on the market or in clinical trials. 
Since the catalytic states of DUBs differ in the presence of regulator, a key question for 
drug design is what the molecular characteristics are for each state. Most of the available 
structures of DUBs are in absence of regulators making this question more pressing. Un-
derstanding how the different activity states of DUBs look like on an atomic scale would 
aid in the development of specific therapeutic compounds. Additionally, since DUBs can 
have multiple substrates and multiple regulators that recruit them to relevant cellular 
systems, elucidating the structure of unique DUB-regulator complexes may in the future 
allow hitting specific pathways with therapeutics.
But aside from possible therapeutical applications, the work described in this thesis 
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will also contribute to a more thorough understanding of the fundaments of enzyme 
mechanism. Particularly, this thesis provides insights into the relation between enzyme 
structural plasticity and catalysis as described in chapter 3.
Outline of the thesis
In chapter 2 an outline is provided for DUB activity regulation. We identify, classify and 
describe the different layers of DUB regulation that have been reported in the literature. 
What will become apparent is the large diversity of regulatory modes that exist between 
different DUBs but also within a DUB.
Chapter 3 explores how the UCH-L5 is activated by regulatory protein RPN13 and 
inhibited by INO80G, a protein related to RPN13. Using crystal structures of the activated 
and inhibited complexes we highlight how conformational plasticity in UCH-L5 is exploited 
by these regulatory proteins to tune the affinity for substrates and consequently regulate 
DUB activity. 
In chapter 4 we examine the mechanism of H2A deubiquitinating by the important tumor 
suppressor BAP1. We demonstrate how ASXL1 activates BAP1 in a two-step process that 
also requires the BAP1 C-terminal extension. Chapter 5 delves into aggregation state of 
BAP1 and the BAP1/ASXL1 complex and the possible consequences for DUB activity.
We conclude with chapter 6 that presents a general discussion about the findings in this 
thesis.
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ABSTRACT 
Proteolytic enzymes such as (iso-)peptidases are potentially hazardous for cells. To 
neutralize their potential danger tight control of activities has evolved. Deubiquitylating 
enzymes (DUBs) are isopeptidases involved in eukaryotic ubiquitylation. They reverse 
ubiquitin signals by hydrolyzing ubiquitin adducts, giving them control over all aspects 
of ubiquitin biology. The importance of DUB function is underscored by their frequent 
deregulation in human disease, making these enzymes potential drug targets. Here we 
review the different layers of DUB enzyme regulation. We discuss how post-translational 
modification, regulatory domains within DUBs and incorporation of DUBs into 
macromolecular complexes contribute to activity. We conclude that most DUBs are likely 
to use a combination of these basic regulatory mechanisms.
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DUB regulation: Background and overview
Conjugation of ubiquitin and ubiquitin-like molecules (Ubl) (Box I) to lysines of target 
proteins represents a major type of post-translational modification (PTMs) that regulates 
countless processes in eukaryotes1. These modifications are catalyzed by an enzymatic 
cascade involving E1 activating enzymes, E2 conjugating enzymes and E3 ligases. Many 
different types of Ub/Ubl modification exist, since targets can be mono-ubiquitylated or 
modified with a variety of polyubiquitin chains that can each have different signaling out-
comes.
Since the ubiquitin signals have profound cellular effects, conjugation events are kept in 
check by ubiquitin deconjugation. This function is performed by a specialized class of 
isopeptidases called deubiquitylating enzymes (DUBs) that hydrolyze the isopeptide bond 
between ubiquitin and target proteins2,3. Five different DUB families have been identified: 
ubiquitin C-terminal hydrolase (UCH), ubiquitin specific protease (USP), ovarian tumor 
(OTU), Machado-Joseph disease (MJD) and Jab1/Mpn/Mov34 (JAMM) families. All of 
these are cysteine isopeptidases except the JAMM family members which have metallo-
isopeptidase activity3. 
Due to their critical role in cellular functions, deregulation of enzymes of the ubiquitin-
system is important in cancer, infectious diseases and neurological diseases4–6. Hence 
there is an increasing interest in targeting these molecules pharmaceutically. Since E2 
conjugating enzymes and most E3 ligases lack distinct catalytic clefts, approaches to 
therapeutic intervention are currently focused on DUBs7. 
In the cell, the activity of degrading enzymes is carefully controlled. This was long known 
for peptidases, the distant cousins of DUBs, which are tightly regulated through production 
as inactive enzymes (zymogens), but also through proteinaceous inhibitors and elaborate 
activation cascades to prevent aberrant proteolysis8. This tight control is essential, as 
unscheduled activation can be disastrous for the cell. It is gradually becoming clear that 
this is also true for the DUB isopeptidases. The need for regulation of DUB activity can be 
explained by the large number of ubiquitin conjugates in cells. Without proper regulation, 
DUBs could unspecifically hydrolyze any ubiquitin conjugate they encounter, potentially 
deregulating cellular physiology.
To cope with this, cells have adopted several strategies to ensure DUB activity is chan-
neled to the right locations at the right time. Some of this regulation takes place at the 
transcriptional level, but the proteins themselves are regulated in many different ways. A 
clear understanding of these processes is important for our knowledge of ubiquitin biolo-
gy and will assist in the development of therapeutic agents targeting specific DUBs. In re-
cent years the insight in DUBs whose catalytic activity is regulated has steadily expanded; 
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through advances in the cellular physiology, biophysics and structural biology of DUBs, we 
are starting to elucidate the intricate mechanisms that underlie DUB regulation. 
The general roles of DUBs and their target and chain specificity have been discussed 
elsewhere3,9,10. Here we discuss the emerging themes in regulation of DUBs at the protein 
level. We distinguish different “layers” of DUB regulation and describe how they affect 
activity (Figure 1). After examination of the individual layers we analyze how these 
different mechanisms can cooperate. Although our list of examples is not exhaustive 
(Table 1), it provides a good basis for discussing the different layers of DUB regulation.
Cellular and target recruitment
In figure 1 we present a simplified classification of the different layers of DUB regulation. 
The first layer we discuss is that of DUB recruitment factors. Guiding the almost hundred 
DUBs encoded in the human genome to their relevant substrates and pathways is cru-
cial for cellular physiology since it insulates DUBs from unwanted interactions and the 
cell from spurious activity. It can be mediated by distinct regions within the enzyme or 
by external factors: For instance, the Ubl domain of USP14 recruits it to the proteasome 
where its activity is increased 500-fold11. The endosomal adaptor protein STAM recruits 
the DUBs AMSH and USP8 to the endosome pathway by interacting with an SH3 binding 
motif or MIT domain respectively12,13.
Another pathway that requires proper DUB recruitment is the DNA damage response 
(DDR). After UV-induced DNA damage mono-ubiquityated PCNA mediates signaling that 
leads to repair. The DUB complex USP1/UAF1 deubiquitylates PCNA after the complex is 
recruited to the substrate by recruitment factor ELG114. BRCC36 is another DUB in DDR 
where it deubiquitylates several proteins as catalytic subunit of the BRCA1-A complex. In 
this complex specialized ubiquitin and SUMO binding domains recruit BRCC36 to sites of 
damage15–19. Finally, also in the nucleus, transcription factor FOXK2 targets the UCH class 
DUB BAP1 to chromatin to facilitate histone H2A deubiquitylation20. 
In NF-κB signaling, ubiquitin conjugation has multiple roles. Different components of the 
Box I: Ubiquitin and ubiquitin-like molecules 
Eukaryotes have a diverse repertoire of post translational modifications to fine-tune or alter molecular 
processes. Among these is ubiquitination, where the small 76 amino acid protein ubiquitin is attached 
to target proteins 1. Ubiquitin is characterized by a globular beta-grasp fold followed by an extended tail 
harboring a Gly-Gly motif required for conjugation to target proteins. Over the past decades other small 
proteins that share these characteristics with ubiquitin have been identified. Among these are NEDD8, 
SUMO-1, SUMO-2, SUMO-3, ATG8, ISG15 and FAT10 but more have been identified, that can be conjugated 
to proteins to alter their fate or function. The enzymes responsible for their conjugation and deconjugation 
are, moreover, also homologous to the enzymes from the ubiquitin-system and follow similar mecha-
nisms. Because of these commonalities with ubiquitin, these proteins are collectively called ubiquitin-like 
molecules (Ubl). 
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pathway recruit the DUBs USP10 and CYLD. MCPIP-1 recruits USP10 whereas CYLD is 
recruited by the E3 ligase HOIP (Figure 1). CYLD moreover contains a B-box domain that 
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promotes its cytoplasmic localization21,22.
The previous examples illustrated how external proteins can recruit DUBs to relevant 
pathways or substrates. While DUBs in general can recognize the ubiquitin part of a sub-
strate via their catalytic domains, sometimes extra specificity is achieved by specialized 
domains that are present in DUBs themselves. One of the best studied examples is the DUB 
USP7. Here, the N-terminal TRAF domain of USP7 binds small peptide motifs in its targets 
EBNA-1, p53 and Mdm2 to facilitate their deubiquitylation (Figure 1)23,24. USP15 employs 
its DUSP-Ubl domain to recruit and deubiquitylate the E3 ligase BRAP25 while the H2A 
deubiquitinase USP3 requires its intact Zinc finger domain to bind H2A26. 
Thus, specialized domains within DUBs and external proteins can guide DUB activity to 
the correct pathways and substrates by functioning as recruitment factors.
Substrate mediated regulation
Besides recruitment, some DUBs require further activation. Surprisingly the cognate 
ubiquitin-like molecule can affect the activity of the DUB or ubiquitin-like protease by 
rearranging the catalytic triad. Early structural studies on the catalytic domain (CD) of 
USP7 revealed that its catalytic triad can exist in an inactive configuration27. Binding of 
a ubiquitin derivative “realigned” the catalytic triad towards an active configuration and 
also changed the conformation of the “switching loop”, a surface loop close to the active 
site that is important for activation27,28. These effects suggest that USP7 CD can only be 
active when ubiquitin is correctly bound. In UCH-L1 (Figure 1), ubiquitin binding at an 
‘exosite’ (i.e. distant from the active site), also induces a cascade of conformational changes 
that rearranges the catalytic triad29. This type of allosteric activation also occurs in the 
SENP class of SUMO proteases, where it has been elegantly quantified. When SENPs are 
incubated with the tail-less SUMO β-grasp domain, this increases the catalytic turnover 
against a model peptide substrate30–32. However, this type of ubiquitin/Ubl induced 
rearrangement is not generically present, since other inactive DUBs do contain correctly 
aligned active sites, even in the absence of ubiquitin. When present, this regulation by 
a Ubl itself cannot give much specificity. Thus, it is not surprising that regulation of for 
example USP7 has further layers of complexity, as discussed later.
Substrates can give rise to more complex types of activation, generating high specificity. 
In OTULIN, a member of the OTU class DUBs, the substrate actively assists in catalysis. 
OTULIN regulates NF-κB signaling by its exclusive ability to disassemble linear ubiquitin 
chains33. In these chains, ubiquitin moieties are linked via the amino terminus at Met1 
instead of via one of its lysines. They are made by the HOIP E3 ligase in the linear chain 
assembly (LUBAC) complex. Interestingly, OTULIN uses this unique linkage to sense its 
substrate. Normally OTULIN Asp336 functions as an auto-inhibitory element that favors 
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an unproductive catalytic triad conformation, but Glu16 of the proximal ubiquitin (the 
target-ubiquitin) in linear chains reorganizes the catalytic triad towards an active state. 
Mutation of this substrate Glu16 reduces the k
cat
 240-fold but hardly affects the binding in-
dicating that actively it promotes catalysis. Of all ubiquitin chain types, only a linear chain 
can bind such that the Glu16 in the proximal ubiquitin is correctly positioned to assist in 
catalysis, explaining how OTULIN activity is specifically restricted to cellular pathways 
that feature linear polyubiquitin signaling.
A different example of substrate-dependent activation is seen in the CSN5, a JAMM-
type DUB found in the eight subunit COP9 signalosome (CSN)34. The CSN deconjugates 
NEDD8 from Cullin Ring ubiquitin E3 ligases (CRLs). Through this activity CSN decreases 
the ubiquitin E3 ligase activity of CRLs. A recent structural analysis of CSN rationalized 
how interaction between DUB and its neddylated CRL substrate leads to activation35. The 
catalytic subunit CSN5 forms a sub-complex with CSN6 and CNS4. In absence of substrate 
a loop in CSN5, Ins1, occludes the active site, leading to auto-inhibition. In the presence of 
neddylated CRLs, the CSN4 subunit undergoes a large conformational change to bind the 
substrate, at the expense of its interaction with the socalled ‘Ins-2’ loop of CSN6. These 
substrate-induced conformational changes alleviate the auto-inhibition and prime CSN 
for deconjugation. Point mutations in the Ins1 and Ins2 loops can activate CSN even in 
the absence of neddylated CRLs confirming that they act as auto-inhibitory elements35. 
The ability of CSN4 to sense neddylated CRLs assures that activation only occurs in the 
presence of the substrate.
The examples above illustrate an important safeguard mechanism for unwanted 
proteolytic activity by only allowing enzymatic activity to take place in the presence of the 
correct substrates. 
DUB regulation by intramolecular and external factors
The next layer of regulation is the direct regulation of DUB catalytic activity. In this mode 
of activation, the catalytic domains (CD) of DUBs can be viewed as core units whose 
catalytic activity is modulated by interaction with other protein modules, either external, 
or within the DUB itself2. 
A common form of regulation of this type is that given by a large molecular machine. There 
are several examples of DUBs that only attain optimal activity and localization within the 
structural integrity of such multi-subunit molecular machines like the COP9 signalosome. 
Other notable examples of this type include USP14 and RPN11 in the proteasome11,36,37, 
BRCC36 within the BRCA1-A and BRISC complexes15,16,38 and Ubp8 in the yeast SAGA DUB 
module39–41. In these cases the DUBs display low activity in isolation, but are robustly acti-
vated within the complex. For Ubp8, complex formation likely stabilizes the active site and 
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the ubiquitin binding surface40,42. In general, the exact molecular mechanism of activation 
in these large complexes remains poorly understood, but may depend on a combination 
of regulatory influences.
Apart from these examples where DUBs are activated as part of large macromolecular 
assemblies, many well studied examples exist where simple domains, within the DUB or 
from outside, specifically modulate the activity of catalytic domains. USP5 contains several 
ubiquitin binding domains (UBDs) that assist in the disassembly of polyubiquitin chains 
of a variety of linkages43. The crystal structure of full length USP5 revealed a previously 
unpredicted domain, named nUBP, that packs tightly against the CD and allosterically 
activates it 1000-fold (Figure 1)44. Moreover addition of free ubiquitin to USP5 can further 
stimulate USP5 activity through binding to the ZnF-UBP domain via an as yet unknown 
mechanism43.
A second example where additional domains are important is USP4, a DUB with roles 
in TGF-β signaling and splicing. The isolated USP4 CD was found to have an unusually 
high affinity for ubiquitin (low nanomolar range) suggesting that it could be constitutively 
product-inhibited in cells, since the ubiquitin concentration is in the range of 4-20 µM45. 
The N-terminal DUSP-Ubl domain present in full length USP4 can however allosterically 
promote product release, thereby increasing k
cat
 of USP4. This effect involves the “switch-
ing loop”, a loop close to the catalytic triad. 
This “switching loop” also plays a role in USP7 or its yeast homolog Ubp15 activity. The 
C-terminal HUBL domain of USP7 can dynamically fold back onto the CD to allow contact 
of a C-terminal peptide at the end of the HUBL domain with the “switching loop”, a region 
close to the catalytic triad. This intramolecular interaction increases both k
cat
 and KM of the 
CD28. Unlike USP7, the N-terminal TRAF domain of Ubp15 also affects intrinsic activity46. 
Apparently the ‘switching loop’ plays a conserved regulatory function in multiple USPs, 
although the details of the activation differ.
External factors such as protein partners can also activate DUBs by either reinforcing the 
stimulatory effects of intramolecular factors or by other means. The intramolecular acti-
vation of the USP7 CD by its HUBL domain is allosterically potentiated by external factor 
GMP synthase (GMPS) that consolidates the active state leading to an additional increase 
in k
cat
28,47. 
One of the best-studied examples of DUB activation by external factors is USP1. This DUB 
controls DNA repair signaling by deubiquitylating FANCD2 and PCNA48,49. USP1 is regu-
lated by auto-cleavage48 and its k
cat
 is strongly stimulated by the WD40 repeat protein 
USP1 associated factor 1 (UAF-1 )50. UAF-1 achieves this by increasing the basicity of the 
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histidine general base in the USP1 catalytic triad51. Two closely related DUBs, USP12 and 
USP46, are similarly activated by UAF-1, but unlike USP1, these can be hyper-activated by 
another WD40 repeat protein named WDR2052–54.
DUB activation also occurs in endocytosis and autophagy pathways. The JAMM class 
enzyme AMSH is recruited to endosomes by the adaptor protein STAM55. Besides 
recruitment, STAM can also directly activate AMSH hydrolysis of polyubiquitin chains on 
endosome-targeted proteins. The exact mechanism of this activation is unclear but both 
k
cat
 and KM effects were suggested
13,55. In autophagy, the activity of USP10 and USP13 is 
modulated by Beclin-1. Beclin-1 is a subunit of the essential Vps34 complexes that play a 
role in phagosome nucleation. These complexes can be rapidly degraded by ubiquitylation 
of Beclin-1. Beclin-1 prevents this however, by binding USP10 and USP13, and stimulating 
these DUBs to remove ubiquitin from itself both in cells and in vitro56.
A particularly interesting example of DUB regulation by external proteins involves 
stimulation of OTUB1 activity by ubiquitin E2 enzymes. OTUB1 can non-catalytically 
interfere with polyubiquitin synthesis by specifically inhibiting E2 enzyme Ubc13 linked to 
ubiquitin at its active site (charged E2)57,58. Conversely, a subset of charged and uncharged 
E2s, including UbcH5B, stimulate Lys48-linked polyubiquitin hydrolysis by OTUB1 by 
increasing substrate affinity59. Crystal structures indicate UbcH5B achieves this increased 
affinity by stabilizing a ubiquitin binding site on OTUB1. Whether charged E2s stimulate 
OTUB1 activity, or whether OTUB1 inhibits polyubiquitin synthesis of the E2 depends 
on the relative concentrations of charged E2 and free ubiquitin. Therefore the authors 
suggested an elegant model wherein OTUB1-E2 complexes can dynamically regulate the 
level of polyubiquitin chains in cells by either activating chain hydrolysis or inhibiting E2-
mediated chain synthesis.
The activities of the UCH family DUBs UCH-L5 and BAP1 are regulated by related DEUBAD 
domains60. BAP1 is a tumor suppressor that is activated by ASX to deubiquitylate H2A in 
Box II : Outstanding questions 
- How is DUB regulation achieved temporally?
- Do DUBs dynamically cycle between different complexes to meet functional requirements or are they    
stably associated in separate complexes?
- Are DUBs merely catalytic modules or do they also perform scaffolding or adaptor functions in large 
molecular assemblies?
- How many different targets do DUBs generally have and how specific are they for these targets?
- Is target specificity intrinsic to a certain DUB or is it achieved through formation of multi protein 
complexes?
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Polycomb gene repression61. In the proteasome, the DEUBAD domain of RPN13 activates 
UCH-L5 by increasing the affinity for substrates62–66. This occurs through a combination of 
mild effects including the allosteric stabilization of the so-called ‘active site crossover loop’ 
and the restriction of the inhibitory mobility of the C-terminal ULD domain of UCH-L565,66.
These examples illustrate how domains within DUBs or external proteins can activate the 
catalytic domains of DUBs through a variety of different mechanisms.
negative regulation of DUBs
While all DUBs discussed so far are activated by intramolecular domains or external pro-
teins, in a limited number of rare cases DUBs are directly inhibited by other proteins. The 
first example of this type is UCH-L5 inhibition by INO80G. INO80G is a metazoan-specific 
subunit of INO80 chromatin remodeling complexes and is associated with UCH-L5 during 
DNA repair67,68. This interaction strongly inhibits UCH-L567. Similar to UCH-L5 activator 
RPN13 (discussed earlier), INO80G contains a DEUBAD domain60 and recent structural 
analyses have revealed that it inhibits UCH-L5 by occupying the ubiquitin docking site on 
the enzyme through an unique hairpin-structure that is absent in the DEUBAD domain of 
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Figure 2. Combining the layers of DUB regulation. The different layers of DUB regulation can co-exist in a 
single DUB. In the picture a model of USP7 (blue surfaces) is presented based on existing structures (1nbf, 
2ylm, 1yy6) where ubiquitin (part of the substrate) in yellow itself can activate the catalytic domain of USP7. 
This activation is reinforced intramolecularly by the HUBL-45 subdomain of USP7 and from outside by GMPS 
(gray cartoon). The USP7 N-terminal TRAF domain can furthermore recruit targets such as EBNA-1 (sphere 
representation) to the DUB. This multi-layered regulation likely exist for many more DUBs.
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activator RPN1365,66. While the DEUBAD domain of RPN13 activates UCH-L5 by increasing 
its affinity for substrates, in INO80G it does the opposite and dramatically decreases the 
affinity for substrates. Thus the regulation of UCH-L5 is achieved at the level of substrate 
affinity, leading to a change in KM rather than kcat as observed in for instance USP1 regu-
lation50. The dual mode of regulation of UCH-L5 suggests that strict spatial and temporal 
control should exist to ensure the right activity at the right place. For example, the inhibi-
tion of UCH-L5 by INO80G must be alleviated during DNA repair since the catalytic activity 
of UCH-L5 is required in this pathway68.
Another example of negative regulation is the inhibition of the yeast endosome associated 
DUB Doa4 by Rfu1. In a yeast genetics screen, deletion of Rfu1 was serendipitously found 
to alter global ubiquitin levels69. DUBs can regulate these levels by liberating conjugated 
ubiquitin from targets. Changes in global ubiquitin levels are often associated with 
cellular stress responses69. Rfu1 was shown to directly inhibit Doa4 activity through a 
mechanism that is unknown on the molecular level, suggesting that Doa4/Rfu1 system 
may contribute to the regulation of global ubiquitin levels69. Interestingly Doa4 can also 
be activated by the endosome associated protein Bro1 indicating that, like UCH-L5, Doa4 
is subject to both positive and negative regulation70.
A final example of negative regulation is the deubiquitylation of mono-ubiquitylated PCNA 
(PCNA-Ub) by the USP1/UAF1 complex. During replication stress the protein Spartan 
binds to mono-ubiquitylated PCNA71,72. This binding event was suggested to protect PCNA-
Ub from deubiquitylation by the USP1/UAF1 complex in order to drive the stress response 
that is dependent on the ubiquitin signal71. This is different from UCH-L5/INO80G, where 
INO80G directly prevents substrate docking onto the DUB; Instead, Spartan blocks the 
DUB-binding site on the substrate, protecting it from deubiquitylation. 
Hence although less common than the stimulation of DUB activity, inhibition of DUBs by 
external proteins constitutes another type of DUB regulation. Activity can however also be 
regulated by direct covalent modification of DUBs through PTMs.
Post-translational modifications
PTMs such as sumoylation, ubiquitylation and phosphorylation are a convenient way for 
cells to further fine-tune DUB activity. An example is DUBA, an OTU class enzyme that plays 
an important role in the immune system. DUBA is only active when it is phosphorylated 
at Ser177 (pSer177)73 and crystal structures demonstrated that phosphorylation refolds 
part of the protein that assists in ubiquitin binding, explaining the importance of the 
modification (Figure 1). This is highlighted in antigen-stimulated macrophages, in which 
pSer177 DUBA levels are increased to regulate the immune response. Activation by 
phosphorylation also takes place during the cell cycle where USP37 is modified by CDK-2 
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to directly stimulate DUB activity74. In an analogous manner USP1 phosphorylation was 
suggested to be required for complex formation with activator UAF-175. 
Phosphorylation can also negatively affect DUB activity. The DUB OTULIN is recruited 
to the NF-κB pathway by binding the HOIP PUB domain with its PUB Interacting Motif 
(PIM)76,77, thus connecting the E3 ligase (HOIP in the LUBAC complex) and the DUB for 
linear ubiquitin chains. Phosphorylation of Tyr56 within the PIM abrogates this interaction 
and the ability of OTULIN to antagonize NF-κB signaling. 
The activity of the NF-κB associated DUB CYLD is negatively affected by both 
phosphorylation and sumoylation78,79, while sumoylation also impedes USP25 activity. 
This multi-domain DUB contains ubiquitin binding domains (UBDs) that are required 
for efficient polyubiquitin hydrolysis. Sumoylation at one of these UBDs decreases USP25 
chain hydrolysis activity80.
In addition to sumoylation, ubiquitylation of DUBs has also been reported to regulate ac-
tivity. UCH-L1 mono-ubiquitylation at Lys157 of the active site cross-over loop decreased 
its activity81. By contrast, ubiquitylation of the MJD class DUBs ATXN3 and JosD1 stimu-
lates their polyubiquitin chain hydrolysis activities82,83.
In some cases PTMs can alter DUB subcellular localization. Ubiquitylation of BAP1 near its 
nuclear localization sequence negatively regulates its activity by excluding BAP1 from the 
nucleus where most of its targets reside84. Similarly, phosphorylation of USP4 by AKT also 
leads to its redistribution from the nucleus to the cytoplasm where it ultimately reach-
es the cell membrane to deubiquitylate the TFG-β receptor I85. Conversely, during DNA 
damage, the predominantly cytoplasmic DUB USP10 is translocated to the nucleus after 
phosphorylation to deubiquitylate p5386.
More unusual modifications also regulate DUBs. Recent reports have illustrated how 
reactive oxygen species (ROS) can regulate DUB activity87–90. ROS can serve as potent 
signaling molecules by reacting with active site cysteines of tyrosine phosphatases 
and some cysteine peptidases to form reversible sulphenic acid adducts or irreversible 
sulphinic or sulphonic acid adducts91. Oxidation of active site cysteines to sulphenic acid 
appears to be widespread in the OTU, USP and UCH classes of DUBs where it reduces DUB 
activity. Functionally the modification may play important roles in cells as exemplified 
by the oxidative inactivation of the PCNA deubiquitinase USP189. This results in the 
accumulation of mono-ubiquitinated PCNA, a mark for cellular stress responses88,89.
In summary, several types of PTMs of DUBs have been described that can have a variety of 
effects on DUBs and thereby further fine-tune activity.
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Multiple layers of regulation
In the previous sections we discussed how certain types of regulation impinge on DUB 
activity separately for illustrative purposes. In practice however many regulatory mecha-
nisms co-exist. This situation sometimes even occurs within a single domain. The RPN13 
DEUBAD domain for example is responsible for both the activation of UCH-L5 and for 
recruiting the enzyme to the proteasome62–64. We expect that more factors exist that have 
multiple regulatory roles at the same time. 
The concept of multiple regulatory layers can best be exemplified by considering USP7 
(Figure 2 and Table 1). The USP7 CD can exist in a catalytically incompetent state that can 
be activated by ubiquitin binding and USP7 HUBL-4527,28. This active state can be further 
reinforced allosterically by the external factor GMPS, which binds to HUBL-12328,47 and 
target recruitment is promoted by its N-terminal TRAF domain23,24. Another example of 
multiple layers of regulation impinging on a single protein is the tumor suppressor BAP1. 
This enzyme is activated by ASXL1 to deubiquitylate H2A and can be targeted to certain 
genomic loci by its association with transcriptional regulators20,61,92. BAP1 can further-
more be spatially separated from its targets by ubiquitylation of its C-terminal nuclear 
localization signal (NLS) by UBE2O, causing mislocalization to the cytoplasm84. This type 
of multi-layered regulation is likely a feature of many DUBs and multi-protein DUB com-
plexes and contributes to tight control of deubiquitylation.
Concluding remarks
Research on the mechanisms of DUB regulation has advanced significantly in the past 
years. The regulation takes place at different layers and a notable feature is the diversity 
of the known mechanisms. This variety is also present at the biochemical level: the ac-
tivation mechanisms range from solely impinging on catalytic activity (k
cat
) to primarily 
substrate interaction (KM) to combinations of both. The accumulated regulatory effects 
of the layers determine DUB activity and ultimately the fate of ubiquitylated substrates.
Even though we understand some aspects of DUB mechanism, there are important 
outstanding questions (Box II), such as how DUB activity is regulated within the large 
macromolecular complexes. For example recently determined UCH-L5/RPN13 structures 
give insights into the basic activation mechanisms of UCH-L565,66, but these do not explain 
the polyubiquitin hydrolysis activity of UCH-L5 as part of the proteasome. Similar 
challenges exist for other DUBs and can only be addressed by studying large holo-enzyme 
complexes over different activation states. 
As more details of DUB/regulator systems become available, an important task will be to 
identify possible common elements in DUB regulation that underlie the apparent diversi-
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ty. This information may allow a more guided design of potential therapeutic compounds. 
That many DUBs are allosterically regulated raises the interesting prospect of developing 
therapeutic agents that target allosteric and exo sites rather than active sites. This type of 
targeting may allow for greater specificity towards certain functions of DUBs since they 
may have multiple substrates. A lack of information about DUB substrates poses a major 
hurdle for targeted therapy and that future studies will need to address. 
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ABSTRACT
Deubiquitinating enzymes (DUBs) control vital processes in eukaryotes by hydrolyzing 
ubiquitin adducts. Their activities are tightly regulated but the mechanisms remain 
elusive. In particular, the DUB UCH-L5 can be either activated or inhibited by conserved 
regulatory proteins RPN13 and INO80G respectively. Here we show how the DEUBAD 
domain in RPN13 activates UCH-L5 by positioning its C-terminal ULD domain and cross-
over loop to promote substrate binding and catalysis. The related DEUBAD domain 
in INO80G inhibits UCH-L5, by exploiting similar structural elements in UCH-L5 to 
promote a radically different conformation and employs molecular mimicry to block 
ubiquitin docking. In this process large conformational changes create small but highly 
specific interfaces that mediate activity modulation of UCH-L5 by altering the affinity for 
substrates. Our results establish how related domains can exploit enzyme conformational 
plasticity to allosterically regulate DUB activity. These allosteric sites may present novel 
insights for pharmaceutical intervention in DUB activity. 
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InTRODUCTIOn
The ubiquitin conjugation machinery regulates almost every process in the eukaryotic 
cell. Deubiquitinating enzymes (DUBs) are a critical component of the machinery since 
they can remove ubiquitin adducts and thereby control the level of ubiquitin signals1. In 
accordance with their important roles, DUBs are frequently deregulated in human pathol-
ogies including cancer and neurological disease2, making DUBs potential prime targets for 
therapeutic intervention.
The level of the intrinsic DUB activity is important and requires precise control. For a 
subset of DUBs there is emerging evidence that the catalytic activity can be modulated by 
regulatory proteins or by internal domains3. Notable examples include USP7 activation by 
its HUBL domain and GMPS4, USP1 activation by UAF15 and Ubp8 activation in the SAGA 
complex6,7. The most striking example is UCH-L5, for which both activation and inhibition 
have been observed8–11, by two different proteins, RPN13 (ADRM1) and INO80G (NFRKB) 
respectively. 
Understanding the mechanisms of DUB activation is important for interpreting their roles 
in specific cellular contexts. Mechanistic insight into regulatory mechanisms can also pro-
vide vital information for development of inhibitors or activators. So far, the only avail-
able crystal structure of a DUB-activator complex is that of the SAGA DUB module12,13, but 
no structure is available for its inactive state. Due to this lack of structural data, detailed 
mechanisms of DUB regulation are still poorly understood.
UCH-L5 (UCH37) is a cysteine protease of the ubiquitin C-terminal hydrolase (UCH) 
family of DUBs, which also includes UCH-L1, UCH-L3 and BAP1. UCH-L5 is overexpressed 
in several carcinomas14–16 and knock-out of the gene is embryonically lethal in mice17. 
Functionally, it has been linked to TGF-β signaling, Alzheimer’s disease and longevity18–21. 
UCH-L5 constitutes a component of proteasomes and INO80 chromatin remodeling 
complexes where it is activated and inhibited respectively. 
As a non-essential component of the proteasome 19S regulatory particle, UCH-L5 
catalyzes K48-linked polyubiquitin hydrolysis. This activity requires the RPN13 subunit 
whose C-terminal domain binds UCH-L59–11. In vitro, RPN13 is able to directly promote 
UCH-L5 activity against a minimal substrate9–11.
UCH-L5 has a less well defined role in metazoan INO80 chromatin remodeling complexes. 
INO80 is an essential determinant of embryonic stem cell identity22,23 and participates in 
the DNA damage response24, but the function of the metazoan-specific subunits, such as 
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INO80G is poorly defined. A recent report has implicated UCH-L5 and INO80G as key fac-
tors of the DNA double strand break response25. Interestingly, in the context of the INO80 
complex the DUB activity of UCH-L5 is inhibited by the INO80G subunit8. Intriguingly an 
artificial shorter version of INO80G was found to activate UCH-L5 in vitro8.
The UCH enzymes have a small highly conserved papain-like catalytic domain character-
ized by a flexible active site cross-over loop (CL). The CL is thought to select substrates 
according to leaving group size26,27. In UCH-L5 and UCH family member BAP1 the CL is 
relatively large, enabling them to process larger substrates27. 
Within the UCH family UCH-L5 and BAP1 are close relatives. BAP1 is a critical tumor sup-
pressor whose regulation is important for proper gene regulation28–30. UCH-L5 and BAP1 
share an unusual C-terminal helical extension, called ULD31. The ULD domain could me-
diate protein-protein interactions, including higher order homo-oligomerization32,33, and 
was proposed to act as an auto-inhibitory module11.
Like UCH-L5, BAP1 can be activated by a regulatory protein, in this case ASX, to promote 
H2A deubiquitination34. Phylogenetic analyses have uncovered a conserved domain with-
in the UCH regulatory proteins RPN13, INO80G and ASX, that was named the DEUBAD do-
main35. As all three proteins affect UCH activity, it was proposed that the DEUBAD domain 
is responsible for this modulation. The conservation suggests a common mechanism of 
regulation, but where ASX and RPN13 activate their cognate DUB, INO80G inhibits it. Thus 
the DEUBAD domain has shifted from activator to inhibitor mode. The mechanistic details 
of this dual mode of action of the DEUBAD domains are unclear.
Here we present structural and functional analyses that explain how DEUBAD domains 
can switch UCH-L5 activity and thus provide either positive or negative regulation. We 
show how the DEUBAD domain in RPN13 activates UCH-L5 by tuning the conformation of 
structural elements in UCH-L5, and inhibits in INO80G, where it exploits molecular mim-
icry and UCH-L5 conformational plasticity to prevent ubiquitin docking and catalysis. We 
also show how the inhibitory domain in INO80G has retained the ability to activate, by 
its N-terminal INO80G
short
 region and identify the structural elements in the DEUBAD do-
mains that confer the activating or inhibitory effects on UCH-L5 enzymatic activity. Our 
data show that this remarkable tuning of activity involves large conformational changes 
and is mediated by precise positioning of both the UCH-L5 C-terminal ULD and active site 
cross over loop (CL).
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ReSULTS
Crystal structures of activated and inhibited UCH-L5 
To study the regulation of UCH-L5 by DEUBAD domains we purified human UCH-L5 in 
complex with the DEUBAD domains of RPN13 (aa 265-388, referred to as RPN13DEU) and 
INO80G (aa 39-170, referred to as INO80GDEU) (Figure 1A). We measured the catalytic 
activity of these complexes towards the minimal substrate ubiquitin-7-amido-4-methyl-
coumarin (Ub-AMC)36,37 in comparison to full-length UCH-L5 alone (U) and its isolated 
catalytic domain (CD). In line with previous data, we find that the DEUBAD domain of 
RPN13 activates UCH-L5 (UR) (Figure 1B)9–11. Since the UCH-L5 CD is more active than the 
full-length alone, the ULD domain partially inhibits activity11. However, in the presence of 
RPN13DEU UCH-L5 is significantly more active than the UCH-L5 CD and therefore RPN13DEU 
does more than simply removing autoinhibition (Figure 1B). Strikingly, INO80GDEU severe-
ly inhibits activity under these conditions (UI) (Figure 1B).
We wondered how these related DEUBAD domains achieve such remarkably opposite 
effects on regulation. To assess this we performed structural studies on UCH-L5 in complex 
with DEUBAD domains and compared them with apo UCH-L5 32(Fig 1C). We determined 
a crystal structure of UCH-L5 in complex with the inhibitory domain INO80GDEU at 3.7 Å 
(Figure 1D). Additionally, we determined crystal structures of UCH-L5 in complex with 
activating RPN13DEU, with and without the suicide inhibitor ubiquitin-propargyl (Ub-Prg) 
38,39 at 2.3 Å and 2.8 Å respectively (Figures 1E and 1F). All structures were refined to 
acceptable statistics (Table 1).
The resulting structures display striking differences (Figures 1D-F). Both RPN13DEU 
and INO80DEU primarily bind the C-terminal ULD domain of UCH-L5, but are positioned 
radically different relative to the UCH-L5 CD, which itself hardly changes conformation 
between all UCH-L5 structures. The differences arise from major changes in orientation 
of the ULDs relative to the catalytic domain (Figure 1G). The ULDs adopt a wide range of 
positions relative to the CD, even in previously known UCH-L5 structures32,40 suggesting 
that this element is flexible in solution. Activator and inhibitor may lock this domain in 
particular conformations.
To allow UCH-L5 binding, RPN13DEU changes conformation compared to the previously 
determined RPN13DEU apo-state41, by rearranging core helices α1- α4 and the α3-α4 loop 
(Figure 1H). In this new conformation, the core of INO80GDEU and RPN13DEU resemble 
each other, underscoring their common ancestry (Figures 1I and S1A). The C-termini of 
the DEUBAD domains, however, diverge dramatically. Where helices α6-α8 (aa 350–384) 
form a platform in RPN13DEU, the equivalent region in INO80GDEU forms a single extend-
ed helix (α6). Another notable difference between the two DEUBAD domains is a short 
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Figure 1 | Crystal structures UCH-L5/DEUBAD complexes. A) Constructs used in this study. B) RPN13DEU acti-
vates UCH-L5 (UR) while INO80GDEU inhibits UCH-L5 (UI) in Ub-AMC enzyme kinetics. The CD is slightly more 
active than FL UCH-L5 (U). See Fig. 1A for naming codes. Error bars represent standard deviation of mean. C) 
Structure of apo UCH-L5 (3ihr). The CD is colored in blue and the ULD domain in light blue. D) Structure of 
UCH-L5/INO80GDEU (INO80GDEU in orange). E) Structure of UCH-L5/RPN13DEU (RPN13DEU in green). F) Structure 
of UCH-L5~ Ub-Prg/RPN13DEU with Ub-Prg in yellow. G) The ULDs are found in different conformations across 
UCH-L5 structures. The catalytic domain is transparent for clarity.H) RPN13DEU (green) changes towards an 
open state upon UCH-L5 complex formation compared to apo RPN13DEU (grey). Helices α1-4 and the α3-4 loop 
that undergo the largest changes are colored in darker shades. I) Superposition of RPN13DEU and INO80GDEU. 
DEUBAD domains deviate most at FRF-hairpin and helix α6.
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hairpin (aa 96-103) exclusively present in INO80G, that we named the FRF-hairpin. It is 
inserted between helix α4 and α5 of the DEUBAD domain and is conserved in INO80G 
orthologs (Figures 1I and S1B). 
The structural conservation of the DEUBAD domains is also reflected in their similar 
binding modes to UCH-L5 (Figures 1D-F and S1C). In both complexes, the core DEUBAD 
domains bind primarily to the C-terminal ULD of UCH-L5 where amphipathic helix α11 
is clasped by the DEUBAD domains and further stabilized by helix α12 in an extensive 
hydrophobic interface (Figure S1D and S1E). DEUBAD domain binding requires these 
helices, since a UCH-L5 variant that lacking these (UCH-L5
Δα11-12
), does not interact with 
RPN13DEU, whereas the wild type UCH-L5 binds tightly (KD=6 nM) in isothermal titration 
calorimetry (ITC) (Figure S1F and Table S4). 
In short, the conserved DEUBAD domains bind to UCH-L5 but show dramatically different 
arrangements. In the next sections we examine how these are achieved and how they can 
lead to differences in UCH-L5 activity. The structural consequences of ubiquitin binding 
are discussed in the light of the mechanism of activation and inhibition.
DEUBAD domains tune UCH-L5 substrate affinity 
Table 1 | Crystallography details
Data collection UCH-L5/RPN13DEU UCH-L5~ UbPrg/
RPN13DEU
UCH-L5/ 
INO80GDEU
UCH-L5~ Ub-Prg/
INO80Gshort
Wavelength (Å) 0.98 0.87 0.91 0.87
Resolution (Å) 33.5(2.8) 45.3(2.3) 47.7(3.7) 47.7(3.7)
Space group P212121 P212121 P4122 C2
Unit cell a,b,c (Å) 56.6, 97.07, 100.6 59.34, 98.6, 100.2 94.88,94.88, 132 152.1, 137.8, 98.9
α, β, γ (˚) 90, 90, 90 90, 90, 90 90, 90, 90 90, 102.5, 90
CC1/2 (%) 99.8(72.9) 99.9(67.6) 98.3(41.8) 98.4(72.6)
Rmerge (%) 7.1(93.0) 12.6(83.2) 20.9(73.2) 19.9(66.4)
I/σI 15.3(2.2) 9.7(1.6) 7.4(2.4) 5.8(1.8)
Completeness (%) 98.5(97.3) 99.8(98.9) 99.5(100) 97.9(90.3)
Redundancy 3.9(3.7) 4.1(4.1) 6.7(6.8) 4.2(4.0)
Refinement
Number of unique reflections 13635 26949 7004 21090
Rwork/Rfree (%) 23.2/28.4 19.5/23.5 30.4/35.4 23.8/26.6
R.m.s.d. Bond lengths (Å) 0.003 0.005 0.004 0.008
R.m.s.d. Bond angles (˚) 0.7 1.0 0.7 1.2
*Ramachandran statistics (%) 
(preferred/allowed/not allowed)
99.2/0.8/0 98.5/1.5/0 97.7/2.03/0 95.02/4.98/0
High resolution shells in parentheses 
*Molprobity
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Analysis of UCH-L5 kinetic parameters (Figure 1B and Table S1) reveals that RPN13DEU 
binding primarily changes the KM of the enzyme but hardly affects kcat. Therefore we won-
dered if changes in  substrate affinity of UCH-L5 could explain regulation by DEUBAD 
domains 
We assessed the ability of UCH-L5 to bind a model substrate in the presence and absence 
of the DEUBAD domains using ITC. The model substrate Ub-GlySerThr was titrated into 
active site cysteine (C88A) mutants of the different UCH-L5 complexes. We observed 
robust binding (KD=4.5 µM) for UCH-L5/RPN13
DEU, whereas binding to UCH-L5 alone, 
UCH-L5 CD and UCH-L5/INO80GDEU did not reach saturation, with the UCH-L5/INO80GDEU 
complex giving the lowest signal (Figures 2A, S2A and Table S3). These results suggest 
that RPN13DEU enhances UCH-L5 substrate binding, whereas INO80GDEU diminishes it. We 
validated these results in fluorescence polarization (FP) binding assays, using Ub-LysGly-
TAMRA as a model substrate42, demonstrating that DEUBAD domains tune UCH-L5 activity at 
the level of substrate binding (Figure 2B). 
Ubiquitin binding by the UCH-L5/RPn13DeU complex
UCH-L5 activation by the RPN13 DEUBAD domain results from enhanced ubiqui-
tin-substrate binding, therefore we analyzed the details of ubiquitin interaction in the 
UCH-L5~UbPrg/RPN13DEU crystal structure (Figures 2C). The presence of Ub-Prg hardly 
changes the global UCH-L5/RPN13DEU conformation (Figure 1). Direct contact between 
ubiquitin and RPN13DEU involves a small interface (286 A2) with three hydrogen bonds 
(Figures 2C and 2D). Moreover, this interface does not affect the position and orientation 
of ubiquitin on UCH-L5, which resembles the previously solved T.spiralis UCH-L5 ubiqui-
tin complex. In fact, it is identical to the canonical ubiquitin binding mode found in all UCH 
family members (Figure 2E).
In practice, ubiquitin binds via its C-terminal tail close to the active site and via its core 
relatively far from the active site, in a series of so-called ‘exosites’. In the UCH-L5 complex, 
the ubiquitin C-terminal tail adopts an extended conformation. It is buried and positioned 
by an extensive network of side chain and backbone interactions with the catalytic domain 
(Figures 2C and 2F). 
The binding of the ubiquitin core creates three specific exosite interactions on the UCH-L5 
CD. The first involves UCH-L5 Trp36, which rearranges, compared to apo UCH-L5/
RPN13DEU, to avoid clashes and to promote a direct contact with ubiquitin Ile44 (Figures 
2C and 2G), the primary hydrophobic binding site on ubiquitin.
A second exosite interaction involves UCH-L5 Ile216 at the C-terminus of helix α8 (Figure 
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2G). This helix melts out in UCH-ubiquitin complexes but is extended in the absence of 
ubiquitin (Figure S2B). Partial melting of α8 is crucial since it rearranges Ile216 from a 
buried position to a position in the α8-β6 connecting loop that is compatible with ubiquitin 
binding, similar to T.spiralis UCH-L5 where Val214 (equivalent to human Ile216) contacts 
the ubiquitin Ile36 patch40 (Figure 2H). Interestingly, in the UCH-L5/RPN13DEU structure, 
the C-terminus of helix α8 is already disordered in the absence of ubiquitin, indicating 
that RPN13DEU may affect this region allosterically to facilitate ubiquitin binding. 
Finally, the melting of helix α8 and ordering of the α8-β6 connecting loop promotes po-
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sitioning of Phe218 and formation of a highly conserved pocket that includes UCH-L5 
Leu38. This hydrophobic pocket on UCH-L5 allows a snug interaction with the ubiqui-
tin β1-β2 hairpin containing Leu8 and Thr9 (Figure 2G). Formation of this pocket was 
described for UCH-L1, upon ubiquitin interaction 43. In UCH-L1 the Phe214 positioning 
promotes rearrangement of Phe53 (equivalent to UCH-L5 residues: Phe218 and Phe56) 
which is necessary to organize the catalytic site conformation. In UCH-L5 this relay is not 
required, since Phe56 is already positioned such that the catalytic triad is active in the 
apo-structure. Nevertheless, the conformational change of UCH-L5 Phe218 in this pocket 
is conserved upon ubiquitin binding, as is the interaction with the ubiquitin β1-β2 hair-
pin. All three exosite interactions are well conserved in the UCH family, explaining the 
remarkably similar ubiquitin positioning on the UCH catalytic domains (Figure 2E). 
The DeUBAD domain of RPn13 activates UCH-L5 by ULD and CL positioning
To investigate how RPN13DEU promotes enhanced substrate binding by UCH-L5 we tested 
the effect of mutations on activity. We first focused on the effect on activation of the 
ubiquitin binding residues in UCH-L5. Mutations in these residues lowered the activity 
substantially, irrespective of the presence of RPN13DEU indicating that they are primarily 
important for basic DUB function (Figure 3A). We then tested mutations of RPN13DEU 
located in the interface with ubiquitin and found that these provided only a limited 
contribution to UCH-L5 activation (Figures 2D and S2C ).
To further explore the molecular origins of the activation we analyzed the evolutionary 
conservation of surface residues on UCH-L5 with ConSurf44. A UCH-L5 sequence align-
ment from species across all major eukaryotic lineages that possess both RPN13 and 
UCH-L5 was projected onto the UCH-L5 structure. This was compared to an analogous 
conservation analysis for UCH-L3, a prototype UCH member that lacks the C-terminal ULD 
domain. We noted several conserved regions. Both UCHs have a conserved surface patch 
where ubiquitin binds (Figure 3B). Adjacent to this patch, we found a second highly con-
served site in UCH-L5 orthologs that is absent in UCH-L3 orthologs. This site centers on 
Glu283, and anchors the ULD to the catalytic domain through a polar interaction network 
(Figure 3C). The strong conservation of this ULD anchor is intriguing as the area is not 
directly involved in ubiquitin or RPN13DEU binding. 
We assessed the functional importance of the ULD anchor by testing UCH-L5 mutants in 
Ub-AMC assays. UCH-L5
E283A
 had similar activity to WT but this mutant could not be ac-
tivated to the same extent as WT by RPN13DEU, mainly due to weaker KM (Figure 3D and 
Tables S1-2). The fact that this E283A mutation does not affect intrinsic UCH-L5 activity, 
but only the activity of the RPN13DEU complex strongly suggests that an intact ULD anchor 
is required for RPN13DEU dependent activation of UCH-L5. Next we tested the effect of 
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E283A mutation on substrate binding. Using ITC and stopped-flow binding analysis we 
found that UCH-L5
E283A
/RPN13DEU shows decreased affinity for Ub-substrates compared 
to WT complex (Figures S2A, S2D and Table S3). This indicates that RPN13DEU induces a 
higher affinity for substrates by utilizing the intact ULD anchor.
Next, we focused our attention on the UCH-L5 cross-over loop (CL) that is disordered in 
most UCH-L5 crystal structures. In our complexes the CL makes contacts with RPN13DEU 
(Figure 3E) via the highly conserved Met148 and Phe149, partially ordering the loop. 
Given the importance of the CL for the ability of UCHs to process larger substrates 26,27 
we made mutants to test whether the interface of the CL with RPN13DEU could affect 
activity by positioning the loop. In a Ub-AMC assay, UCH-L5
M148A/F149A
 hydrolyzed Ub-AMC 
comparable to WT indicating that the mutant was still functional. However, this mutant 
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Figure 3 | Activation mechanism RPN13DEU. A) Mutations in the ubiquitin interface severely compromise 
DUB activity irrespective of RPN13DEU (top). Location mutants (yellow sticks) on UCH-L5 (bottom). B) Surface 
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completely abrogated in comparison to WT (UR and U from Figure 1B).
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was only marginally activated by addition of RPN13DEU (2.7 fold instead of 7-fold in WT) 
indicating that UCH-L5 activation by RPN13DEU requires an intact CL (Figure 3F and Tables 
S1-2). Interestingly, unlike the ULD anchor mutant, the CL mutant and WT complexes bind 
model substrates with similar affinities (Figures S2A and S2D and Table S3).  
Combining the CL and ULD anchor mutants into UCH-L5
double
 resulted in an almost com-
plete abrogation of RPN13DEU mediated activation illustrating that the CL and ULD anchor 
are the principal regulatory sites used by RPN13DEU (Figure 3G). As none of the UCH-L5 
mutants were compromised in RPN13DEU binding as shown by ITC (Figure S2E and Table 
S4) we conclude that RPN13DEU exerts its stimulatory effect on UCH-L5 through position-
ing of the CL and ULD anchor. 
Mechanism of UCH-L5 inhibition by InO80GDeU 
Our binding assays show that INO80GDEU decreases the affinity of UCH-L5 for substrates 
(Figures 2A and 2B). To understand this effect we analyzed how INO80GDEU affects UCH-L5 
conformation (Figure 1) in more detail. INO80GDEU alters the ULD domain´s relative po-
sition and conformation in two specific ways. First, helix α9 and α10 are tilted by ~30 
degrees compared to the active ULD conformation and second, the C-terminal end of helix 
α10 is bent towards the catalytic domain (Figure 4A). As a result, sections of the ULD 
and INO80GDEU occupy the canonical ubiquitin binding exosites on UCH-L5 and thus pre-
vent substrate docking (Figure 4A). The blockage of the exosites by the INO80GDEU com-
plex present a structural rationale for the decreased substrate binding that we observe, 
and provides a simple yet unexpectedly striking explanation of the INO80GDEU inhibition 
mechanism.
Analysis of the UCH-L5/INO80GDEU interface shows how the large conformational changes 
in UCH-L5 organize novel interfaces where key elements for ubiquitin binding and 
RPN13DEU mediated activation are exploited by INO80GDEU to inhibit UCH-L5 activity. First, 
ULD conformational changes allow INO80GDEU helix α6 to contact the UCH-L5 CD possibly 
stabilizing the inhibitory conformation of the ULD (Figures 1D and S1D). Second, in a 
neat example of molecular mimicry, the INO80G FRF-hairpin binds to the UCH-L5 Leu38 
pocket in a fashion that resembles the binding of the structurally analogous ubiquitin β1-
β2 hairpin to this pocket (Figures 4B and 4C). Next, the C-terminus of UCH-L5 helix α8 
refolds to make the extra helical turn seen in the apo-structure. As a result, UCH-L5 Ile216 
rearranges towards the hydrophobic core, preventing the possibility of the important 
interaction with the ubiquitin Ile36 patch (Figure 4D). Finally, helix α10 bending in the 
INO80GDEU complex relocates the ULD anchor residues towards UCH-L5 Trp36 creating a 
novel intramolecular interface consisting of a cation-π stacking interaction between the 
indole ring of the Trp36 and Arg287 in UCH-L5 helix α10 (Figure 4E). This relocation 
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simultaneously precludes Trp36 availability for ubiquitin binding and impedes the 
formation of the intricate polar interaction network in the ULD anchor that is required 
for UCH-L5 activation by RPN13DEU (Figure 3C). Thus all elements for ubiquitin binding in 
UCH-L5 are effectively obscured by INO80GDEU binding. 
The fRf hairpin creates the activity switch in DeUBAD domains
To study what features in INO80GDEU are required to achieve UCH-L5 inhibition we 
analyzed its differences with the activating DEUBAD domain of RPN13. The most striking 
difference between the DEUBAD domains of RPN13 and INO80G is the C-terminal part 
where three helices α6-α8 in RPN13DEU change to the extended α6 in INO80GDEU that packs 
against the CD (Figures 5A and S1D). Therefore we created a shorter version of INO80GDEU, 
where helix α6 is removed (Figure 1A, residues 39-118, INO80GDEU
Δα6
). Surprisingly, the 
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truncated protein, INO80GDEU
Δα6 
still inhibited UCH-L5 (Figure 5B), demonstrating that 
helix α6 is not required for inhibition under these conditions. 
We next assessed the importance of the INO80G FRF-hairpin which is the other major 
structural difference between the RPN13DEU and INO80GDEU (Figures 5A and 1I). In the 
hairpin, the side chain of the highly conserved Phe100 (Figure S1B) is accommodated 
by the UCH-L5 Leu38 pocket (Figure 4C), suggesting that this interaction is important 
for INO80G function. To address the relevance of this interaction we made a single point 
mutant F100A in INO80GDEU. 
This point mutant, INO80GDEU
F100A
, has lost the ability to inhibit UCH-L5 in Ub-AMC assays. 
In fact, it restores activity to the level of UCH-L5 alone, highlighting the importance of 
the FRF-hairpin interaction for UCH-L5 inhibition (Figure 5C and Tables S1-2). Moreover, 
the F100A complex gained a significant substrate binding ability in contrast to the WT 
INO80GDEU complex (Figure 5D). Loss of the phenylalanine interaction will make the 
Leu38 pocket available again for binding of the β1-β2 hairpin of ubiquitin (Figure 2G), but 
most likely also allows helix α10 to revert to its extended state, affecting the ULD position.
The structural changes in the DEUBAD domains may have been a crucial evolutionary 
event facilitating novel regulatory modes of the DEUBAD domain. To test this we created a 
chimeric RPN13DEU variant (RPN13DEU
chimera
) by inserting the INO80G FRF-hairpin into the 
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Figure 5 | The FRF-hairpin drives UCH-L5 inhibition. A) INO80GDEU differs from RPN13DEU mainly in the 
FRF-hairpin and helix α6 (orange surfaces). B) Helix α6 of INO80GDEU dispensable for inhibition in Ub-AMC 
assays. C) Inhibition is completely lost in the INO80GDEU F100A mutant (UI
F100A
) on Ub-AMC. D) Mutant com-
plex F100A gains Ub-GlySerThr binding ability compared to WT INO80GDEU complex (from Figure 3A) in ITC. 
E) Insertion of the FRF-hairpin in RPN13DEU
chimera
 abolishes the activation effect of WT RPN13DEU on UCH-L5 (UR 
and U from Figure 1B).
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structurally equivalent position in RPN13DEU (Figure S3A). The chimera formed a stable 
complex with UCH-L5 (Figure S3B), but completely abolished the activation effect. The 
inserted FRF-hairpin was not sufficient to inhibit UCH-L5 to the same extent as INO80GDEU 
however (Figure 5E and Table S1). In RPN13DEU
chimera
 the presence of the FRF-hairpin likely 
diminishes ubiquitin binding as it would be overlapping with the ubiquitin binding site 
explaining the loss of activation potential. These results demonstrate that the FRF-hairpin 
and its location within the DEUBAD domain have a crucial effect on UCH-L5 activity. 
The InO80Gshort activation mechanism also relies on ULD positioning
We wondered how lack of the FRF hairpin would affect the stucture of UCH-L5 and 
INO80G. To this end we determined the 3.7 Å structure of UCH-L5 in complex with 
Ub-Prg and INO80G
short
 (aa 39-101), a shorter fragment of INO80GDEU (Figure 1A). The 
artificial INO80G
short
 construct has the remarkable capability to activate UCH-L5 in vitro8. 
INO80G
short
 starts at the same residue as INO80GDEU but terminates in the middle of the 
FRF-hairpin and is hence predicted not to contain a folded FRF-hairpin. Indeed, in the 
crystal structure, the C-terminal end of INO80G
short
 could not be unambiguously modeled, 
indicating that the FRF hairpin is not formed in this complex.
Strikingly, the UCH-L5~UbPrg/INO80G
short
 crystal structure resembles the activated 
RPN13DEU complex rather than the inhibited state (Figure 6A and S4A-B). In this complex, 
the ULD has largely reverted to the conformation seen in the activated RPN13DEU complexes 
with an extended helix α10 (Figure S4C). All conformational changes in UCH-L5 required 
to create the canonical ubiquitin binding mode are now also in place (Figure S4D-E). The 
structure of INO80G
short 
itself and its binding mode to UCH-L5 are moreover identical to 
INO80GDEU (apart from FRF-hairpin and α5-6) and RPN13DEU (Figure S4F).
Enzyme kinetics analysis confirmed that INO80G
short
 activates UCH-L5 on Ub-AMC (Figure 
6B). The activation effect correlates with increased affinity for substrates since UCH-L5 
binds substrates better in the presence of INO80G
short
 in ITC binding assays (Figure 6C). 
These results stress that DEUBAD domains mainly modulate activity by tuning substrate 
affinity.
The similarity in structure to the RPN13DEU complex, suggests that INO80G
short
 makes use 
of the same activation mechanism. To test this hypothesis we used the UCH-L5
E283A
 ULD 
anchor mutant, asking whether loss of the ULD anchor would also affect the activation in 
this case. We found that the UCH-L5
E283A
/INO80G
short
 mutant complex was compromised 
in Ub-AMC hydrolysis (Figure 6C and Table S1-2), reverting to the activity observed for 
UCH-L5 alone. This indicates the importance of the ULD anchor (Figure 6D) for INO80G
short
 
activation and suggests that ULD positioning in general is a major feature of the activation. 
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INO80G
short
, containing only the helices α2-α4 of the DEUBAD domain, can activate UCH-L5 
demonstrating that the core DEUBAD fold is already sufficient to bind and provide modest 
activation. The INO80G
short
 complex does not attain UCH-L5/RPN13DEU activity levels 
however. Most likely this is because it lacks helix α5, which RPN13DEU uses to position the 
CL (Figure S4G). 
Collectively the UCH-L5/INO80G
short
 structure analysis reconciles all our previous findings. 
First, it confirms that the FRF-hairpin is the crucial factor for inhibition since absence of 
this element results in loss of inhibition. Second, loss of the FRF-hairpin destabilizes the 
inhibitory ULD conformation causing it to snap back to a substrate binding competent 
conformation. Third, the core DEUBAD fold is sufficient to provide the basic UCH-L5 
activation function. Like RPN13 it executes activation by stabilizing the substrate binding 
competent conformation of the ULD through ULD anchor. 
DISCUSSIOn
Our data show how UCH-L5 activity can be modulated by DEUBAD domains present in 
RPN13 and INO80G through remarkably large conformational changes. Functionally, the 
activity of UCH-L5 is tuned at the level of substrate affinities where RPN13DEU increases 
the affinity for substrates and INO80GDEU dramatically decreases substrate affinity. Our 
structural and biochemical analyses indicate that RPN13DEU achieves this effect by precise 
positioning of the ULD anchor and CL. The direct contact between RPN13DEU and ubiquitin 
furthermore confers a mild activation effect on UCH-L5 by stabilizing ubiquitin. Converse-
ly INO80GDEU exploits molecular mimicry and ULD conformational plasticity to prevent 
ubiquitin docking and catalysis. We show which structural changes in DEUBAD domains 
may have been instrumental for the evolution of different modes of UCH-L5 regulation.
The proposed evolutionary conservation of the DEUBAD domains35 is confirmed by 
structural analyses in this study. The DEUBAD domains appear to be modular. The core 
DEUBAD fold (α1-α4) is shared among INO80GDEU, RPN13DEU and INO80G
short
 and is 
responsible for binding to UCH-L5 and modest activation. Accessory structural modules 
in RPN13DEU (helix α5 that positions the CL) and INO80GDEU (FRF-hairpin) lead to full 
activation or inhibition of UCH-L5. The modular nature of the DEUBAD domains explains 
their versatility as regulatory domains. 
A key feature of UCH-L5 activity modulation is the conformational plasticity of the ULD 
that is found in a variety of conformations in the available UCH-L5 crystal structures (Fig-
ure 1G). This plasticity and the current data are consistent with a model where the UCH-L5 
ULD can adopt a multitude of possible conformations in a dynamic fashion when free in 
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solution (Figure 6E). As a consequence of the ULD’s proximity to the ubiquitin docking 
site, some of these conformations will be sterically incompatible with ubiquitin binding 
while others will allow efficient ubiquitin binding. The DEUBAD domain in RPN13DEU and 
INO80GDEU restricts ULD conformational plasticity by preferentially stabilizing specific 
conformations. RPN13DEU activates and increases the affinity for substrates by fixing the 
ULD into a substrate binding competent conformation, using the ULD anchor. Additionally, 
full activation is achieved by the stabilization of the ubiquitin orientation by RPN13DEU and 
correct positioning of the CL. On the other hand, INO80GDEU binds to UCH-L5 and uses ULD 
conformational flexibility to dock its unique inhibitory FRF-hairpin into the Leu38 pocket. 
This interaction fixes the ULD in such a way that the ubiquitin binding site is blocked by 
INO80GDEU and the ULD. In the process key molecular elements for ubiquitin binding and 
RPN13 dependent activation are masked or disrupted, effectively inhibiting activity. 
This regulatory model may co-exist with possible roles of the UCH-L5 oligomeric state for 
regulation of its activity11,32,33. As the enzyme concentrations under our assay conditions 
are low it is unlikely that we capture these phenomena. However, we cannot exclude that 
additional layers of regulatory complexity may exist in cells that involve UCH-L5 oligo-
meric states.
Our structures of UCH-L5/RPN13DEU explain the basic mechanisms of activation by the 
RPN13 DEUBAD module. It will be interesting to investigate the additional activation that 
is required to hydrolyze K48-polyubiquitin in the proteasomal 19S regulatory particle. It 
is conceivable that efficient K48 polyubiquitin hydrolysis will only take place after steps 
that are possibly related to proper positioning and unfolding of the compact K48 poly-
ubiquitin chains. A key step here will be the identification of the minimal proteasomal 
complex required to perform chain hydrolysis. 
The UCH-L5/INO80GDEU structure may provide novel approaches in unraveling the enig-
matic role of UCH-L5 and INO80G in INO80 chromatin remodeling complexes. INO80G is a 
key factor in embryonic stem cells and knock out leads to loss of pluripotency23. Of specific 
interest is why UCH-L5 is kept in an inhibited state in the INO80 complex8. A possibility is 
that INO80 controls UCH-L5 in a temporal manner where in some circumstances UCH-L5 
is inhibited while under other circumstances post-translational modifications and/or 
conformational changes release the inhibition and activate UCH-L5, allowing for addition-
al layers of regulation. We have already seen in INO80G
short
 that the core DEUBAD fold has 
the intrinsic ability to activate UCH-L5 and all that is required for INO80GDEU to relieve 
inhibition is disruption of the FRF-hairpin. Such relief of inhibition would be important for 
the recently reported UCH-L5/INO80G role in DNA double strand break response, since 
UCH-L5 catalytic activity is required for proper DNA end resection25.
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A unique element of the INO80GDEU domain is the extended helix α6. This helix packs 
against the CD close to the active site and was therefore initially thought by us to confer 
INO80GDEU inhibitory function. In our in vitro assays this is element is dispensable for 
inhibition, but this may be different in a cellular context, where the additional contacts 
between this helix and the catalytic domain may further stabilize the inactivated state. An 
interesting feature of helix α6 is the presence of a large solvent exposed positively charged 
patch. We speculate that this patch may be important in cells as a binding platform for 
INO80 chromatin remodeling factors. As the equivalent region in RPN13DEU folds into a 
helical platform it may also be possible that under some conditions, driven by e.g. post 
translational modifications (PTMs), α6 could refold into a conformation seen in RPN13 to 
meet functional requirements. DUB activity regulation by PTMs such as phosphorylation 
have been shown previously to be important for DUBA45.
The ULD is conserved in UCH family member BAP1 that is activated by the ASXL1 DEU-
BAD-domain to deubiquitinate H2A34. Because of the strong conservation of key elements 
between UCH-L5/RPN13DEU and BAP1/ASXL1 we anticipate that the ASXL1 DEUBAD do-
main employs similar strategies to activate BAP1. Both BAP1 and ASXL1 are important 
cancer drivers. BAP1 is a key tumor suppressor that is mutated in a number of cancers 
where loss of BAP1 is associated with poor prognosis and tumor aggressiveness28,30. Our 
crystal structures have valuable implications for BAP1 function in its cellular roles and 
pathogenesis. 
The mechanisms of DUB regulation that we describe are different from those in previously 
studied DUB regulators. UAF1 increases the basicity of the USP1 catalytic histidine, 
increasing its potency as a general base46. Likewise, incorporation of Ubp8 in the SAGA 
complex stabilizes the catalytic center, also facilitating catalysis12,13. Activation of USP7 
by GMPS against a minimal substrate changes only k
cat
4. All of these differ from UCH-L5 
where a major part of the activity modulation involves tuning substrate affinities, rather 
than actual catalytic steps. 
Whereas inhibition of DUBs by proteins is still a rare phenomenon, inhibition of general 
proteases by proteins has been well described47,48. Serpins inhibit serine proteases 
by irreversibly trapping the acyl-enzyme intermediate. Additionally general cysteine 
proteases can be inhibited by cystatins and related proteins by occupying active site clefts. 
Instead INO80G functions as an exosite inhibitor where not the active site cleft but an 
exosite, in this case the ubiquitin-core docking site, is blocked. Enzyme exosite targeting 
by a naturally evolved inhibitor could provide powerful clues about the most efficient way 
for DUB inhibition and may thus be promising from a pharmaceutical perspective.
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eXPeRIMenTAL PROCeDUReS
Plasmids and cloning
Human UCH-L5, RPN13 and INO80G cDNA were subcloned from the HAP1 cell line. 
RPN13DEU
chimera
 was purchased as a synthetic construct. All constructs were cloned into 
the pGEX or pET bacterial expression vectors of the NKI LIC suite49. 
Protein expression and purification
All protein variants and protein complexes were (co-) expressed in E.coli. UCH-L5 and 
variants were purified using GST affinity purification (GSH 4B sepharose, GE Healthcare) 
followed by a desalting (HiPrep 26/10, GE Healthcare) and final size exlusion chroma-
tography step (Superdex S200, GE Healthcare). UCH-L5 complexes were purified simi-
larly except for an additional first nickel purification step. RPN13DEU alone was expressed 
in E.coli and purified using nickel affinity chromatography, desalting and size exclusion 
chromatography (Superdex S75, GE Healthcare).
Ub-AMC enzymatic assays
Enzyme activity was followed as release of fluorescent AMC from the quenched Ub-AMC 
substrate, providing a direct read-out of DUB activity. Michealis-Menten parameters 
were determined using 1 nM of enzyme while varying the substrate concentration. Initial 
rates were plotted against substrate concentration and fitted to the Michealis-Menten 
model using non-linear regression in Prism 6. In single concentration experiments, 1 nM 
of enzyme was allowed to react with 1 µM of substrate. Activity was quantified by calcu-
lating the initial rates.
fP binding assays
Binding assays between UCH-L5 complexes and model substrate Ub-LysGlyTAMRA were 
performed by measuring fluorescence polarization. Model substrate (5 nM) was 
incubated at 25˚C with varying amounts of different UCH-L5 complexes to obtain binding 
curves. To prevent substrate hydrolysis inactive C88A mutants of UCH-L5 were used.
Stopped-flow fluorescent polarization binding assay
Pre-steady state binding events between UCH-L5 (C88A) complexes and Ub-LysGlyTAMRA 
were monitored in stopped-flow fluorescent polarization experiments. Varying concen-
trations of UCH-L5 variants were injected together with 20 nM (final concentration) 
Ub-KGTAMRA after which fluorescent polarization was followed during 10 s. Association 
binding traces were fitted to a one-phase exponential model in Prism6 to obtain k
obs
. The 
k
obs
 values were plotted against protein concentration to estimate k
on
, k
off
 and KD. 
Isothermal Titration Calorimetry
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ITC experiments were performed in a VP-ITC Microcal calorimeter at 25˚C. In 10 ul 
injections, 450 µM UbGlySerThr was titrated into 45 µM of UCH-L5 (C88A). or 110 µM 
UCH-L5 into 12.5 µM RPN13DEU. Data were fitted to a one-site binding model with the 
manufacturer’ Origin software.
Structure determination
Data collection was done at the ESRF and SLS at 100K. Images were integrated with 
XDS50 and merged/scaled with Aimless51, followed by molecular replacement with 
Phaser52. Model refinement was carried out by Phenix53, autoBUSTER54 and Refmac55 and 
models were build using COOT56. All structure figures were generated using PyMOL.
Supplemental information
Detailed experimental procedures, supplemental figures and tables can be found in the 
supplemental data. 
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Figure S1 | Binding of DEUBAD domains to UCH-L5. A) Structure based sequence alignment DEUBAD do-
mains RPN13 and INO80G. B) The INO80G FRF-hairpin is highly conserved. C) DEUBAD domains of both 
RPN13 and INO80G bind UCH-L5 helices α11-α12 in a highly similar fashion. D) Binding interfaces of the 
UCH-L5/INO80GDEU complex. The ULD is clasped by the INO80G DEUBAD domain in an hydrophobic inter-
face (1). Helix α6 packs against the UCH-L5 catalytic domain (2 and 3). E) Close up of the main interface be-
tween RPN13DEU and UCH-L5.  F) UCH-L5 helices α11-α12 are required to bind RPN13DEU in ITC binding assays.
69
Mechanism of UCH-L5 activation and inhibition
3
UCH-L5E283A/RPN13
DEUUCH-L5/RPN13DEU UCH-L5M148A/F149A/RPN13
DEUUCH-L5 CD
α8
UR
U
URS333A/Q335A/Q338A
URQ337A/Q338A
A
D
C
B
5 µM
2,5 µM
1,25 µM
0,6125 µM
0 µM
5 µM
2,5 µM
1,25 µM
0,6125 µM
0 µM
Association traces Residuals linear tsWT
M148A/F149A
5 µM
2,5 µM
1,25 µM
0,6125 µM
0 µM
5 µM
2,5 µM
1,25 µM
0,6125 µM
0 µM
M148A/F149A
20 µM
10 µM
5 µM
E283A
20 µM
10 µM
5 µM
UCH-L5 UCH-L5M148A/F149A UCH-L5E283A UCH-L5double
E
Figure S2 | UCH-L5 activation. A) UCH-L5 variants binding to model substrate Ub-GlySerThr in ITC assays. 
UCH-L5/RPN13DEU from Figure 2. B) In UCHs in complex with ubiquitin (pdb codes: 1ucha, 1xd3, 2etl, 2wdt, 
2we6, 3irt, 3kvf, 3kw5, 4dm9, 4i6n, 4ig7, 4jkj, UR, URUB shown in blue/green tints.) helix 8 is partially melted 
at the C-terminus. This is in contrast with apo UCH structures (pdb codes: 1cmx, 2len, 3a7s, 3ihr, 3rii, 3ris, 3tb3 
shown in gray tints.) were helix 8 makes an extra turn C) RPN13DEU mutants in the ubiquitin interface have a 
small effect on UCH-L5 activation. “U” from Figure 1B D) Stopped flow fluorescence polarization binding as-
says between UCH-L5 complexes and model substrate Ub-LysGlyTAMRA. E) All UCH-L5 variants bind RPN13DEU 
with similar affinity in ITC.
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Figure S4 | The UCH-L5~ Ub-Prg/INO80Gshort complex. A) Asymmetric unit of UCH-L5~ Ub-Prg/INO80Gshort 
shows 4-fold non-crystallographic symmetry. B) Superposition of the UCH-L5~ Ub-Prg/INO80Gshort (UCH-L5 
in blue) and UCH-L5~ Ub-Prg/RPN13DEU (UCH-L5 in gray) shows that the complexes look similar. C)  The ULD 
of the INO80Gshort complex (lightblue) has reverted from the inhibited orientation (darkgrey) to a orientation 
similar to the RPN13DEU complex (lightgray). D and E) Ubiquitin binding occurs in canonical fashion in the 
INO80Gshort complex. F) The DEUBAD domain of INO80Gshort and its binding mode to UCH-L5 are highly 
similar to the RPN13DEU and INO80GDEU complexes. G) INO80Gshort lacks helix α5 that RPN13
DEU employs to 
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SUPPLeMenTAL TABLeS
Table S1 | Ub-AMC Enzyme kinetics parameters, related to figures 1, 3, 5 and 6.
kcat (s-1)     KM (µM)       kcat/ KM (M-1s-1) *1e-5
UCH-L5 4,2 ± 0,3 23,5 ± 3,2 1,8
UCH-L5 CD 4,8 ± 0,2 14,9 ± 1,2 3,2
UCH-L5/RPN13DEU 6,4 ± 0,2 4,4 ± 0,4 14,5
UCH-L5E283A 2,8 ± 0,2 24,2 ± 2,2 1,2
UCH-L5E283A/RPN13
DEU 5,4 ± 0,3 15,2 ± 1,3 3,6
UCH-L5M148A/F149A 3,1 ± 1,0 25,5 ± 14,3 1,2
UCH-L5M148A/F149A/RPN13
DEU 5,6 ± 0,7 17,5 ± 4,3 3,2
UCH-L5double 2,1 ± 0,2 20,1 ± 3,2 1,0
UCH-L5double/RPN13
DEU 3,3 ± 0,2 19,4 ± 2,0 1,7
UCH-L5/INO80GDEU 0,3 ± 0,05 13,5 ± 4,5 0,2
UCH-L5/INO80GDEUF100A 6,5 ± 0,2 28,1 ± 1,0 2,3
UCH-L5/INO80Gshort 4,5 ± 0,04 9,2 ± 0,2 4,9
UCH-L5E283A/INO80Gshort 3,7 ± 0,04 14,3 ± 0,3 2,6
UCH-L5/RPN13DEUchimera 3,6 ± 0,3 17,8 ± 1,2 2,0
Table S2 | Fold activation effect on kcat/Km per UCH-L5 variant, related to figures 1, 3, 5 and 6.
Enzyme variant Modulator Fold Activation effect by modulator  
(kcat/Kmmodulated)/(kcat/Kmunmodulated)
UCH-L5 RPN13DEU 8
UCH-L5E283A RPN13
DEU 3
UCH-L5
M148A/F149A
RPN13DEU 2,7
UCH-L5double RPN13
DEU 1,7
UCH-L5 INO80GDEU 0,1
UCH-L5 INO80GDEU
F100A
1,3
UCH-L5 INO80Gshort 2,7
UCH-L5E283A INO80Gshort 2
UCH-L5 RPN13DEU
chimera
1,1
Table S3 | Substrate binding parameters, related to figures 2, 5, 6,  and S2.
ITC Ub-GlySerThr binding Stopped-flow Ub-LysGlyTAMRA binding
N ΔH  
(kcal/mol)
TΔS  
(kcal/mol)
KD 
(µM)
KD (µM) koff (s
-1) kon (µM
-1s-1)
UCH-L5 nf nf nf nf
UCH-L5/RPN13DEU 0,83 ± 0,01 -18,27 -10,96 4,5 2,3 2,1 ± 0,3 0,9  ± 0,1
UCH-L5E283A/RPN13
DEU nf nf nf nf 18 7,4 ± 1,7 0,42 ± 0,13
UCH-L5M148A/F149A/RPN13
DEU 0,93 ± 0,02 -19,15 -12,07 6,5 3,6 2,5 ± 0,2 0,7  ± 0,07
UCH-L5/INO80Gshort 0,81 ± 0,01 -22,25 -15,67 9,8 11 11,6 ± 1,3 1,1  ± 0,1
UCH-L5 CD nf nf nf nf
Nf: Model not fitted. The UCH-L5/INO80GDEU complex results are omitted since it did not show binding signal in binding experiments. Gray 
boxes represent experiments that were not done.
Table S4 | ITC parameters RPN13DEU binding, related to figures S1 and S2.
 KD (nM) ΔH (kcal/mol) TΔS (kcal/mol)
UCH-L5 6,4 -17,0 -6,2
UCH-L5
Δα11-12 nf nf nf
UCH-L5E283A 5,1 -9,35 -5,2
UCH-L5M148A/F149A 25 -16,5 0,8
UCH-L5double 17 -13,7 -3,1
Nf: Model not fitted. Stoichiometry in these ITC experiment was fixed at 1 (see supplemental experimental procedures).
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SUPPLeMenTAL eXPeRIMenTAL PROCeDUReS
Plasmids and cloning
Human UCH-L5 (uniprot Q9Y5K5, isoform3) RPN13 (uniprot Q16186), INO80G (uniprot 
Q6P4R8) were produced from a cDNA library originating from HAP1 cells1 by PCR and were 
subsequently cloned into bacterial expression vectors from the NKI Ligation Independent 
Cloning (LIC) Suite2. Specifically full length UCH-L5 was cloned into pGEXNKI-GST3C-
LIC (carbenicilin), RPN13DEU (aa 265-388) into pCDFNKI-his3C-LIC (streptomycin), 
INO80GDEU (aa 39-170), INO80GDEU
Δα6
 and INO80G
short
 (aa 39-101) into pETNKI-his3C-LIC 
(kanamycin), Point mutations were generated using site directed mutagenesis procedure 
by Quikchange (Agilent). Ub-GlySerThr was produced from WT ubiquitin (pET 3A) via 
Quikchange insertional mutagenesis. DNA for RPN13DEU
chimera
 was purchased commercially 
as a codon optimized gene (Figure S3A) and cloned into pETNKI-his3C-LIC (kanamycin). 
All clones were verified using DNA sequencing.
Protein expression and purification
All proteins were expressed in BL21 Rosetta2 T1-resistent competent cells (Novagen). 
Cells were grown at 37˚C to an OD
600
 of ~0.6 before inducing protein expression by the 
addition of 0.25 mM IPTG. Expression took place for 4-6 hours at 25˚C after which cells 
were harvested. UCH-L5 complexes, UCH-L5 complexes UCH-L5/RPN13DEU, UCH-L5/
INO80GDEU, UCH-L5/INO80G
short
 and their mutants were co-expressed.
All purification steps were performed in the cold room or on ice. Cells were lysed by 
sonication in lysis buffer (50 mM Tris-HCl pH 8.0, 200 mM NaCl, 50 mM Imidazole and 
0.5 mM TCEP) in the presence of complete EDTA-free protease inhibitor cocktail (Roche). 
GST-tagged UCH-L5 variants were purified by GST affinity chromatography using GSH 
4B sepharose beads (GE Healthcare) and eluted with 25 mM Tris-HCl pH 8.0, 150 mM 
NaCl, 50 mM GSH
reduced
 pH 8.0, 10% glycerol, 0.5 mM TCEP after first washing beads with 
>10 column volumes (CV) lysis buffer. Excess of DNA was removed by ResourceQ anion 
exchange chromatography (GE Healthcare) using a linear gradient from 0-75% buffer B 
(25 mM Tris-HCl pH 8.0, 1000 mM NaCl, 0.5 mM TCEP). The column was equilibrated with 
Buffer A (25 mM Tris-HCl pH 8.0, 50 mM NaCl, 0.5 mM TCEP).
In case of the UCH-L5 complexes, first nickel affinity chromatography was performed 
using chelating sepharose (GE Healthcare) pre-loaded with Ni2+ to pull down either His-
RPN13DEU, His-INO80GDEU or His-INO80G
short
. Protein was eluted using 25 mM Tris-HCl pH 
8.0, 200 mM NaCl, 250 mM Imidazole pH 8.0, 10%gly and 0.5 mM TCEP before applying 
the resulting eluate to GST affinity chromatography (see above). His tagged RPN13DEU 
alone was purified by nickel affinity chromatography as described above. INO80GDEU or 
its variants were unstable/insoluble and were therefore not purified as single proteins.
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After the initial affinity or anion exchange chromatography steps samples all single 
variants proteins and complexes were desalted against desalting buffer (25 mM Tris-HCl 
pH 8.0, 150 mM NaCl, 10% glycerol, 0.5 mM TCEP) using a 26/10 desalting column (GE 
Healthcare). For GST-fusion proteins, this was followed by o/n cleavage with GST-3C-
protease in the cold room. A GlyProGly tripeptide remained at the protein N-terminus 
after 3C cleavage. GST and GST-3C-protease were removed by reverse purification 
using GSH beads (GE Healtcare). Samples were next concentrated with Amicon Ultra 
15 concentrating columns (Millipore) and injected onto a Superdex S200 or S75 size 
exclusion chromatography column (GE Healthcare) in gel filtration buffer (10 mM HEPES 
pH 7.5, 100 mM NaCl, 0.5 mM TCEP). Positive fractions were concentrated to 3-15 mg/ml, 
aliqotted and flash frozen in liquid nitrogen to be stored at -80˚C. 
Preparation of Ub-Propargyl complexes
Ubiquitin-propargyl (UbPrg) is a suicide inhibitor3,4 that reacts selectively with the DUB 
active site cysteine creating an irreversible quarternary vinyl thioether bond, that serves 
as transition states mimic. UbPrg was synthesized and purified as described3. Typically 10-
40 µM of either UCH-L5/RPN13DEU or UCH-L5/INO80G
short
 was reacted with a 2-fold molar 
excess of UbPrg. The reaction took place in desalting buffer supplemented with 5 mM DTT 
and was allowed to proceed for 3h on ice or o/n. The reaction mixture was subsequently 
fractionated on a Superdex S200 size exclusion chromatography column (GE Healthcare) 
in gel filtration buffer after which the positive fractions were concentrated to ~10 mg/ml 
and used in crystallization trials.
Ub-AMC enzymatic assays
Enzyme activity was followed as release of fluorescent AMC from the quenched Ub-AMC 
substrate, providing a direct read-out of DUB activity5. Ub-AMC was synthesized as described 
previously6. The purified Ub-AMC was dissolved in pure DMSO. The residual amount of 
DMSO left in the enzymatic reaction was never higher than 6%. Kinetic parameters were 
determined using 1 nM of enzyme while varying the substrate concentration in 30µl 
reactions using reaction buffer (25 mM HEPES pH 7.5, 150 mM NaCl, 5 mM DTT and 0.05% 
Tween-20) at 25˚C. Reactions took place in black 384-well non-binding surface low flange 
plates (Corning). In the single concentration experiments, 1 nM of enzyme was allowed 
to react with 1 µM of substrate and activity was quantified by calculating the initial rates. 
Experiments were performed in a Pherastar (BMG Labtechnologies) plate reader using 
350 nm and 450 nm excitation and emission wavelengths respectively. Measurements 
were taken every 10 s for 10 minutes. Fluorescence and velocities were related using an 
AMC standard curve. The initial rates were plotted against substrate concentration and 
fitted to the Michealis-Menten model using non-linear regression in Prism 6. Error bars 
represent the standard deviation. At least 2 different preparations were measured in 
74
Chapter 3 | Supplemental information
3
duplicate per enzyme/complex variant.
equilibrium fP binding assays
Binding assays between UCH-L5 complexes and model substrate Ub-LysGlyTAMRA 7 were 
performed by measuring fluorescence polarization at room temperature. In this substrate 
a TAMRA-labeled Lys-Gly dipeptide is conjugated to ubiquitin via an isopeptide bond. To 
prevent hydrolysis of the substrate in these assays, the active site cysteine of UCH-L5 was 
mutated to alanine (C88A). Assays were carried out using 10 nM model substrate Ub-
LysGlyTAMRA with varying concentrations of UCH-L5 variants at 25˚C in FP binding buffer 
(25 mM HEPES pH 7.5, 150 mM NaCl, 0.05% Tween-20, 1mg/ml BSA, 0.5 mM TCEP). 
Reactions were 10-20 ul volumes and were allowed to equilibrate before measuring FP 
in a Pherastar (BMG Labtechnologies) with an excitation filter of 531 nm, and P and S 
emission filters of 579 nm. Error bars represent the standard deviation.
Stopped-flow fluorescent polarization binding assays
Pre-steady state binding events between UCH-L5 (C88A) complexes and Ub-LysGlyTAMRA 
were monitored in stopped-flow fluorescent polarization experiments. The experiments 
were performed on a TgK Scientific stopped-flow system (model SF-61DX2) equipped 
with a photomultiplier tube R10699 (Hamamatsu). Monochromatic light at 544 nm and 
a 570 nm cutoff filter were used for excitation and readout, respectively. The light was 
polarized using a calcite prism for the incident beam and dichroic sheet polarizers in front 
of each of two photo-multiplier detectors arranged in a T-configuration. 
The experiments were performed in stopped-flow binding buffer (25 mM HEPES pH 7.5, 
150 mM NaCl, 0.05% Tween-20 and 0.5 mM TCEP) at 20˚C. For the association 20 nM 
of Ub-LysGlyTAMRA (final concentration) and various concentrations of UCH-L5 variant 
complexes (C88A mutant) were injected in equal volumes and rapidly mixed after which 
FP signal was followed during 10 s. For each concentration 10 injections were averaged to 
improve signal. Association binding traces were fitted to a one-phase exponential model 
in Prism6 to obtain k
obs
. The k
obs
 values were plotted against protein concentration to 
estimate k
on
, k
off
 and -KD.
Isothermal titration calorimetry
To determine the affinities between UCH-L5 variants and RPN13DEU and UCH-L5 complexes 
to model substrate UbGlySerThr ITC experiments were performed. In UbGlySerThr, 
ubiquitin Gly76 is fused via a peptide bond to the tri peptide GlySerThr. Measurements 
were done in a VP-ITC Microcal calorimeter at 25˚C in binding buffer (25 mM HEPES pH7.5, 
150 mM NaCl, 10% Glycerol and 0.5 mM TCEP). Prior to the experiment both binding 
partners were dialyzed separately in the same container to equilibrate buffers. The syringe 
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contained 450 µM UbGlySerThr while 45 µM of UCH-L5 variant was present in the cell. For 
the UCH-L5/RPN13 binding, 110 µM UCH-L5 was present in the syringe. Ten µl of sample 
was added to the cell per injection. Data were fitted to a one-site binding model with the 
manufacturer’s Origin software. Experiments not showing saturation were not fitted. 
Due to lack of absorbance at 280 nm and weak Coomassie staining, RPN13DEU 
concentrations were difficult to estimate. Therefore a 1:1 stoichiometry of UCH-L5 and 
RPN13DEU was assumed during curve fitting, in line with the crystal structures. In this way, 
the concentration of RPN13DEU in the cell was calculated to be 12.5 µM.
Structure determination 
The complexes were crystallized using the vapor diffusion method in sitting drops. X-Ray 
data collection was done at the European Synchrotron Radiation Facility (ESRF) and 
Swiss Light Source (SLS) at 100K. The images were integrated with XDS8 or iMosflm9 and 
merging/scaling was performed in Aimless10. 
In all cases starting phases were obtained by molecular replacement (MR) in Phaser 
(McCoy et al., 2007). Model refinement was carried out in Phenix12, autoBUSTER13 and 
Refmac14 with TLS. Models were build using COOT 15. Data collection and refinement 
results are presented in table 1.
UCH-L5/RPN13DEU was crystallized at 4˚C in 100 mM Bis-Tris-Propane pH 6.4, 230 mM 
NaBr, 21%PEG 3350. Data was collected at ESRF ID14-4. UCH-L5 (3ihr) was used as a MR 
search model. Initial MR with apo RPN13 failed due to the large conformational changes 
in complexed RPN13DEU. Initial electron density maps showed density for RPN13DEU 
helix α5. After iterative cycles of manual building of RPN13DEU refinement in refmac 
and autoBUSTER, most of the RPN13DEU backbone and side chains could be discerned. 
To confidently build RPN13DEU helices 1 and 2, the UCH-L5~UbPrg/RPN13DEU structure 
that was obtained later at higher resolution was used. Of the 328 residues in full length 
UCH-L5, 7-150, 163-244 and 254-315 were build into density. Of the RPN13DEU construct 
(aa 265-388), residues 287-384 were modeled.
To determine the structure of the UCH-L5~UbPrg/RPN13DEU complex, we crystallized 
the complex at 4˚C in 100 mM Bis-Tris-Propane pH 5.8, 300 mM NaBr, 21%PEG 3350 
and measured diffraction at ESRF ID23-2. MR was performed using the partially build 
UCH-L5/RPN13DEU structure. After obtaining a solution, ubiquitin could be unambiguously 
docked into the difference density. Cycles of building and refinement with Refmac allowed 
completion RPN13DEU model, where residues 287-384 could be modeled (of 265-388). 
UCH-L5 residues, 6-153, 160-245 and 253-320 were build into density. All residues of 
ubiquitin were build. 
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The inhibitory UCH-L5/INO80GDEU was crystallized at room temperature in 100 mM 
Tris pH 9.0, 200 mM LiCl, 17% PEG 8000. Two isomorphous datasets were collected on 
ID23-2 at the ESRF, and PXIII at the SLS, that were merged. Initial phases of the UCH-L5/
INO80GDEU structure were obtained by MR using UCH-L5 (3ihr) as a search model. 
Electron density maps clearly indicated the altered ULD conformation. After refinement 
with Refmac and docking the ULD into the density, more features of INO80GDEU became 
visible. Multiple rounds of manual building and refinement using autoBUSTER, phenix.
den_refinement16 led to complete tracing of the INO80GDEU main chain. The quality of the 
maps around INO80GDEU helix α6 allowed modeling of side chains from halfway helix α5 
up to residue 153. Extensive refinement with phenix.refine and autoBUSTER allowed 
modeling of the FRF-hairpin and modeling of side chains in parts of α2-4. Additionally, 
using phenix feature enhanced maps IN80GDEU Phe49 and Phe50 could be modeled. The 
structure was completed using models that were obtained later of the UCH-L5~UbPrg/
INO80G
short
 complex. In the end residues, 6-147, 160-243 and 254-320 of UCH-L5 were 
build into density. Of the crystallized INO80GDEU construct (aa 39-170), residues 44-153 
were modeled.
The UCH-L5~UbPrg/INO80G
short
 complex was crystallized at 4˚C in 100 mM MIB pH 
5.0, 250 mM ammonium acetate, 25% PEG 3350. Data were collected at ESRF beamline 
ID23-2. The structure was determined 3.7 Å resolution by using the UCH-L5~UbPrg 
structure from UCH-L5~UbPrg/RPN13DEU complex and residues 44-101 of the INO80GDEU 
(discussed above) as MR search models. Four-fold non-crystallographic symmetry (NCS) 
was present and this was exploited using NCS map averaging in COOT to obtain higher 
quality maps. After this procedure several residues in INO80GDEU including anchor residue 
Trp58 could be modeled with confidence. By iteratively model building/refinement and 
switching between the UCH-L5~UbPrg/INO80G
short
 and UCH-L5/INO80GDEU structures, all 
remaining unmodelled side chain could be built in both INO80G structures. NCS restraints 
were employed during refinement as well as high-resolution target restraints. UCH-L5 
and ubiquitin from the 2.3 Å UCH-L5~UbPrg/RPN13DEU structure were used a target in 
autoBUSTER and phenix.refine. 
Structure improvement and validation were performed by PBD_redo and Molprobity17,18.
Structure and sequence alignments
Visual analysis of our UCH-L5 structures indicated that the ULD is the main 
conformationally flexible region. Pairwise structural superpositions of our complexes 
with RAPIDO 19 confirmed this and identified the UCH-L5 catalytic domain (aa 1-226) 
as common invariant region. All subsequent structural alignments of UCH-L5 complexes 
were subsequently performed using aa 1-226 in SSM to allow for multiple structural 
alignments. Structural superpositioning of the DEUBAD domains was performed by SSM, 
77
Mechanism of UCH-L5 activation and inhibition
3
using the pdbeFold webserver20. 
Other multiple sequence alignment were generated using the MAFFT algorithm21. 
Sequence alignment figures were generated with Jalview22.
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ABSTRACT
The deubiquitinating enzyme BAP1 is an important tumor suppressor that has drawn 
attention in the clinic since its loss leads to a variety of cancers. BAP1 is activated by 
ASXL1 to deubiquitinate mono-ubiquitinated H2A at K119 in Polycomb gene repression, 
but the mechanism of this reaction remains poorly defined. Here we show that the BAP1 
C-terminal extension is important for H2A deubiquitinating activity by auto-recruiting 
BAP1 to nucleosomes in a process that does not require the nucleosome acidic patch. This 
initial encounter-like complex is unproductive and needs to be activated by the DEUBAD 
domains of ASXL1, ASXL2 or ASXL3 to increase BAP1’s affinity for mono-ubiquitinated 
H2A, and drive the deubiquitination reaction. The reaction is specific for Polycomb 
modifications of H2A as the complex cannot deubiquitinate the DNA damage-dependent 
ubiquitination at H2A K13/15. Our results contribute to the molecular understanding of 
this important tumor suppressor.
83
H2A deubiquitination by BAP1/ASXL1
4
InTRODUCTIOn
The deubiquitinating enzyme (DUB) BRCA-1 Associated Protein 1 (BAP1) is a critical 
tumor suppressor that has attracted medical interest in the past years since its loss leads 
to a variety of cancers1 including  metastatic cutaneous and uveal melanoma, pleural 
mesothelioma, renal cell carcinoma and bladder tumors2–8. Germ-line loss of BAP1 
leads to a predisposition for cancer and BAP1 tumors are associated with high tumor 
aggressiveness and poor prognosis9. The molecular pathogenesis of disorders associated 
with BAP1 dysfunction is poorly understood which reflects our incomplete understanding 
of BAP1 biology. 
BAP1 has several targets and functions of which many take place in the nucleus. 
It participates in the DNA damage response (DDR), DNA synthesis and cell cycle 
progression10–12. For many of these functions the catalytic activity of the enzyme is required. 
An emerging, but poorly understood role for BAP1 is in transcriptional regulation. Several 
studies indicate that BAP1 associates with transcription related proteins such as FOXK2, 
HCF-1, OGT, LSD2, MBD-6, MBD-5, ASXL1 and ASXL2  to regulate the expression of target 
genes8,13–15. 
One function of BAP1 in transcriptional regulation is its role in Polycomb gene repression. 
A hallmark of Polycomb repression is the monoubiquitination of histone 2A (H2A) at K119 
by the Polycomb Repressive complex-1 (PRC-1) . Paradoxically both the generation and 
removal of this modification are required for gene repression. In Drosophila the removal 
is catalyzed by the Polycomb Repressive DUB complex that consists of BAP1 and the 
Polycomb protein ASX, a protein necessary for the long-term repression of HOX genes16 17. 
In this complex BAP1 is activated by ASX to deubiquitinate H2A16. The complex is highly 
conserved and also deubiquitinates H2A in mammals7,11,14.
Humans possess three homologs of Drosophila ASX, named Additional sexcombs like 1 
(ASXL1), ASXL2 and ASXL3 which are all linked to gene regulation and are often disrupted 
in human cancers18. ASXL1 disruption is especially detrimental, as it is strongly associated 
with acute and chronic myeloid leukemia, chronic myelomonocytic leukemia and other 
cancers18. ASXL1 deregulation is also linked to myelodysplastic syndrome, a disorder that 
conditional BAP1 knock-out mice also develop, and can lead to leukemia8. Additionally, 
ASXL1 is together with ASXL3 implicated in the Böhring-Opitz syndrome, a disorder char-
acterized by malformation of the body and intellectual disability19.
BAP1 is a member of the ubiquitin C-terminal hydrolase family of DUBs, together with 
UCH-L1, UCH-L3 and UCH-L5. These are all cysteine proteases with a conserved catalytic 
UCH domain (CD). Only BAP1 and UCH-L5 share a conserved ULD domain at their C-ter-
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mini. In UCH-L5 the orientation of the ULD domain is important for enzymatic activity20,21. 
The ULD domain in BAP1 is likely structurally related to the UCH-L5 ULD, but BAP1 con-
tains a ~350 aa insert between CD and ULD. This insert does not resemble any known 
conserved domains but is nevertheless important for certain functions such as binding to 
the HCF-1 protein7,13.
While regulation of DUB activity by protein partners is widespread22,23, in the UCH family, 
BAP1 and UCH-L5 are known to be regulated by protein partners. Phylogenetical analysis 
of these protein partners, ASXL1 for BAP1, and RPN13 and INO80G for UCH-L5, indicates 
that they all share a conserved DEUBiquitinase ADaptor (DEUBAD) domain24. While for 
UCH-L5 regulators RPN13 and INO80G the regulatory mechanisms have been described 20,21, it is still unknown whether the putative ASXL1 DEUBAD domain is sufficient to regu-
late BAP1 and if this mechanism is related to the UCH-L5 regulatory mechanism.
Here we analyze the mechanism of H2A deubiquitination by the BAP1/ASXL1 complex. We 
demonstrate that the enzymatic activity is mechanistically similar to the related UCH-L5/
RPN13 complex. The DEUBAD domains of ASXL1, ASXL2 and ASXL3 can activate BAP1 
by increasing its affinity for ubiquitin. This by itself not sufficient for deubiquitination of 
BAP1’s physiological substrate mono-ubiquitinated H2A K119, but also requires the BAP1 
C-terminal extension that auto-recruits BAP1 to nucleosomes. 
ReSULTS
ASX family DeUBAD domains activates BAP1 deubiqitination of H2A K119
The N-terminus of ASXL1 is responsible for BAP1 activation16. This region contains a pre-
dicted HARE-HTH DNA binding domain and DEUBAD domain (Fig. 1a)24,25. We expressed 
and purified constructs of these domains and tested what their contribution was to BAP1 
activation in vitro using the minimal DUB substrate ubiquitin-7-amido-4-methylcoumarin 
(Ub-AMC)26. We found that ASXL1
1-390
 could activate the reaction (Fig. 1b). Within this 
region most of the activity in present in the ASXL1 DEUBAD domain (ASXL1DEU), since a 
construct (238-390), lacking the HARE-HTH domain (ASXL1HH), could activate BAP1 to 
the same extent (Fig. 1b). Enzyme kinetics analysis indicated that the activation effect of 
ASXL1DEU is modest on this artificial substrate, lowering the KM 4-fold while it has a minor 
effect on k
cat
 (Fig. 1c and Supplementary Table 1). 
To investigate BAP1 activity on a relevant substrate, we purified oligonucleosomes and 
mono-ubiquitinated H2A at K119 with the E3 ligase RING1B/BMI1, one of the possible 
catalytic modules for PRC-1 complexes (Supplementary Fig. 1a). Like on Ub-AMC, ASXL1
1-
390
 could activate BAP1 to the same extent as ASXL1DEU (Fig. 1d). The activation effect 
was however more dramatic on H2A compared to Ub-AMC. The ASXL1HH domain hardly 
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affected BAP1 activity on Ub-AMC, but since this construct contains a putative DNA binding 
domain, we tested if it was active on nucleosomal H2A. This was not the case; the ASXL1HH 
construct had no effect on H2A deubiquitination, confirming that the ASXL1-dependent 
activation effect is fully contained in the DEUBAD domain (Fig. 1d). 
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ASXL2 and ASXL3 also contain predicted DEUBAD domains (Supplementary Fig. 1b), with 
more than 60% sequence identity to ASXL1. Proteomics analyses have observed interac-
tion of BAP1 with ASXL2DEU, but not yet with ASXL3DEU. We tested whether the ASXL2 and 
ASXL3 DEUBAD domains could also stimulate H2A deubiquitination by BAP1. This was 
the case for both ASXL2DEU and ASXL3DEU, with kinetics comparable to ASXL1DEU (Fig. 1e). 
These results establish that the DEUBAD domains in all human ASXL paralogs can stimu-
late BAP1 activity.
The BAP1/ASXL1 complex specifically deubiquitinates the Polycomb site
Besides mono-ubiquitination of H2A at K119 in Polycomb repression, H2A is also 
ubiquitinated at the K13/15 site by RNF168 in the early stages of the DNA double 
strand break response27,28. Since K119 and K13/15 reside at distinct locations in the 
nucleosome (Supplementary Fig. 1c) we asked whether BAP1 could also deubiquitinate 
K13/15. We tested this by ubiquitinating oligonucleosomal H2A with full length RNF168 
(Supplementary Fig. 1d) before providing the resulting conjugate as a substrate to the 
BAP1/ASXL1DEU complex. While the activity was low on the K13/15 site, the complex 
robustly deubiquitinated the Polycomb site indicating a strong preference for this site 
over the K13/15 site (Fig. 1f). Since the N-terminal tail of H2A, that contains K13/15 and 
the C-terminal tail that contains K119, differ in sequence the low activity on the K13/15 
site could simply reflect a structural incompatibility between the tail and the active site of 
BAP1. To investigate whether this is the case, we incubated BAP1 and the BAP1/ASXL1DEU 
complex with N and C terminal peptides derived from H2A, ubiquitinated on either the 
K13 or K119, and measured hydrolysis. Peptides were obtained by solid phase peptide 
synthesis followed by chemical ubiquitination using thiolysine mediated ubiquitin 
conjugation29. In both cases, either BAP1 alone or in complex with ASXL1DEU could 
deubiquitinate the substrates. Moreover the enzyme was more efficient in hydrolyzing 
the K13 site on this peptide (Fig. 1g). These data show that the specificity of the BAP1/
ASXL1 complex for the Polycomb site (K119) is not determined by the local  environment 
of the scissile isopeptide bond, but at regions outside the ubiquitinated tail such as the 
nucleosome core.
BAP1 binds ASXL1DeU similar to the UCH-L5/RPn13DeU complex
The BAP1/ASXL1 complex has two closely related counterparts, the UCH-L5/RPN13 and 
UCH-L5/INO80G that are present in the proteasome and in INO80 chromatin remodel-
ing complexes respectively. In these two complexes a DEUBAD domain is present in the 
regulatory proteins, RPN13 and INO80G, that binds to the C-terminal ULD domain of the 
UCH-L5. RPN13DEU binding activates UCH-L5 via a combination of mild allosteric effects 
that increase UCH-L5’s affinity for substrates. First RPN13 positions the active site cross-
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over loop (CL) in an active conformation. The CL is a flexible loop close to the active site 
in UCH enzymes that limits enzymatic activity. RPN13DEU binding furthermore precisely 
anchors the ULD domain to the catalytic domain of UCH-L5 using a highly conserved in-
terface that is also present in BAP1(Fig. 2a, inset). Since the ULD domain is close to the 
ubiquitin binding site, this positioning of the “ULD anchor” lockes the ULD domain in a 
conformation that allows ubiquitin binding. This positioning also creates a small interface 
between ubiquitin and RPN13DEU itself that gives an additional effect on UCH-L5 activa-
tion.
The sequence and functional similarity between the BAP1/ASXL1DEU and UCH-L5/
RPN13DEU complexes prompted us to examine whether the BAP1/ASXL1 complex 
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functions in a similar fashion (Fig. 2a). We first characterized complex formation by 
deleting the predicted ASXL1DEU binding site on BAP1, based on the crystal structure of 
the UCH-L5/RPN13DEU complex (Fig. 2b). As expected this construct, BAP1
1-670
, did not 
interact with ASXL1DEU in isothermal titration calorimetry binding assays (ITC) and also 
not in gel filtration (data not shown). In contrast,  WT BAP1 bound ASXL1DEU with a KD of 
18 nM (Fig. 2c and Supplementary Table 2). These results indicate that BAP1 and UCH-L5 
use the same region in the ULD to bind their activator. The ULD of BAP1 is largely similar 
to UCH-L5 except that it contains an approximately 20 amino acid C-terminal extension 
(CTE) (Fig. 2a). The CTE is not important for ASXL1DEU binding though, since both full 
length BAP and BAP1
1-710
 (construct lacking the CTE) could bind ASXL1DEU with similar 
affinity (Fig. 2c and Supplementary Table 2). 
Even though BAP1 and UCH-L5 use the same region to dock their activator, the ITC analysis 
indicated a notable difference between these complexes. While the UCH-L5/RPN13 
complex is equimolar at 1:1, our ITC analysis suggests that the BAP1/ASXL1 complex is 
asymmetric and consists of two BAP1 molecules bound to one ASXL1DEU molecule. This 
result is in agreement with a previous quantitative mass spectrometry study that also 
suggested a 2:1 stoichiometry for the BAP1/ASXL1 complex in cells15.
ASXL1DeU increases BAP1’s affinity for ubiquitin
ASXL1DEU stimulates BAP1 by lowering the KM on Ub-AMC (Supplementary Table 1). 
Therefore we tested whether ASXL1DEU can activate BAP1 by increasing its affinity for 
ubiquitin. To this end, we analyzed the rate of Ub-AMC hydrolysis by BAP1 or the BAP1/
ASXL1DEU complex, in the presence of increasing concentrations of a novel non hydrolysable 
H2A-peptide ubiquitin conjugate. The conjugate was obtained using an azido-alkyne click 
reaction between Ub-75-propargyl (Ub-75-Prg) and azido ornithine followed by thorough 
purification to remove any traces of Ub-75-Prg which is a covalent DUB inhibitor30. The 
resulting conjugate mimics substrates31 (Fig. 3a) and will therefore compete with Ub-
AMC for binding to BAP1 leading to inhibition of Ub-AMC hydrolysis. While the conjugate 
inhibited BAP1 with an IC
50
 of approximately 45 µM, the IC
50
 of the BAP1/ASXL1DEU 
complex was more than 10 fold lower indicating that ASXL1DEU induces a higher affinity 
of BAP1 to the conjugate (Fig. 3a and Supplementary Table 3). The H2A corresponding 
peptide without a conjugated ubiquitin molecule did not inhibit Ub-AMC hydrolysis at all, 
and ubiquitin alone had only a minor inhibitory effect on the rate of the BAP1/ASXL1DEU 
complex (Supplementary Figs. 2a and 2b). The fact that an ubiquitin-conjugate can inhibit 
BAP1 to a greater extent than ubiquitin alone, illustrates how this DUB prefers binding its 
target (ubiquitin-conjugate) over its product (ubiquitin alone).
To validate this result in a more relevant setting we performed band shift assays with 
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Figure 3 | ASXL1DEU activates BAP1 by increasing its affinity for ubiquitin. A) BAP1 is inhibited more readily 
by the non-hydrolyzable ubiquitin conjugate in the presence of ASXL1DEU. Inset: Schematic of the non-
hydrolyzable H2A ubiquitin conjugate. Error bars, SD (n=2 independent experiments). B) In the presence 
of ASXL1DEU, BAP1 has a higher affinity for monoubiquitinated NCPs than BAP1 alone in band shift assays 
(2-fold dilutions starting from 15 µM). C) Using stopped-flow fluorescence polarization binding assays we 
confirmed that the BAP1/ASXL1DEU complex (top) binds better to monoubiquitinated nucleosomes than BAP1 
alone (bottom). D) BAP1 and BAP1/ASXL1DEU bind unmodified NCPs with similar affinities in band shift assays 
(2-fold dilutions starting from 15 µM). E) The BAP1 ULD anchor mutant (D663A/R667A, DR) is less active in 
H2A deubiquitination. F) BAP1
DR
/ASXL1DEU complex has a 3-fold weaker KM than the WT complex (see also 
Table S1). Error bars, SD (n=3 independent experiments). G) ASXL1
NEF
DEU  (N310A/E311K/F312A, NEF) binds 
BAP1with similar affinity as WT ASXL1DEU in ITC. H and I) ASXL1
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reconstituted recombinant nucleosome core particles (NCPs), modified with N-terminally 
TAMRA labeled ubiquitin (TAMRAUb-NCP) using the E3 ligase RING1B/BMI1 (Supplementary 
Fig. 2c). In these assays the BAP1/ASXL1DEU complex shifted TAMRAUb-NCP more readily 
compared to BAP1 alone as indicated by the high molecular weight bands appearing 
already at low concentrations (Fig. 3b). This effect is mainly mediated through BAP1 
since ASXL1DEU alone did not bind TAMRAUb-NCP (Supplementary Fig. 2d). We could confirm 
our result in a stopped-flow fluorescence polarization binding assay where the BAP1/
ASXL1DEU complex could bind to TAMRAUb-NCP (KD= 4µM)  better than BAP1 alone of which 
we could not quantify the affinity constant (Figs. 3c and Supplementary 2e).  Surprisingly, 
when we tested binding to unmodified nucleosomes,  BAP1 and the complex could shift 
the NCPs equally well (Fig. 3d). Thus ASXL1DEU specifically promotes the binding of the 
conjugated ubiquitin and not the nucleosome by itself.
As the region of BAP1 equivalent to the ULD anchor in UCH-L5 (see earlier) is highly con-
served (Fig. 2a) we assessed whether it contributes to BAP1 activation. To test this we in-
cubated an ULD anchor mutant of BAP1 (D663A/R667A referred to as DR) and WT com-
plex with mono-ubiquitinated H2A and Ub-AMC. The ULD anchor mutant complex BAP1
DR
 
/ASXL1DEU was indeed slightly impaired in H2A deubiquitination and had a weaker KM 
than the WT complex in Ub-AMC hydrolysis (Figs. 3e and 3f and Supplementary Table 
1). Using the non-hydrolyzable ubiquitin-H2A conjugate (Fig. 3a), we found that the mu-
tant complex had a weaker IC
50
 for the conjugate than the WT complex in Ub-AMC assays 
(Supplementary Fig. 2f and Supplementary Table 3). This suggests that like the UCH-L5/
RPN13DEU complex, ASXL1DEU stabilizes the BAP1 ULD domain by anchoring it to the CD 
allowing more efficient substrate binding.
We next focused our attention on ASXL1DEU. After analysis of a multiple sequence align-
ment of the ASX family we noticed a highly conserved “NEF” region that suggests it is 
important for ASXL1DEU function (Supplementary Fig. 2g).  To test this hypothesis we gen-
erated a triple mutant containing N310A, E311K and F312A (referred to as ASXL1
NEF
DEU). 
We first validated that ASXL1
NEF
DEU was not impaired in BAP1 binding using ITC (KD= 45 
nM) (Fig. 3g and Supplementary table 2). Then we tested activity against mono-ubiquiti-
nated nucleosomes and found that this mutant was impaired in activating BAP1 compared 
to WT ASXL1DEU (Fig. 3h). We quantified the activation effect using Ub-AMC as a substrate 
and noted a 3-fold weaker KM but surprisingly also a 3-fold lower kcat compared to WT (Fig. 
3i and Supplementary Table 1) conforming that this region of the protein affects BAP1 
activation.
as WT ASXL1DEU using mono-ubiquitinated H2A or Ub-AMC as a substrate. Error bars, SD (n=3 independent 
experiments). J) Surface representation of DEUBAD domains of RPN13 (left) and INO80G (right) indicate high 
conservation of a region(dotted circle) between helix 4 and 5 (middle: RPN13 green, INO80G orange). 
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To rationalize the effect of the ASXL1DEU  “NEF” mutant, we examined the crystal structure 
of the UCH-L5/RPN13DEU complex bound to ubiquitin20,21. In the structure, the RPN13 
region equivalent to the “NEF” region stabilizes ubiquitin and thereby contributes to 
activation of UCH-L5 (Supplementary Fig. 2h). Thus it seems likely that ASXL1DEU also uses 
this ubiquitin interface to stabilize ubiquitin binding of BAP1 and stimulate activity.
This region in DEUBAD domains in general seems to be important for their function. 
Analysis of the surface conservation in this region of the DEUBAD domains of UCH-L5 
activator RPN13 or inhibitor INO80G, reveals that it is highly conserved within the 
RPN13 and INO80G proteins (Fig. 3j), but not between these two proteins. In contrast 
to RPN13DEU, which facilitates ubiquitin binding, residues in this conserved region in 
INO80G block ubiquitin binding20,21. The fact that in all DEUBAD domains, this region is 
highly conserved and of functional importance, points out that it is a critical site for BAP1/
UCH-L5 regulation.
In summary, we have shown that ASXL1DEU activates BAP1 by increasing the affinity for 
ubiquitin through a combination of mild effects including stabilization of the BAP1 ULD 
anchor. On the ASXL1DEU side, the highly conserved “NEF” region contributes to the activa-
tion likely by stabilizing ubiquitin as in the UCH-L5/RPN13DEU complex. 
The BAP1 C-terminus is required for H2A deubiquitination activity
BAP1 is frequently mutated in a various tumor types. A subset of mutations in BAP1 result 
in frame-shifts that lead to premature stop-codons. In some cases, the catalytic domain 
is still intact suggesting that regions outside this domain are important for proper BAP1 
functioning. Therefore we assessed the effect of H2A deubiquitination activity of BAP1 
variants truncated at different points: BAP1
1-235
 consisting of only the catalytic domain, 
BAP1
1-670
 ,which has a disrupted ULD domain and BAP1
1-710
, that lacks the C-terminal 
extension (CTE) of BAP1. While the WT BAP1/ASXL1DEU complex was active in H2A 
deubiquitination, BAP1
1-235
 and BAP1
1-670
 had low activity towards H2A irrespective of the 
presence of ASXL1DEU (Fig. 4a). This is in accordance with the our binding data (Fig. 2c) 
that indicates that these constructs lack the ASXL1DEU docking site. Surprisingly, BAP1
1-710
 
that only lacks the CTE compared to WT and still binds ASXL1DEU similar to WT, had a low 
activity despite the presence of ASXL1DEU (Fig. 4a). These results suggested that the BAP1 
CTE is important for activity.
To exclude that the intrinsic catalytic activity was affected by the truncation mutants we 
tested their activity on the minimal substrate Ub-AMC. In contrast to the nucleosomal 
substrate, we found that all BAP1 variants were active on Ub-AMC, with BAP1
1-235
 and 
BAP1
1-670
 being even slightly more active than WT demonstrating that the intrinsic 
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activity was not compromised (Fig. 4b). On this model substrate, WT BAP1 and BAP1
1-710
 
were equally active in absence of ASXL1DEU , and could be activated to the same extent in 
presence of ASXL1DEU (Figs. 4b and 4c and Supplementary table 1). Apparently the CTE 
does not affect ASXL-dependent activity, but instead it has a substrate-specific role. The 
tail does not interfere with the intrinsic ability of BAP1 to be activated on the Ub-AMC 
substrate but is important for activity on the oligonucleosomal H2A substrate.
The BAP1 C-terminus auto-recruits BAP1 to nucleosomes
After establishing that the CTE is important on BAP1’s natural substrate H2A we sought to 
determine the basis of this requirement. The nucleosomal substrate can be considered to 
consist of two functional parts; the globular core containing the DNA wrapped around the 
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Figure 4 | The BAP1 C-terminal extension is required for H2A deubiquitination. A) Only WT BAP1 can be 
activated for H2A deubiquitination in oligonucleosomes (time points: 0, 1, 5, 25 min). B) All BAP1 variants 
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histone octamer, and the ubiquitinated H2A tail protruding from this core (Fig. 5a). We in-
terrogated the role of the BAP1 CTE by decomposing the nucleosomal substrate and only 
using a synthetic ubiquitinated H2A tail at K119 as a substrate. On this reduced substrate, 
both WT and BAP1
1-710
/ASXL1DEU complexes were equally active indicating (Fig. 5b) that 
the BAP1 CTE is not important at this region of the substrate.
To study how the CTE confers activity on the nucleosomal substrate core (Fig. 5a) we 
studied a multiple sequence alignment of this region. It contains a nuclear localization 
sequence32, is conserved across species and highly cationic (Fig. 5c). The presence of these 
conserved positive charges suggest they may participate in electrostatic interactions with 
the regions of the nucleosome core that tether BAP1 to the substrate. In this hypothesis, 
co-incubation of BAP1 with a peptide derived from the CTE would compete with the 
BAP1/ASXL1DEU complex for nucleosome binding leading to decreased DUB activity. We 
tested this hypothesis, by incubating WT BAP1/ASXL1DEU and BAP1
1-710
/ASXL1DEU with 
increasing concentrations of a synthetic peptide of the CTE. In absence of peptide, the 
WT BAP1/ASXL1DEU complex, deubiquitinated H2A robustly as observed before (Fig. 
5d). But indeed, in the presence of increasing concentrations of the peptide DUB activity 
was inhibited for the WT complex (Fig. 5d). The synthetic peptide did not inhibit the 
intrinsic DUB activity on Ub-AMC demonstrating that the observed effect is specific for 
nucleosomes (Fig. S3a). Interestingly, a scrambled peptide of the CTE also inhibited H2A 
deubiquitination, suggesting that not the actual sequence but most likely the charge 
composition is important for the inhibition (Supplementary Fig. 3b). 
We then asked if charges on the nucleosome were required for the interaction. An increas-
ing number of chromatin associated proteins are reported to require the acidic patch on 
nucleosomes for binding or proper functioning33–35. This acidic patch is formed at the in-
terface between the H2A/H2B dimer and is prominently solvent exposed. Since the BAP1 
CTE is positively charged at physiological pH, we wondered whether it uses the acidic 
patch to electrostatically recruit itself to nucleosomes in band shift assays. We found how-
ever, that BAP1 does not require the acidic patch for binding since it shifted WT NCPs and 
the acidic patch mutant of the NCPs (NCP-EA) in a similar fashion (Fig. 5e). This indicates 
that BAP1 binds to nucleosomes in a way that is distinct from other nucleosome binding 
proteins.
We then tested if the CTE was important for BAP1 recruitment to the nucleosome in a 
direct binding assay. In band shift assays, BAP1/ASXL1DEU could shift the NCPs whereas 
BAP1
1-710
/ASXL1DEU complex was less capable of shifting the NCPs indicating again that 
the C-terminus is important for binding to nucleosomes (Fig. 5f). In short, these results 
are consistent with a model that the BAP1/ASXL1DEU complex has two main binding com-
ponents. The BAP1 CTE is required for binding to the NCP core, and presence of ASXL1DEU 
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increases BAP1’s affinity for the ubiquitin moiety at the protruding H2A tail. 
DISCUSSIOn
BAP1 is a critical tumor suppressor that is frequently mutated in human cancer. In 
this paper we describe that similar to the homologous UCH-L5/RPN13DEU complex, the 
DEUBAD domains of ASXL1, ASXL2 and ASXL3 can activate BAP1 by increasing BAP1’s 
affinity for ubiquitin through a combination of mild effects. We observed that activation by 
ASXL proteins is not sufficient for deubiquitination of BAP1’s natural substrate H2A. This 
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Figure 5 | The BAP1 C-terminal extension auto-recruits BAP1 to nucleosomes. A) The nucleosomal H2A 
substrate can be decomposed into two functional parts. B) While the BAP11-710/ASXL1
DEU complex is inactive on 
oligonucleosomes, it is as active as the WT complex on a minimal H2A substrate (time points: 5, 15, 30 min). 
C) The BAP1 tail is highly positively charged. D) A synthetic peptide of the BAP1 C-terminus inhibits activity 
of BAP1/ASXL1DEU on oligonucleo-somes (time points: 0, 1, 5, 25 min). E) BAP1 does not require the H2A/H2B 
acidic patch to bind the nucleosome (2-fold dilutions starting from 15 µM). F) BAP1 that lacks its C-terminal 
tail is impaired in binding NCPs in band shift assays (1, 5, 10 µM of BAP1 variant).
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requires the BAP1 C-terminal extension that binds to nucleosomes. 
We propose a model where H2A deubiquitination by the BAP1/ASXL1DEU complex consists 
of two key processes. The BAP1 CTE tethers BAP1 to the nucleosome core. This initial 
encounter-like complex is however unproductive due to BAP1’s low affinity for the mono-
ubiquitinated H2A tail in absence of an activator. In a second key process ASXL1DEU can 
convert this complex into a productive one by increasing BAP1’s affinity for ubiquitin (Fig. 
6). 
The mechanism by which ASXL1DEU increases BAP1’s affinity for ubiquitin is related to 
that of the UCH-L5/RPN13DEU complex of which crystal structures were reported recent-
ly20,21. RPN13DEU activates UCH-L5 by decreasing the mobility of the ULD domain, a domain 
close to the ubiquitin binding site. By fixating it to the UCH-L5 CD via the ULD anchor, 
RPN13DEU exposes the ubiquitin docking site on UCH-L5 thereby increasing the affinity for 
ubiquitin. RPN13DEU also mildly contributes to UCH-L5 activation by directly contacting 
ubiquitin, and by positioning the active-site cross over loop (CL). The CL is a flexible loop 
close to the active site in UCH enzymes that limits enzymatic activity. Individually these 
effects are mild but combined they provide substantial regulation. 
For BAP1 we observe similar effects. The ULD anchor has a mild effect on affinity, and the 
region on ASXL1DEU that is equivalent to the region of RPN13DEU that contacts ubiquitin 
also affects BAP1 activity. The effect of the latter is however stronger in ASXL1DEU than in 
RPN13DEU. This highlights that although the regulatory regions are similar in the UCH-L5/
RPN13DEU or BAP1/ASXL1DEU complex, their relative individual contribution to activation 
may be different. The lack of conservation between the UCH-L5 and BAP1 CLs made it 
difficult to assess whether ASXL1DEU  also positions the BAP1 CL towards an active con-
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Figure 6 | Model for H2A deubiquitination by the BAP1/ASXL1 complex. BAP1 (blue) binds nucleosomes 
monoubiquitinated at K119 using its C-terminal extension (red). This complex has low DUB activity due to 
BAP1’s low affinity for ubiquitin (orange). Binding of the DEUBAD domain of ASXL1 (purple) allosterically 
activates BAP1 by increasing its affinity for the ubiquitin moiety, driving the DUB reaction.
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formation. Therefore we omitted this aspect from our analysis but we do not exclude that 
this may occur. 
Our data suggest that the BAP1 CTE is an important component for nucleosome binding. 
Even though BAP1 is recruited to nucleosomes by various proteins in cells, it is possible 
that BAP1’s relative orientation towards H2A-Ub in these complexes is suboptimal for 
substrate binding and catalysis. This could be the reason why the BAP1 CTE is required. In 
addition to the function ascribed to the BAP1 CTE in this study, others have shown that it 
also hosts a nuclear localization signal that can be ubiquitinated by UBE2O to mislocalize 
BAP1 to the cytoplasm 32,36 underscoring the importance of this small region of BAP1. The 
multiple functions of the CTE also make analysis of its importance in cells difficult.
While ASXL1 and ASXL2 are known to interact with BAP1, ASXL3 was not. Our in vitro 
analysis indicates that also ASXL3 can bind and activate BAP1, which is not surprising in 
the light of the high sequence similarity between the DEUBAD domains in the ASXL family. 
It suggests that there may be a functional association between BAP1 and ASXL3 in cells 
and further cell based work is required to shed more light on this issue.
We found that in a nucleosomal context, the BAP1/ASXLDEU complex is specific for H2A 
mono-ubiquitinated at the Polycomb site K119 and not on the DNA damage site K13/15. 
BAP1 has been suggested to play a role in DNA repair but its exact role is unclear. Our re-
sults indicate that it is unlikely that the BAP1/ASXL1 complex regulates the DNA damage 
response by deubiquitinating H2A at K13/15. The specificity for the Polycomb site may be 
governed by interfaces of the complex with the nucleosome. Therefore we also assessed 
whether BAP1 can bind the acidic patch on the nucleosome and found that the complex 
does not rely on this site for binding unlike other nucleosome binding proteins. 
An unexpected finding was the stoichiometry of the BAP1/ASXL1 complex where one 
molecule of ASXL1 is present for two BAP1 molecules. DUB dimers are not unusual. The 
JAMM proteins RPN11 and BRCC36 both require hetero-dimerization with RPN8 and 
Abro1 or Abraxas respectively, but in these cases only the first protomer is active. It may 
also be possible that only one subunit is active in the BAP1/ASXL1 complex. It is conceivable 
that the BAP1 dimerization is a manifestation of selective pressures on BAP1 to be part 
of multi-protein complexes where one monomer functions as an assembly platform for 
other proteins. Future studies will be necessary to further examine the possible functional 
implications of the BAP1/ASXL1 stoichiometry.
BAP1 associates with many factors to form multi-protein complexes. One of the main 
outstanding questions is whether multiple mutually exclusive BAP1 complexes exist and 
whether BAP1 catalytic activity is required in all of these complexes. Perhaps BAP1 can 
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also serve as a scaffold in some of these complexes to recruit other chromatin modifiers. 
An important step in understanding the carcinogenesis in BAP1 deficiency will therefore 
rely on a thorough understanding of the different BAP1 complexes and the effects on 
BAP1 activity. Our comprehensive biochemical analysis of binding interfaces, activation 
mechanism and recruitment factors of the BAP1/ASXL1 complex provides a framework 
for future work on the possible role of  these larger BAP1 complexes in tumorigenesis.
MATeRIALS & MeTHODS
Protein expression and purification
His-tagged full length BAP1, BAP1
1-710
 BAP1
1-670
 and their mutants were expressed in sf21 
insect cells using the Bac-to-Bac baculovirus expression system (Invitrogen) and purified 
by nickel affinity, anion exchange and size exclusion chromatography. Full length RNF168 
was prepared as described previously27.His-ASXL1DEU (aa 238-390), GST-ASXL1
1-94
, His-
ASXL1
1-390
, His-ASXL2DEU (aa 261-380), His-ASXL3DEU (aa 188-304) and HisSUMO-BAP1
1-235
 
were expressed in E.coli. These proteins were purified using nickel and/or GST affinity 
chromatography, followed by ion exchange chromatography and/or size exclusion chro-
matography. Nucleosome core particles were prepared as described previously using ei-
ther the 147 or 167 bp widom601 DNA positioning sequence37–39.
Oligonucleosome DUB assays
Oligonucleosomes were purified from HEK 293T cells as described previously40 and 
mono-ubiquitinated at Lys119 in a reaction mixture that also contained 500 nM Uba1, 2 
µM UbcH5c, 2 µM RING1B/BMI1 and 7.5 µM Ubiquitin. For ubiquitination of H2A K13/15, 
1 µM of full length RNF168 was used. The reaction took place for 1 hour in reaction buffer 
(25 mM HEPES pH 7.5, 150 mM NaCl, 2 µM ZnCl2, 5 mM DTT, 5 mM ATP and 3 mM MgCl2) 
at 30˚C. Reactions were terminated by depleting ATP using Apyrase (Sigma-aldrich). The 
DUB reaction was performed by addition of 50-100 nM BAP1 variant or BAP1/ASXL1DEU 
variant at 30˚C. Prior to the reaction the BAP1/ASXL1 complexes were allowed to form 
on ice for 10-30 minutes. Reaction were terminated by the addition of SDS-PAGE protein 
loading buffer and analyzed by Western blotting using anti-H2A (07-146,  Millipore).
Reconstitution of nucleosome core particles
Recombinant nucleosome core particles were prepared as described previously33. Xeno-
pus histones and 167 bp widom 601 strong positioning sequence were used to reconsti-
tute the core particles.
Ub-AMC enzymatic assays
Enzyme activity was followed as release of fluorescent AMC from the quenched Ub-AMC 
substrate, providing a direct read-out of DUB activity. Michealis-Menten parameters were 
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determined using 1 nM of enzyme either with or without 1 µM of ASXL1 variant while 
varying the substrate concentration. Complexes were allowed to form for 30 minute on ice 
prior to the reaction. Initial rates were plotted against substrate concentration and fitted 
to the Michealis-Menten model using non-linear regression in Prism 6. In single concen-
tration experiments, 1 nM of enzyme was allowed to react with 1 µM of substrate. Activity 
was quantified by calculating the initial rates. For the inhibition assays 500 pM enzyme 
and 2 µM of Ub-AMC was used while titration the non-hydrolyzable ubiquitinated H2A 
peptide staring from 200 µM with 2-fold dilutions. IC50 values were obtained by fitting 
the data to the “log inhibitor vs normalized response” model in Prism6.
Synthesis non-hydrolyzable H2A-ubiquitin conjugate
For the synthesis of non-hydrolyzable H2A-ubiquitin conjugates, an H2A peptide was 
prepared with the target lysine mutated to azidonorvaline. This peptide was subsequently 
coupled to a modified form of ubiqutin which has its C-terminal glycine mutated to 
propargylamine (Ub-Prg)30. Both polypeptides were obtain through linear full-length 
synthesis29. Ub-Prg was coupled to the azide-functionalized peptide under 8M urea 
denaturing conditions using a Cu(I)-catalyzed alkyne-azide cycloaddition (CuAAC, click 
reaction) to afford a non-hydrolysable triazole linked peptide-ubiquitin conjugate. This 
conjugate was purified using C18 reverse phase HPLC and gelfiltration.
H2A-peptide conjugate hydrolysis assay
Native H2A-peptide ubiquitin conjugates were chemically synthesized as described previ-
ously29,41. Twenty µM of conjugate was incubate with 100 nM of enzyme or enzyme com-
plex in reaction buffer (25 mM HEPES pH 7.5, 150 mM NaCl and 5 mM DTT and incubated 
at 30 degrees Celsius. Reactions were terminated by the addition of protein loading buffer 
and analyzed by SDS-PAGE.
Band-shift assays
Band-shift assays were performed using native gel electrophoresis on 4–12% Pre-Cast 
Tris-Glycine gels (Life Technologies), pre-run for at least 1 h at 125 V in Novex Tris-Gly-
cine buffer at 4 degrees Celsius. NCPs or monoubiquitinated NCPs (both 100 nM) were 
incubated with increasing amounts of BAP1 or ASXL1 variant or BAP1/ASXL1 variant and 
the gel was run for 90 min at 125 V at 4 dregrees Celsius. BAP1/ASXL1 complexes were 
allowed to form for 10-30 minutes on ice prior to electrophoresis. Bands were visualized 
by DNA staining with GelRed or uing the TAMRA signal in a ChemiDoc XRS instrument 
(Biorad).
Isothermal Titration Calorimetry
ITC experiments were performed in a VP-ITC Microcal calorimeter at 25˚C. All proteins 
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were dialyzed to ITC buffer  (25 mM HEPES pH7.5,  150 mM NaCl, 10% glycerol, 0.5 mM 
TCEP) prior to the experiment. Using 10 or 5 ul injections, 30 µM ASXL1DEU was titrated 
into 13 µM of BAP1 variant. Data were fitted to a one-site binding model using the manu-
facturer’s Origin software.
Stopped-flow fluorescent polarization binding assay
Pre-steady state binding events between BAP1 (C91A) or BAP1(C91A)/ASXL1DEU and 
NCPs monoubiquitinated with TAMRAUb (TAMRAUb-NCPs) were monitored in stopped-flow 
fluorescent polarization experiments. Varying concentrations of BAP1 or complex were 
injected together 20 nM (final concentration) TAMRAUb-NCPs after which fluorescent po-
larization was followed during 10 s. Association binding traces were fitted to a one-phase 
association model in Prism6 to obtain k
obs
. The k
obs
 values were plotted against protein 
concentration to estimate k
on
, k
off
 and KD. 
Supplemental information
Detailed methods, supplementary figures and tables can be found in the supplementary 
information section.
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Figure S1 | ASXL DEUBAD domains stimulate H2A K119 deubiquitination by BAP1. A) Monoubiquitina-
tion of H2A K118/119 by full length Ring1b/Bmi1. B) Multiple sequence alignment of the DEUBAD domains in 
ASXL1, ASXL2 and ASXL3. The sequence identity among the family members is >60%. C) The Polycomb (green 
spheres) and DNA damage (yellow spheres) ubiquitination sites on H2A (blue) are situated at distinct location 
in the nucleosome core particle (H2A in blue).  D) Ubiquitination of lysine 13 and 15 by full length RNF168 
(time points: 0, 15, 30, 45, 60, 90 min). Time point 0 was not adjacent to other time points on gel.
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Figure S2 | Activation mechanism ASXL1DEU. A) Ubiquitin alone does not inhibit BAP1 and mildly inhibits 
BAP1/ASXL1DEU (blue). B) The C-terminal H2A peptide cannot inhibit BAP1 (black) nor the complex (blue). 
C) Monoubiquitination of H2A in nucleosome core particles with TAMRAUb by full length RING1B/BMI1. D)
ASXL1DEU cannot shift TAMRAUb-NCPs (concentration series is 2-fold dilution starting from 15 micromolar). 
E) Residuals and linear plot for binding of BAP1/ASXL1DEU to TAMRAUb-NCPs in stopped-flow fluorescent po-
larization binding assays gives an approximate Kd of 4 micromolar. BAP1 alone data could not be fitted. F) 
BAP1DR/ASXL1DEU (black) has a higher IC50 than the WT complex (blue) when inhibited by a non-hydrolyzable 
H2A-ubiquitin conjugate in Ub-AMC assays. G) The DEUBAD domains in the ASXL family are highly conserved 
around the “NEF” region. H) In the structure of UCH-L5 (blue) in complex with RPN13DEU (green) and ubiquitin 
(yellow), the region equivalent to the ASXL1DEU “NEF”  region in RPN13DEU(residues in boxes) contact ubiquitin.
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Figure S3 | A BAP1 CTE derived peptide does not inhibit intrinsic catalysis. A) The intrinsic enzymatic 
activities of full length BAP1 (orange) and BAP11-710 (blue) are not affected by various concentrations of the 
BAP1 C-terminal peptide in an Ub-AMC assay. Dotted lines represent the rate in absence of peptide. B) A 
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15, 22.5, 30min). Concentration peptides was 100 µM.
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SUPPLeMenTAL TABLeS
Table 1 | Ub-AMC Enzyme kinetics parameters
kcat (s
-1)     KM (µM)       kcat/ KM  
(M-1s-1) *1e-5
BAP1 2,5 ± 0,2 5,9 ± 1,1 4,2
BAP1/ASXL1DEU 1,8 ± 0,1 1,3 ± 0,2 13,9
BAP11-710 1,6 ± 0,1 3,1 ± 0,6 5,2
BAP11-710/ASXL1
DEU 1,6 ± 0,1 0,5 ± 0,1 32
BAP1/ASXL1NEF
DEU 0,6 ± 0,03 3,9 ± 0,4 1,5
BAP1DR/ ASXL1
DEU 4,6 ± 0,3 2,9 ± 0,4 16
Table 2 | ITC parameters binding experiments
 Cell Syringe KD (nM) ΔH  
(kcal/mol)
TΔS  
(kcal/mol)
N
BAP1 ASXL1DEU 18 -49 -38 0.37
BAP11-710 ASXL1
DEU 5 -51 -40 0.27
BAP11-670 ASXL1
DEU n/a n/a n/a n/a
BAP1 ASXL1NEF
DEU 46 -44 -34 0.32
Table 3 | IC50 values for inhibition assays 
 IC50 (µM)
BAP1 45 ± 0,1
BAP1/ASXL1DEU 3,3 ± 0,02
BAP1DR/ASXL1
DEU 52 ± 0,1
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SUPPLeMenTAL eXPeRIMenTAL PROCeDUReS
Plasmids and cloning
Full length cDNA’s for BAP1 (uniprot Q92560), ASXL1 (uniprot Q8IXJ9) and ASXL2 
(uniprot Q76L83) were kindly provided by Dr. Jürg Müller. cDNA for the ASXL3 DEUBAD 
domain (uniprot Q9C0F0) was purchased as a codon optimized gBlock (Integrated DNA 
Technologies). All constructs were cloned into expression vectors of the NKI Ligation 
Independent Cloning Suite 1. Full length BAP1, BAP1
1-710
 and BAP1
1-670
 were cloned 
into pFastBac-NKI-his-3C-LIC vector; BAP1
1-235
 into pET-NKI-strepII-3C-LIC; ASXL1DEU, 
ASXL2DEU, ASXL3DEU and ASXL1
1-390
 into pET-NKI-his-3C-LIC (carbenicilin); and finally 
ASXL1HH into pGEX-NKI-3C-LIC. All clones were verified by DNA sequencing.
Protein expression and purification
Full length BAP1, BAP1
1-710
, BAP1
1-670
, full length Ring1b/Bmi1 and their variants were 
expressed as His-tagged fusion constructs in Sf9 cells for 48-72 hours at 27˚C, where-
as His-ASXL1DEU (aa 238-390), His-ASXL2DEU (aa 261-380), His-ASXL3DEU (aa 188-304), 
His-ASXL1
1-390
, GST-ASXL1HH (1-94), StepII-BAP1
1-235
 and their variants were expressed in 
Escherichia coli. For bacterial expression, cell were grown to an OD of 0.6 at 37˚C before 
inducing expression with 0.5 mM IPTG at 25˚C for 4-6 hours. All cells were lysed by either 
bead beating or sonication using lysis buffer (50 mM Tris pH 8.0, 200 mM NaCl, 50 mM 
Imidazole pH 8.0, 0.5 mM TCEP) supplemented with complete EDTA-free protease inhib-
itor cocktail (Roche).
For the insect cell expressed constructs, cleared lysates were incubated with chelating 
sepharose beads (GE Healthcare) pre-charged with Ni2+. After washing with >15 column 
volume (CV) lysis buffer and elution with elution buffer (20 mM Tris pH 8.0, 150 mM NaCl, 
500 mM Imidazole pH 8.0, 10% Glycerol and 0.5 mM TCEP), the sample was purified in 
anion exchange chromatography using Poros HQ resin (Applied Biosystems). A linear salt 
gradient from 0-75% buffer B (20 mM Tris pH 8.0, 1 M NaCl, 5% Glycerol, 0.5 mM TCEP) 
was used to elute the protein from the column that was previously equilibrated in buffer 
A (20 mM Tris pH 8.0, 50 mM NaCl, 5% Glycerol, 0.5 mM TCEP). As a final step, the sample 
was fractionated on a Superose6 (GE Healthcare) size exclusion chromatography (SEC) 
column for full length BAP1 and  BAP1
1-710 
or on a Superdex 200 SEC column for BAP1
1-670
 
in gel filtration buffer (10 mM HEPES pH 7.5, 150 mM NaCl, 10% Glycerol and 0.5 mM 
TCEP).
The BAP1 catalytic domain was purified using StrepTactin beads (GE Healthcare). After 
washing the beads with <10CV lysis buffer, protein was eluted with Strep elution buffer 
(20 mM Tris pH 8.0, 150 mM NaCl, 10% Glycerol, 2.5 mM Desthiobiotin and 0.5 mM TCEP. 
This was followed by a final SEC step using a Superdex 75 (GE Healthcare) equilibrated in 
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gel filtration buffer.
Cleared lysates of ASXL constructs were purified using His-tag affinity chromatography 
using chelating sepharose beads (GE Healthcare) pre-charged with Ni2+. After washing 
with >10 column volume (CV) lysis buffer and elution with elution buffer (20 mM Tris 
pH 8.0, 100 mM NaCl, 500 mM Imidazole pH 8.0, 10% Glycerol and 0.5 mM TCEP), the 
sample was purified in anion exchange chromatography using Poros HQ resin (Applied 
Biosystems) for the DEUBAD domains. A linear salt gradient from 0-75% buffer B (20 
mM Tris pH 8.0, 1 M NaCl, 5% Glycerol, 0.5 mM TCEP) was used to elute the protein from 
the column that was previously equilibrated in buffer A (20 mM Tris pH 8.0, 50 mM NaCl, 
5% Glycerol, 0.5 mM TCEP). For the ASXL1HH and ASXL1
1-390
 constructs, a cation exchange 
step using a Poros HS (Applied Biosystems) was introduced instead of the anion exchange 
step. Here, a linear salt gradient from 0-75% buffer B (20 mM Bis-Tris pH 6.5, 1 M NaCl, 
5% Glycerol, 0.5 mM TCEP) was employed to elute the protein from the column that was 
previously equilibrated in buffer A (20 mM Bis-Tris pH 6.5, 50 mM NaCl, 5% Glycerol, 
0.5 mM TCEP). The final step was SEC using a Superdex75 (GE Healthcare) column 
equilibrated in gel filtration buffer.
Full length RING1B/BMI1-his was lysed in 50 mM Tris pH8.0, 500 mM NaCl, 50 mM 
Imidazole pH 8.0, 10% Glycerol, 2 µM ZnCl2 and 0.5 mM TCEP. The cleared lysate was 
incubated with chelating sepharose beads (GE Healthcare) pre-charged with Ni2+. After 
washing with >10 column volume (CV) lysis buffer and elution with elution buffer (50 
mM Tris pH8.0, 500 mM NaCl, 500 mM Imidazole pH 8.0, 10% Glycerol, 2 µM ZnCl2 and 
0.5 mM TCEP). Hereafter, the sample was fractionated on a Superdex200 SEC column (GE 
Healthcare) in 10 mM HEPES pH 7.5, 400 mM NaCl, 10% Glycerol, 2 µM ZnCl2 and 0.5 mM 
TCEP. Full length RNF168 was purified as described before2. After SEC, all samples were 
concentrated using AMICON Ultra concentration columns (Millipore) to 2-20 mg/ml and 
flash frozen in liquid nitrogen.
Ub-AMC enzymatic assays 
Enzyme activity was followed as the release of fluorescent AMC from the quenched Ub-
AMC substrate, providing a direct read-out of DUB activity 3. Ub-AMC was synthesized as 
described previously4. The purified Ub-AMC was dissolved in pure DMSO. The residual 
amount of DMSO left in the enzymatic reaction was never higher than 6%. Kinetic parameters 
were determined using 1 nM of enzyme while varying the substrate concentration in 30μl 
reactions using reaction buffer (25 mM HEPES pH 7.5, 150 mM NaCl, 5 mM DTT and 0.05% 
Tween-20) at 25˚C. Reactions took place in black 384-well non-binding surface low flange 
plates (Corning). In the single concentration experiments, 1 nM of enzyme was allowed 
to react with 1 μM of substrate and activity was quantified by calculating the initial rates. 
Experiments were performed in a Pherastar (BMG Labtechnologies) plate reader using 
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350 nm and 450 nm excitation and emission wavelengths respectively. Measurements 
were taken every 10 s for 10 minutes. Fluorescence and velocities were related using 
an AMC standard curve. The initial rates were plotted against substrate concentration 
and fitted to the Michealis-Menten model using non-linear regression in Prism 6. Three 
different independent experiments were performed with at least two different enzyme 
preparation.
For the inhibition assays, increasing concentrations of the non-hydrolyzable H2A 
ubiquitin conjugates were incubated with 500 pM enzyme and 2 µM of substrate. Data 
were normalized by setting the no-inhibitor control at 100% activity. Inhibition data were 
fitted to a “log inhibitor vs. normalized response” model to obtain values for the IC
50
 value 
in Prism 6. 
Synthesis non-hydrolyzable H2A-Ub conjugates
The H2A derived peptide was obtained through standard linear FMOC-based pep-
tide synthesis on WANG resin. The target lysine in the peptide (K119) was sub-
stituted for Azidonorvaline (incorporated as Fmoc-azidonorvaline). Ubiquitin 
with a C-terminal propargyl (Ub-Prg) was obtained as described previously5. The 
Tris triazole ligand (tris(1-(O- ethylcarboxymethyl)-1H-1,2,3-triazol-4-ylmeth-
yl)amine) used in the click reactions was synthesized as previously described6.  
For the reaction to be successful it is important that the source of Cu(I) is pure and 
free of oxidized byproduct, Cu(II). CuBr was obtained in 99% purity and was a green/
brown powder indicating traces of Cu(II). Cu(II)Br was suspended 10% v/v in high pu-
rity (glacial) acetic acid. This suspension was vigorously stirred under nitrogen over-
night. After stirring overnight the suspension was filtered and the off-white residue 
separated from the greenish solution. The solid was washed with ethanol and dried un-
der high vacuum. The obtained off-white powder was stored under inert atmosphere.  
Both the functionalized H2A peptide and Ub-Prg dissolved in DMSO at 50 mg/
ml and heated to facilitate solubilization. The peptide was dissolved in DMSO at 
50 mg/ml and heated in case it failed to dissolve. Ub-Prg was dissolved in DMSO at 
50 mg/ml and heated to make a proper solution. To 1 ml of 8M Urea (0.1M Phos-
phate Buffer pH 8), was added 100uL of Ub-Prg solution and 100 uL of peptide solu-
tion. After mixing the peptide and the ubiquitin the click solution was prepared.  
A fresh solution of CuBr was prepared (20 mg/ml in Acetonitrile) and a stock solution 
of ligand (50 mg/ml in Acetonitrile were used. 19.2 uL of CuBr solutions was added to 
30uL of ligand solution. The Cu/Ligand solutions was then added in 5 equal steps to the 
110
Chapter 4 | Supplemental information
4
reaction mixture, each addition being vortexed and left for a few minutes before adding 
another 10uL of Cu/Ligand mix. The progression of the reaction was checked using using 
LC-MS. After completion of the reaction 50uL of a 0.5M EDTA pH 7 solution was added to 
quench the reaction and dissolve remaining Cu(II) species. As a final step, The reaction 
mixture was applied directly to reversed phase HPLC for purification. Fractions were ana-
lysed for presence of product, pooled and lyophilized.
H2A-peptide-ubiquitin hydrolysis assays
Native ubiquitin conjugates were synthetized as described previously4,7. Reactions were 
performed in reaction buffer (see above) at 30 degrees Celsius using 20 µM of substrate 
and 50 nM of enzyme. Time points were taken and the reactions were terminated by the 
addition of protein loading buffer before analysis by SDS-PAGE. The experiments were 
performed at least three independent times.
Stopped-flow fluorescent polarization binding assays
Pre-steady state binding events between inactive mutants (C91A) of BAP1 or BAP1/
ASXL1DEU and NCPs monoubiquitinated with TAMRA-ubiquitin at K118/119 (TAMRAUb-NCP) 
by Ring1b/Bmi1 were monitored in stopped-flow fluorescent polarization experiments. 
The experiments were performed on a TgK Scientific stopped-flow system (model SF-
61DX2) equipped with a photomultiplier tube R10699 (Hamamatsu). Monochromatic 
light at 544 nm and a 570 nm cutoff filter were used for excitation and readout, respectively. 
The light was polarized using a calcite prism for the incident beam and dichroic sheet 
polarizers in front of each of two photo-multiplier detectors arranged in a T-configuration. 
The experiments were performed in stopped-flow binding buffer (25 mM HEPES pH 7.5, 
150 mM NaCl, 0.05% Tween-20 and 0.5 mM TCEP) at 20˚C. For the association 20 nM 
of TAMRAUb-NCP (final concentration) and various concentrations of BAP1 or BAP1/ASXL-1DEU were injected in equal volumes and rapidly mixed after which FP signal was followed 
during 10 s. For each concentration 3 injections were averaged to improve signal. Asso-
ciation binding traces were fitted to a one-phase association model in Prism6 to obtain 
k
obs
. The k
obs
 values were plotted against protein concentration to estimate k
on
, k
off
 and -KD. 
BAP1 association traces did not come close to saturation and were therefore not fitted.
nucleosome core particle preparation
Recombinant nucleosome core particles were prepared as described previously8. Xenopus 
histones and 167 bp widom 601 strong positioning sequence were used to reconstitute 
the core particles.
Band shift assays
Band-shift assays were performed using native gel electrophoresis on 4–12% Pre-Cast 
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Tris-Glycine gels (Life Technologies), pre-run for at least 1 h at 125 V in Novex Tris-Gly-
cine buffer at 4 degrees Celsius. NCPs or monoubiquitinated NCPs (both 100 nM) were 
incubated with increasing amounts (typically seven 2-fold dilutions starting from 15 µM 
final concentration) of BAP1 or ASXL1 variant or BAP1/ASXL1 variant and the gel was run 
for 90 min at 125 V at 4 dregrees Celsius. BAP1/ASXL1 complexes were allowed to form 
for 10-30 minutes on ice prior to electrophoresis. Bands were visualized by DNA staining 
with GelRed in a ChemiDoc XRS instrument (Biorad). The experiments were performed at 
least two times with differents batches of NCPs.
Surface conservation DeUBAD domains
Twenty or more sequences across all eukaryotic lineages containing both UCH-L5 and 
RPN13 or INO80G where aligned using the MAFFT algorithm9 with default settings. PBD 
codes for the DEUBAD domains are 4uem and 4uf5. The structures of the DEUBAD do-
mains where superimposed using pdbeFOLD 11.
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ABSTRACT
The deubiquitinating enzyme (DUB) BAP1 is a critical tumor suppressor that is activated by 
ASXL1 to remove ubiquitin from Histone 2A (H2A) K119 during Polycomb gene repression. 
The BAP1/ASXL1 complex consists of two BAP1 molecules but only one ASXL1 molecule. 
The functional consequences of this asymmetric stoichiometry are not understood. In this 
study, we characterize the oligomeric state of the BAP1/ASXL1 complex and investigate 
its possible relevance for DUB activity. We find that the full length BAP1 alone forms 
large oligomers via its C-terminal ULD domain and that truncation of this domain shifts 
the oligomeric state to a monomer dimer equilibrium. A single ASXL1 binds to a ULD 
domain and stabilizes BAP1 as dimer, to the 2:1 state. In this heterotrimeric BAP1/ASXL1 
complex one ASXL1 molecule can stimulate both copies of BAP1 to deubiquitinate H2A. 
These results provide a basis for further studies on the role of BAP1 oligomeric states in 
enzymatic activity.
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InTRODUCTIOn
BRCA-1 associated protein 1 (BAP1) is an important deubiquitinating enzyme (DUB) with 
tumor suppressor activity that is mutated in a wide variety of tumors1,2. In these tumors 
both somatic and germ line mutations of BAP1 are found3–5 with individuals possessing 
germline mutations in BAP1 being predisposed to the BAP1 cancer syndrome6. In general 
BAP1 mutants in cancer are associated with poor prognosis and high tumor aggressive-
ness7. How BAP1 disruption contributes to tumorigenesis is not known.
Recent studies have revealed that BAP1 has important roles in key nuclear processes 
such as DNA repair, DNA replication and the regulation of gene expression4,8–12and these 
are countered by an army of deubiquitinating enzymes (DUBs. In Drosophila BAP1 
participates in gene regulation by being part of the evolutionarily conserved Polycomb 
Repressive DUB13genetic studies identified more than 15 different PcG proteins that are 
required to repress homeotic (HOX. Polycomb gene repression is characterized by the 
mono-ubiquitination of H2A at K119 by the E3 ligase RING1B/BMI114. BAP1 is responsible 
for the deubiquitination of mono-ubiquitinated H2A at K119. For this function BAP1 is 
activated by Polycomb protein ASXL1 and this deubiquitination event contributes to gene 
repression13.
BAP1 belongs to the UCH family of DUBs together with UCH-L1, UCH-L3 and UCH-L5. All 
these enzymes contain an N-terminal UCH domain whereas BAP1 and UCH-L5 also con-
tain an C-terminal ULD domain. In UCH-L5 the ULD domain directly follows the UCH do-
main, but in BAP1 an 350 aa insert is present between its UCH and ULD domains. The ULD 
domains have important roles. In UCH-L5 the C-terminal helices of this domain bind the 
DEUBAD domain of activator RPN13, which subsequently restricts the mobility of the ULD 
to increase UCH-L5’s affinity for ubiquitin15. This mechanism is conserved in the BAP1/
ASXL1 complex, with the DEUBAD domain of ASXL1 employing a similar mechanism to 
increase BAP1’s affinity for ubiquitin (Sahtoe et al, chapter 4). In addition to ASXL1, effi-
cient H2A deubiquitination also requires recruitment of the complex to nucleosomes by 
the BAP1 C-terminal extension (CTE) (Sahtoe et al, chapter 4).
Studies on the stoichiometry of BAP1 have revealed a surprising asymmetry, the complex 
consists of two BAP1 molecules in complex with one ASXL1 molecule16. This is surprising 
since the homologous UCH-L5/RPN13 complex is equimolar, consisting of one UCH-L5 
molecule bound to one RPN13 molecule15. Nonetheless UCH-L5 has previously been 
suggested to form functionally important higher order oligomers. Based on its crystal 
structure and biochemical analysis17–20”it was proposed that UCH-L5 forms an inactive 
tetramer, via its ULD domain, that could be disrupted by RPN13 binding and thus activate 
the enzyme17,19. However, this finding has never been confirmed in solution. For BAP1 it 
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is currently unknown whether the protein can form oligomers in isolation, and what the 
functional significance of the asymmetric BAP1/ASXL1 complex could be. For example, 
to deubiquitinate H2A a number of requirements need to be satisfied. BAP1 has to be 
recruited to the nucleosome by the CTE, BAP1 needs to bind ASXL1 and perform actual 
catalysis. How these functions are distributed over the subunits in the asymmetric 
complex is unclear.
In this study, we characterize the oligomeric states of BAP1 and the BAP1/ASXL1 complex. 
We demonstrate that BAP1 in isolation forms higher order oligomers driven by its ULD 
domain. Disruption of the ULD domain abrogrates oligomer formation but instead pro-
motes a monomer-dimer equilibrium, that is stabililzed into the dimer state by binding of 
ASXL1. Using Ub-AMC assays we find that BAP1 truncation mutants that are deficient in 
higher order oligomerization, are probably not affected in enzymatic activity, in absence 
of ASXL1. Furthermore, we show that in the BAP1/ASXL1 complex, both BAP1 molecules 
are capable of H2A deubiquitination.
ReSULTS
BAP1 can form dimers
To understand the functional consequences of the asymmetry of the BAP1/ASXL1DEU com-
plex, we first characterized the oligomeric states of BAP1 (MW=80 kDa) and ASXL1DEU 
(MW=17 kDa) separately. We expressed full length (FL) BAP1 in insect cells and purified 
the protein to homogeneity. We noticed that in the final size exclusion chromatography 
(SEC) step BAP1 eluted from the column as a broad peak (Figure 1A) with a molecular 
weight of more than 440 kDa based on SEC calibration curves. Because the MW of a BAP1 
monomer is 80 kDa, we conclude that our BAP1 sample forms a range of oligomers. In-
terestingly, the BAP1/ASXL1DEU complex eluted from SEC-MALLS in a peak with an MW of 
145 kDa (Figure 1B), in line with previous studies showing that it is not a stoichiometric 
1:1 complex. The shift in oligomeric state when BAP1 is in complex with ASXL1DEU sug-
gests that ASXL1DEU abolishes the propensity of BAP1 to oligomerize and favors a dimeric 
BAP1 form ASXL1DEU itself was a monomer in MALLS analysis (Figure 1C).
Crystal structure and biophysical analyses have indicated that UCH-L5 can dimerize and 
tetramerize via its ULD (Figure 1D), but the biological significance of this phenomenon 
is unclear. We wondered whether the BAP1 C-terminal ULD could also mediate BAP1 
oligomerization, and therefore we truncated BAP1 at residue 670 and expressed this 
variant in insect cells. This construct lacks the equivalent region in UCH-L5 that mediated 
tetramerization in the crystal structure17. In contrast to FL BAP1, the BAP1
1-670
 variant (73 
kDa), eluted as two peaks and at much lower molecular weight from SEC instead of one 
broad peak (Figure 1E). This suggests that this C-terminal ULD indeed mediates BAP1 
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oligomerization. Using MALLS we could show that these two peaks represent a monomer-
dimer equilibrium (Figure 1E). The region responsible for the dimerization interface lies 
outside the BAP1 catalytic domain since this catalytic domain alone did not dimerize, but 
instead eluted as a single peak, with a mass equivalent to a monomer in MALLS analysis 
(Figure 1F). Deletion of the BAP1 CTE only, did not change the oligomeric state (data not 
shown).
To assess whether BAP1 oligomerization affects enzymatic activity, we analyzed the 
enzyme kinetics of different BAP1 constructs using the minimal substrate ubiquitin-7-
amido-4-coumarin (Ub-AMC). In these assays BAP1
1-670
 and the BAP1 catalytic domain 
(BAP1
1-235
) had similar activity (Figure 1G). In comparison to FL BAP1, both constructs 
were more active. This difference was mainly mediated by k
cat
 and left KM unaffected. We 
suspect that the effect in the truncation variants, is likely due to protein stability effects 
rather than an intrinsic difference in activity mediated by oligomeric state, since BAP1
1-670
 
and BAP1
1-235 
are more stable than FL BAP1 during expression and purification. 
In summary, we show that BAP1 forms a range of oligomers mediated by its C-terminal 
ULD region. ASXL1DEU binding reorganizes the oligomeric state and activates the enzyme.
functional analysis of BAP1/ASXL1DeU asymmetry
Several questions arise from the observed asymmetry in the BAP1/ASXL1DEU complex, 
especially regarding the task of each BAP1 molecule in H2A deubiquitination. First, are 
both BAP1 molecules functionally equivalent? Which BAP1 molecule binds ASXL1DEU, and, 
is the BAP1 molecule that binds ASXL1DEU also the molecule that is activated by ASXL1DEU 
to deubiquitinate H2A (activation in cis). Or does ASXL1DEU bind one molecule of BAP1 and 
activate the other (activation in trans) (Figure 2A)? 
We have recently shown that the C-terminal extension (CTE) of BAP1 is necessary for 
binding to the nucleosome (Sahtoe et al, chapter 4). Since there are also two CTE’s in the 
complex the number of options is even larger. Analogously to the activation, we can ask if 
the BAP1 that binds the nucleosome via the CTE is also the BAP1 molecule that performs 
the catalysis (nucleosome binding in cis) or instead, does one CTE binds the nucleosome 
and the other BAP1 molecule perform catalysis (nucleosome binding in trans) (Figure 
2A)?
We investigated these possible scenarios by mixing different BAP1 variants and testing 
H2A DUB activity using purified oligonucleosomes that we mono-ubiquitinated at 
H2A K119. This allows reconstitution of specific “mixed” complexes and separation of 
functions for each BAP1 monomer in H2A deubiquitination reactions. For example mixing 
an excess of a FL BAP1 variant with an active site C91A mutation with a BAP1 variant 
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that cannot bind ASXL1DEU and cannot bind the nucleosome (BAP1
1-670
), would favor 
the formation of a BAP1
C91A
 -BAP1
1-670
/ASXL1DEU complex. In this complex ASXL1DEU can 
only bind to FL BAP1
C91A
 since the other variant does not have an ASXL1DEU binding site. 
Similarly nucleosome binding could only be conferred by FL BAP1
C91A
 since it is the only 
subunit with a CTE. Since this BAP1
1-670
 variant is normally inactive on H2A (Sahtoe et al, 
chapter 4), any H2A deubiquitination activity would necessarily come from the BAP1
1-
670
 variant since the active site cysteine of the FL is mutated. This would indicate that 
ASXL1DEU activates BAP1
1-670
 in trans. We could indeed detect an increased DUB activity 
upon mixing of BAP1
1-670
 with a 20 fold excess of BAP1
C91A
 and ASXL1DEU suggesting that 
ASXL1DEU mediated activation and nucleosome binding can both occur in trans (Figure 2B, 
146
146
146
147
147
189
V I NNA CA TQ A I I S V L L NCT HP DML L G E T L T E F K E F S NS F DA AMKG L A L S NS E V I RQ V HNG F A RQ
V I NNA CA TQ A I V S V L L NCT HP DML L G E T L T E F RE F S L S F DA AMKG L A L S NS E V I RQ V HNS F A RQ
V I NNA CA TQ A I V S V L L NCT HQ DV HL G E T L S E F K E F SQ S F DA AMKG L A L S NS DV I RQ V HNS F A RQ
L I P NS CA T HA L L S V L L NC - - S S V DL G P T L S RMK DF T KG F S P E S KG Y A I G NA P E L A K A HNS HA RP
L I P NS CA T HA L L S V L L NC - - SG V E L GMT L S RMK A F T KG F NP E S KG Y A I G NA P E L A K A HNS HA RP
V V P NS CA T HA L L S V L L NCNE NNL Q L G DT L S RL K T HT KGMS P E NKG L A I G NT P E L A CA HNS HAMP
241
241
241
333
331
303
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
I Q T HK SQ E SQ L P E E S K S A S NK S P L V L E A NRA P A A S EG NHT DG A E E A AG S CAQ A P S HS P P NK P K
SGQ DRKQQDS S S S E DT P P V V K K E - - - - E VQ E T P I P SG A EQ A T P T E AQ EG A A S L P - - - S P AG K V R
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
255
255
255
512
519
330
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
SQ K DL - - - - - S I P L S I K T S SG AG S P A V A V P T HSQ P S P T P S NE S T DT A S E I G S A F NS P L RS P I R
Q RK DA L A T TG S T P L NV RT EG RTG - - G I S I T S A CQ P S P T P S NE S T DT A S E I G S A F NS P L RS P A R
306
306
306
685
711
390
- - - - - - - - - - - - - - - H L S S I Q S E I A K YQ L L I E E E NQ K L K RY K V E N I RRK HNY L P F I ME L L K T L A E Y
- - - - - - - - - - - - - - - L L S S I Q S E I A K YQ L L I E E E NQ K L K RY K I E N I RRK HNY L P F I ME L L K T L AQ Y
- - - - - - - - - - - - - - - ML S A I Q S E V A K NQML I E E E VQ K L K RY K I E N I RRK HNY L P F I ME L L K T L A E H
SG E K Y S P K E L L A L L K CV E A E I A NY E A CL K E E V E K RK K F K I DDQ RRT HNY DE F I CT F I SML AQ E
K P PG E K Y T P K E L L A L L K Y V E A D I A NY E V Y L K E E V E K RK K Y K I DDQ RRT HNY DE F I CT F I SML AQ E
- - - - - - A F T A RDL Q S L L K NL DT E I A I NEQ HL A DE NDRRHMF K V DA S RRT HNY DK F I CT F L SML A HQ
329
329
329
729
755
471
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Dr.UCHL5/1-329
SmeltUCHL5/1-329
Hs.UCHL5/1-329
Hs.Bap1/1-729
Dr.Bap1/1-755
Dm.Calypso/1-471
Tetramerization
region
FL BAP1
BAP11-670
BAP11-235
FL BAP1
BAP11-670 3,9 ± 0.44.1 ± 0.9
5.9 ± 1.0 2.5 ± 0.2
4.1 ± 0.9 4.0 ± 0.3BAP11-235
Km (µM) kcat (s
-1)
A B C
D E
F G
MWmalls
145 kDa
MWmalls17 kDa
MW 17 kDa
MWcc >440 kDa
MW  80 kDa
MWcc 200 kDa
MW1:1 100 kDa
MWcc 30 kDa
MWmalls150 kDa
MW 73 kDa
MWcc 300 kDa
MWmalls22 kDa
MW 26 kDa
MWcc 30kDa
MWmalls80 kDa
MWcc 100 kDa
Figure 1 | Analysis oligomeric state BAP1/ASXL1. A) BAP1 elutes as a broad peak from size ex-clusion chro-
matography (SEC). The molecular weight of BAP1 based on calibration curve (MW
cc
) is 440 kDa. Throughout 
this gure “MW” represents the molecular weight of a monomer, “MW
cc
” the molecular weight based on the SEC 
calibration curve for globularly shaped proteins, and “MW
malls
” the molecular weight as measured by MALLS. 
B) The BAP1/ASXL1DEU complex is not a 1:1 complex as shown by MALLS. C) ASXL1DEU is monomeric with a MW 
of 17 kDa. D) Crystal structure of full length UCH-L5 (3ihr) shows tetramer that is mediated via a tetrameriza-
tion region (arrow). E) Disruption of the region equivalent to the UCH-L5 tetramerization region in BAP1, shifts 
the BAP1 oligomer observed in FL to a monomer-dimer equilibrium as shown by MALLS. F) The BAP1 catalytic 
domain is monomeric in MALLS. G) The BAP1 catalytic domain and BAP11-670 are more active than WT BAP1 
(Error bars, SD).
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lanes 11-13) . This activity was not as effective however as the WT (Figure 2B, lanes 5-7) 
or all cis (Figure 2B, lanes 8-10) complexes.
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Figure 2 | Functional analysis BAP1/ASXL1 stoichiometry in H2A deubiquitination. A) Possible scenario’s 
of ASXL1DEU activation and nucleosome binding with respect to the BAP1 molecule that performs the DUB 
reaction(yellow star). The CTE that does not bind the nucleosome is faded. B) Left; Anti-H2A blot showing 
that both BAP1 molecules are capable of deubiquitinating H2A although WT and “all cis” complexes more 
active than the “in trans” complexes. Time points: 1, 5 and 25 min. Right; schematic depiction of reconstituted 
heterotrimeric mutant BAP1 complexes used in Figure 2A. Red cross represents the inactivate C91A mutants. 
C) Two preparations of BAP1C91A/ASXL1DEU are not active on the substrate even after 25 minutes at 2 μM.
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After establishing that BAP1 activation by ASXL1DEU as well as nucleosome binding can 
occur in trans, we wondered how this compared to “all cis” activity. To test this we mixed 
WT BAP1 with a 20-fold excess of a BAP1
1-670
 variant containing an active site mutant 
(C91A) enabling the formation of a BAP1
670_C91A
-BAP1/ASXL1DEU complex. In this complex, 
any observed activity should be in cis as BAP1
1-670
C91A does not have an active site, cannot 
bind ASXL1DEU and lacks the CTE. This complex variant had similar activity to WT and 
was thus more active than the “all trans” variant . This may suggest that the physiological 
relevant activity mode is to have both activation by ASXL1DEU and nucleosome binding in 
cis. The FL BAP1
C91A
/ASXL1DEU complexes by themselves were devoid of DUB activity when 
incubated with the substrate for 25 minutes at concentrations of 2 µM (Figure 2C).
In summary, our results suggest that both BAP1 molecules in the BAP1/ASXL1DEU complex 
can be activated by ASXL1DEU and bind to nucleosome. In cis activation and binding 
however seems to be more efficient suggesting that this is the primary mode of H2A 
deubiquitination.
DISCUSSIOn
Previous studies indicated that the BAP1/ASXL1 complex is asymmetric consisting of two 
BAP1 molecules and one ASXL1 molecule. In this study we characterized the oligomeric 
state of the BAP1/ASXL1DEU complex and its possible relevance for H2A deubiquitination 
activity and find that in vitro both molecules can have H2A deubiquitination activity al-
though only one BAP1 molecule is bound by ASXL1DEU.
We showed that similar to the crystal structure of UCH-L517, BAP1 can form high MW 
oligomers mediated by its C-terminal ULD domain. Disruption of this region redistributes 
the oligomers to a monomer-dimer equilibrium. For UCH-L5, the tetramerization was pro-
posed to inhibit the enzyme since in this arrangement, the ubiquitin binding sites were 
blocked. Since the UCH-L5 activator, RPN13, binds to the tetramerization region, activa-
tion was suggested to merely prevent tetramerization. Since these UCH-L5 tetramers have 
not been observed in solution17,19,20each of the catalytic domains was blocking the other’s 
ubiquitin (Ub, it is not clear how important they are functionally. Moreover, deletion of the 
tetramerization region does not activate UCH-L5 to the same extent as RPN13, indicating 
that loss of tetramerization per se does not explain the activation of the enzyme. RPN13 
instead mediates allosteric activation by positioning of the UCH-L5 cross-over loop and 
ULD domain15,20.
Our results on the increased activity of BAP1 truncation mutants, that cannot oligomer-
ize anymore, on the minimal substrate Ub-AMC suggested that unlike in UCH-L5, BAP1 
oligomerization could inhibit enzyme activity (Figure 1G). Several observations indicate 
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that this is unlikely though. First the observed lower activity is at least partially due to 
the fact that FL BAP1 was expressed at lower levels and prone to time-dependent inac-
tivation during purification. This is underscored by the fact that the difference between 
FL BAP1 and the truncation mutants is in k
cat
. This value is very sensitive to the fraction 
of active enzyme in a mixture, and thus suggests that FL BAP1 is simply less stable than 
the truncation mutants. Second, if truncation of FL BAP1 would be enough for activation, 
the activation effect observed in the truncation mutants should affect the KM of the BAP1/
ASXL1DEU complex (since ASXL1DEU activates KM)  rather than kcat. 
Addition of ASXL1DEU stabilized the BAP1 oligomer towards a 2:1 complex. By mixing 
different BAP1 variants we obtained results that suggest that both BAP1 variants in the 
complex can deubiquitinate H2A. This is interesting because of the inherent asymmetry 
in a 2:1 complex. Of special interest, is the observed in trans H2A deubiquitination. In this 
activity mode, the BAP1 molecule that does not bind the nucleosome and that does not 
bind ASXL1DEU can be stimulated to deubiquitinate H2A albeit with lower efficiency that 
WT complexes and in cis activity. A question regarding the all trans  activity mode is how 
binding of ASXL1 on one BAP1 molecule can stimulate the other BAP1 molecule. We spec-
ulate that ASXL1 may achieve this by increasing the affinity for ubiquitin through indirect 
stabilization of the ULD domain of the active BAP1 subunit. Enzyme kinetics experiments 
of the in trans complex could partially resolve this question by revealing whether the ac-
tivation is on KM. 
Our variant BAP1/ASXL1DEU complexes were reconstituted by mixing one BAP1 variant 
with an excess of another BAP1 molecule. This would ensure the incorporation of two 
BAP1 molecules of different type in one complex. Even though we have no direct evidence 
for the actual formation of such complexes via direct binding assays, the fact that we ob-
served increased activity of the FL BAP1
C91A
-BAP1
1-670
/ASXL1DEU complex compared to 
BAP1
1-670
/ASXL1DEU, strongly indicates that such complexes form. This is because BAP1
1-
670
 can only associate with ASXL1DEU, and, can only be bound to nucleosomes in presence 
of an ASXL1DEU binding region and CTE respectively, both of which BAP1
1-670
 lacks. These 
elements can only be provided by complex formation of BAP1
1-670
 with a FL BAP1 variant, 
in this case BAP1
C91A
. Nonetheless additional direct controls are necessary for definitive 
proof of formation of such mixed complexes. 
For the sake of simplicity we assumed a division of labor between the two BAP1 molecules 
with respect to nucleosome binding, ASXL1 binding and catalysis. It is however possible 
that both monomers contribute equally to H2A deubiquitination. What the relevance 
could be of the 2:1 stoichiometry remains to be discovered. Our results suggest that 
it does not generate a strict partition of functions (i.e. one BAP1 molecule performing 
catalysis and the other nucleosome binding). In fact, because the “all cis” activity mode 
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displayed activity close to WT, it is likely that one BAP1 molecule in the WT performs 
all H2A deubiquitination related functions. A possibility could be that the other BAP1 
molecule then functions as an assembly platform for other proteins in one of the many 
multi-protein complexes that BAP1 is thought to form. 
eXPeRIMenTAL PROCeDUReS
Molecular biology and antibodies
FL BAP1 and its variant except for the BAP1 CD were cloned into the pFastbac vector of 
the NKI LIC suite21 or pFastbac HTa (Invitrogen). BAP1 CD was cloned into the his-SUMO 
vector of the NKI LIC suite. ASXL1DEU was cloned into the pET-NKI-his vector of the NKI LIC 
suite. Histone H2A in oligonucleosomes was visualized by western blotting using rabbit 
anti-H2A (07-146, Millipore).
Protein expression and purification
All BAP1 variants except for the catalytic domain BAP1 were expressed in insect cells us-
ing the Bac-to-Bac expression system (invitrogen). BAP1 CD and ASXL1DEU were expressed 
in E.coli using the pET expression system. 
For all constructs, cells were resuspended in lysis buffer (50 mM Tris pH 8.0, 200 mM NaCl, 
50 mM Imidazole pH 7.5, 0.5 mM TCEP) supplemented by complete EDTA-free protease 
inhibitor tablets (Roche) and lysed by sonication. Lysates were cleared by centrifugation 
and subsequently incubated with chelating sepharose beads (GE Healthcare) pre-charged 
with Ni2+ for 30 minutes after which beads were washed with typically 20CV of lysis buffer. 
The proteins were eluted using elution buffer (20 mM Tris pH 8.0, 150 mM NaCl, 500 mM 
Imidazole pH 7.5, 10% glycerol and 0.5 mM TCEP) and diluted 2-3 times before applying 
the sample to a Poros Q (GE Healthcare) anion exchange chromatography column 
equilibrated in 20 mM Tris pH 8.0, 50 mM NaCl, 5% glycerol and 0.5 mM TCEP. Samples 
were eluted by a linear salt gradient from 0% buffer B to 75% buffer B over 7-10CV, with 
buffer B containing 20 mM Tris pH 8.0, 1000 mM NaCl, 5% glycerol and 0.5 mM TCEP.
For BAP1CD and ASXL1DEU the affinity tag was cleaved overnight with either SENP or 3C 
protease while dialyzing against 20 mM Tris pH 8.0, 150 mM NaCl, 10% glycerol and 0.5 
mM TCEP. Uncleaved protein, SENP or 3C were captured using a reverse purification step 
on the affinity resin.
The final purification step for all proteins was a size exclusion chromatography (SEC) 
in 10 mM HEPES pH 7.5, 150 mM NaCl, 10% glycerol and 0.5 mM TCEP. FL BAP1 was 
purified on a Superose 6, BAP1
1-670
 on a Superdex 200 and BAP1CD and ASXL1DEU on a 
Superdex 75 SEC column (all GE Healthcare). Proteins were concentrated to 2-20 mg/ml 
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using AMICON concentration columns and flash-frozen in aliqots using liquid nitrogen for 
storage at -80 degrees Celsius.
Multi angle laser light scattering (MALLS)
MALLS experiments were performed on a Mini-Dawn light scattering detector (Wyatt 
Technology) coupled to a Superose 6, Superdex 200 10/30 or Superdex 75 10/30 column 
equilibrated in 25 mM HEPES pH 7.5 150 mM NaCl, 10% glycerol and 0.5 mM TCEP at 4 
degrees Celcius. Refractive index and light scattering detectors were calibrated against 
toluene and BSA. Molecular weights were calculated using the manufacturer’Astra soft-
ware.
Oligonucleosome deubiquitination assay
Oligonuclesomes were purified from HEK293T cells as described previously22 and mono-
ubiquitinated at K119 using 3 µM of the ubiquitin E3 ligase Ring1b/Bmi1 in a reaction 
that also contained 500 nM E1, 2 µM UbcH5c and 7.5 µM ubiquitin at 30 degrees Celsius 
for 90 minutes. The reaction was terminated by ATP depletion using the ATPase Apyrase 
(Sigma). DUB reactions were performed in 10 µl reaction using 7.5 µl of the ubiquitinated 
oligonucleosomes and 100 nM of DUB or DUB complex. DUB complexes were preincubated 
on ice for at least 15 min prior to addition of substrate. For reactions where different BAP1 
variants were mixed, 2 µM of excess of one DUB variant was used (indicated) while the 
other variant was kept at 100 nM. In these “mixed” reactions 2 µM of ASXL1DEU was used 
instead of 100 nM. DUB reactions were terminated by the addition of SDS-PAGE loading 
buffer before analysis by western blotting.
Ubiquitin-AMC enzyme kinetics assay
Enzyme activity was followed as the release of fluorescent AMC from the quenched Ub-
AMC substrate, providing a direct read-out of DUB activity. Michealis-Menten parameters 
were determined using 1 nM of enzyme variant while varying the substrate concentration. 
Initial rates were plotted against substrate concentration and fitted to the Michealis-Ment-
en model using non-linear regression in Prism 6.
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Deubiquitinating enzymes (DUBs) are key components of the ubiquitin-system. These 
enzymes hydrolyze the ubiquitin adducts and therefore control all processes affected by 
ubiquitination. To properly carry out this function their activities are tightly regulated 
by several factors in cells. Since the ubiquitin-system is often disrupted in human dis-
ease, DUBs hold a promise as “druggable” components of the system. A clear and detailed 
understanding of DUB function at the molecular level and in cellular context is required 
for the development of therapeutics. In this thesis, we described the different regulatory 
layers that exist for DUBs and investigated the molecular details of the regulation of the 
closely related DUBs UCH-L5 and BAP1.
DeUBAD domain regulation of BAP1 and UCH-L5
In chapters 3 and 4 we described how the enzymatic activities of the related DUBs UCH-L5 
and BAP1 are modulated by DEUBiquitinase ADaptor (DEUBAD) domains present in their 
cognate regulatory proteins1. Activity modulation by these domains takes place mainly 
at the level of substrate binding rather than at the level of catalysis as observed for other 
DUBs2,3. Mechanistically the activation of UCH-L5 and BAP1 follow similar strategies. In 
both cases, the DEUBAD domains activate the DUB using a combination of mild allosteric 
effects. Our structural analysis indicates that UCH-L5 activity modulation is made possible 
by the intrinsic flexibility of structural elements such as the active-site cross over loop 
(CL) and the ULD domain. In absence of a regulatory protein, this flexibility generates a 
wide range of conformations of which some severely limit enzyme activity while others 
promote enzyme activity. It is likely that this conformational plasticity has been exploited 
in cells by the evolution of the DEUBAD domains of RPN13 and INO80G, which lock the 
ULD domain in conformations that either allow or block ubiquitin binding. While ULD 
domain conformation is affected by both RPN13 and INO80G, we observe that the confor-
mation of the CL is only affected by RPN13 that directly binds and positions it. Mutational 
analysis indicated that disruption of this interface resulted in a weaker Km suggesting that, 
like the ULD anchor mutant, stabilization of the CL by RPN13, increases ubiquitin binding. 
Interestingly however, we found that CL mutant complexes bind ubiquitin with the same 
affinity as WT complexes suggesting that the CL does not affect substrate binding but rath-
er actual catalysis (k
cat
). Further studies are required to elucidate the role of the CL in UCH 
enzyme catalysis.
The activation effects that we observe for BAP1 and, especially, UCH-L5, are not as dramatic 
as observed in other DUBs. In the latter set of DUBs, virtually no enzymatic activity is 
observed in isolation but they can be dramatically activated, in some cases several orders 
of magnitude, by activators. The milder activation of UCH-L5 and BAP1 in the presence of 
their cognate DEUBAD domains suggests that under physiological conditions additional 
factors may be present that further stabilize the active state of the DUB to yield full activity. 
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The requirement of multiple additional factors for full enzymatic activity has been well 
established for certain biochemical reactions. The mono-ubiquitination of the DNA sliding 
clamp PCNA for example by the Rad6/Rad18 complex is greatly enhanced when PCNA is 
loaded onto DNA by a sliding clamp loading complex, compared to the situation where 
PCNA is not loaded onto DNA. This example stresses the importance of studying complete 
“holoenzyme” complexes where all components that drive the reaction are present the 
reaction mixture. Such activity enhancing factors may also exist for UCH-L5 and BAP1. Our 
minimal UCH-L5/RPN13 complex for example does not hydrolyze its natural substrate, 
K48 polyubiquitin chains. For this activity UCH-L5 needs to be embedded within the 19S 
proteasomal regulatory particle4. Future studies on UCH-L5 activity in the proteasome 
should be directed towards understanding this requirement by identifying stable (sub)
complexes capable of chain hydrolysis.
While challenges still exist for UCH-L5’s role in the proteasome, our structural analysis of 
the UCH-L5/INO80G complex, and the identification of a single point mutant that alleviates 
UCH-L5 inhibition, can provide novel insights into the still mysterious role of UCH-L5 in 
INO80 chromatin remodeling complexes. UCH-L5 is inhibited in these complexes, but 
both complex formation with INO80G and UCH-L5’s catalytic activity are required to 
drive DNA end resection, suggesting that strict temporal regulation of UCH-L5 inhibition 
exists that ensures that the inhibition is alleviated when UCH-L5’s DUB activity is required 
in the pathway5. Besides clarifying these issues, our point mutant can provide a unique 
opportunity to de-couple proteasome and INO80 related functions of UCH-L5 since this 
mutant is predicted to leave proteasome-associated function of UCH-L5 unaffected. In 
general, mutants identified in vitro that can de-couple different functions are instrumental 
for studying the functional relevance of certain steps in a reaction.
In contrast to the UCH-L5/RPN13 complex, the BAP1/ASXL1 DEUBAD complex is active 
on its natural substrate, H2A mono-ubiquitinated at K1196. We show in chapter 4 that this 
is made possible by the BAP1 C-terminal extension (CTE), an element unique to BAP1 and 
absent in UCH-L5. Whereas DUBs often require external factors to recruit substrates, the 
BAP1 CTE is one of the examples where the DUB itself can also recognize the target (nucle-
osome). This target recognition comes on top of the generic ability of DUBs to recognize 
ubiquitin and thereby increases the specificity for the substrate. Substrate specificity is a 
remarkable characteristic of the BAP1/ASXL1 complex as it can only deubiquitinate H2A 
ubiquitinated at K119 and not K13/15, the DNA damage response modification. BAP1 has 
a not fully understood role in DNA repair7, but our analysis rules out that the DEUBAD 
domain of ASXL1 can stimulate deubiquitination of K13/15 by BAP1. In cells other factors 
may exist though, that could confer K13/15 DUB activity to BAP1. How the specificity is 
achieved is unclear, but since the BAP1 CTE is involved in nucleosome binding, it seems 
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plausible that it has a role in determining specificity.
Even though the BAP1/ASXL1 is active on its natural substrate, it is however unclear if 
this activity reflects “holoenzyme” activity or whether additional factors exist that can 
further activate BAP1. This DUB is present in large multi-protein complexes with proteins 
such as, OGT, HCF-1, YY1, ASXL2, FOXK2, UBE2O, MBD5/6, KDM1A/B, where its catalytic 
activity is required to regulate gene expression programs8–12. It is conceivably that in these 
complexes, some of the BAP1 partners can further stimulate its activity in addition to the 
stimulation by ASXL1.
The BAP1/ASXL1DEU and UCH-L5/RPN13DEU complexes share many features, but a major 
significant difference is the stoichiometry of the complex with the DEUBAD domain 
protein. While UCH-L5/RPN13DEU is stoichiometric at 1:1, the BAP1/ASXL1DEU complex 
consists of two BAP1 molecules in complex with one ASXL1DEU molecule. The results 
obtained in chapter 5 suggest that both BAP1 molecules can be activated by ASXL1DEU 
to deubiquitinate H2A. The presence of multiple DUB-like proteins in complexes occurs 
often in the JAMM class of DUBs. These DUBs are heterodimers consisting of an active and 
inactive JAMM DUB where the inactive variant stabilizes the active DUB and functions 
as a scaffold for the binding of additional proteins13–15. Even though the relevance of 
the asymmetric stoichiometry of the BAP1/ASXL1DEU complex is unclear, it is possible 
that one BAP1 variant similarly functions as an assembly platform for other proteins. 
Another possible explanation could be that the binding of one complex would facilitate 
the deubiquitination of both H2A proteins present in one nucleosome simultaneously, 
although it is questionable why this could be beneficial. A major focus in investigating the 
relevance of the BAP1/ASXL1DEU stoichiometry for function would be to identify mutants 
that result in an obligate 1:1 BAP1/ASXL1DEU complex and see how this affects BAP1 
function.
Conserved architecture of DUB complexes
A curious aspect of a series of multi-protein DUB complexes is that they are present in a 
set of slightly different variants that play roles in separate pathways. The first example of 
this are the UCH-DEUBAD domain complexes studied in this thesis. Here, BAP1/ASXL1, 
UCH-L5/RPN13 and UCH-L5/INO80G form a UCH-DEUBAD DUB module that have roles in 
three very different cellular processes4,6,13–15. This situation also occurs in other DUB fami-
lies. In the USP family, USP1 and its most closely related paralogs USP12 and USP46 are all 
activated by proteins containing WD40 type β-propellers. All three DUBs are activated by 
UAF-1, and, USP12 and USP46 are moreover further activated by WDR20, a protein similar 
to UAF116–18. Some DUBs of the JAMM family exist in large architecturally similar molecu-
lar assemblies. BRCC36 is the catalytic subunit of the BRCA1-A and BRISC complexes19,20 
and the DUBs CSN5 and RPN11 are present in the COP9 signalosome and proteasome 
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regulatory particle respectively21,22. Many of the subunits are conserved across these four 
different complexes, suggesting that they share common regulatory themes. Even though 
the presence of multiple homologs is very common in eukaryotes, they often evolve to 
bind very different proteins and perform different functions. 
In this light, the co-evolution of entire sets of molecular architectures, that occurred 
multiple times, for the DUBs discussed above is remarkable. It suggests that these 
molecular architectures exist because they are highly useful for cells and can be easily 
integrated into different pathways. This is further underscored by the elongation initiation 
factor 3 complex (eIF3) that regulates translation. This complex is devoid of DUB activity 
but shares its molecular architecture with the four JAMM complexes mentioned above23.
DUBs regulatory mechanism are diverse
On a very basic biochemical level, DUB regulation can be defined as forces acting on 
actual catalysis (k
cat
 ) or substrate binding (KM or KD). In chapter 2 we illustrate how these 
two regulatory modes manifest themselves in cells. We find that the manner by which 
the k
cat
 and KM of DUBs are regulated are highly individual and diverse, suggesting that 
the regulatory modes are precisely tailored for each DUB. The diversity itself opens up 
avenues for future targeted therapy that is not directed towards active sites of DUBs but 
towards regulatory sites. This may be useful since active sites of DUBs are often highly 
conserved raising concerns regarding the specificity of active site inhibition. Crystal 
structure analysis would aid in the pursuit of therapies targeting regulatory sites, since 
it will reveal the details of the relevant complexes and thus serve as starting points for 
the development of inhibitors of specific protein-protein interactions. Together with the 
potentially powerful structure-based drug design methods, emerging fragment-based 
drug design methods will make all current and future structures invaluable sources of 
information24.
A fundamental question in the DUB field is why so many DUBs are subject to tight 
regulation. A prevailing idea is that DUBs require tight regulation because they are 
relatively unspecific enzymes. This is because they are specialized in recognizing ubiquitin 
and can therefore potentially deubiquitinate the vast numbers of ubiquitinated proteins 
in a cell. Regulation, hence, aims at either providing specificity via recruitment factors 
and/or catalytic activation to DUBs. Stimulation of DUBs with low activity, is necessary 
since these enzymes display very low catalytic efficiencies (in the order of 103 M-1 s-1) 
when studied in isolation on minimal substrates25. Interestingly, this is several orders 
of magnitudes lower than the average catalytic efficiencies (105 M-1 s-1) found for other 
enzymes26 and well below that of diffusion limited enzymes (108-109 M-1 s-1)26. This low 
activity may support a scenario that some DUBs were “actively” kept in a low activity 
state during evolution to protect cells from harmful unspecific deubiquitination. Tight co-
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evolution of regulatory proteins hence evolved to provide sufficient activity modulation 
and specificity to allow deubiquitination of relevant substrates. It would be informative 
to know the catalytic properties of the ancestral DUB from which the “low activity” DUBs 
are derived, as has been done for other protein families27,28. If this ancestral DUB was 
catalytically more proficient than extant DUBs, it would suggest that the extant DUBs 
were evolutionarily downgraded supporting the idea that DUB regulation emerged as a 
consequence of too high activity towards ubiquitin conjugates. Studying these aspects of 
DUB enzymology may result in a general better understanding of ubiquitin biology.
In summary our analyses of the regulation of the UCH class DUBs UCH-L5 and BAP1, 
two essential DUBs that are deregulated in multiple medical conditions, have highlight-
ed remarkable allosteric regulatory modes that are associated with large conformational 
changes. These different conformations reflect the activity states of the DUBs, providing 
opportunities for the development of allosteric therapeutics. This work will provide a 
framework for future structural and cell based studies on these enzymes.
References
1. Sanchez-Pulido, L., Kong, L. & Ponting, C. P. A common ancestry for BAP1 and Uch37 regulators. 
Bioinformatics 28, 1953–6 (2012).
2. Keusekotten, K. et al. OTULIN antagonizes LUBAC signaling by specifically hydrolyzing Met1-linked 
polyubiquitin. Cell 153, 1312–26 (2013).
3. Cohn, M. A. et al. A UAF1-containing multisubunit protein complex regulates the Fanconi anemia pathway. 
Mol. Cell 28, 786–97 (2007).
4. Yao, T. et al. Proteasome recruitment and activation of the Uch37 deubiquitinating enzyme by Adrm1. Nat. 
Cell Biol. 8, 994–1002 (2006).
5. Nishi, R. et al. Systematic characterization of deubiquitylating enzymes for roles in maintaining genome 
integrity. Nat. Cell Biol. (2014). doi:10.1038/ncb3028
6. Scheuermann, J. C. et al. Histone H2A deubiquitinase activity of the Polycomb repressive complex PR-DUB. 
Nature 465, 243–7 (2010).
7. Yu, H. et al. Tumor suppressor and deubiquitinase BAP1 promotes DNA double-strand break repair. Proc. 
Natl. Acad. Sci. U. S. A. 111, 285–90 (2014).
8. Dey, A. et al. Loss of the tumor suppressor BAP1 causes myeloid transformation. Science 337, 1541–6 
(2012).
9. Misaghi, S. et al. Association of C-terminal ubiquitin hydrolase BRCA1-associated protein 1 with cell cycle 
regulator host cell factor 1. Mol. Cell. Biol. 29, 2181–92 (2009).
10. Ji, Z. et al. The forkhead transcription factor FOXK2 acts as a chromatin targeting factor for the BAP1-
containing histone deubiquitinase complex. Nucleic Acids Res. 42, 6232–42 (2014).
11. Baymaz, H. I. et al. MBD5 and MBD6 interact with the human PR-DUB complex through their methyl-CpG-
binding domain. Proteomics 14, 2179–89 (2014).
12. Mashtalir, N. et al. Autodeubiquitination Protects the Tumor Suppressor BAP1 from Cytoplasmic 
Sequestration Mediated by the Atypical Ubiquitin Ligase UBE2O. Mol. Cell 54, 392–406 (2014).
133
General discussion
6
13. Yao, T. et al. Distinct modes of regulation of the Uch37 deubiquitinating enzyme in the proteasome and in 
the Ino80 chromatin-remodeling complex. Mol. Cell 31, 909–17 (2008).
14. Qiu, X.-B. et al. hRpn13/ADRM1/GP110 is a novel proteasome subunit that binds the deubiquitinating 
enzyme, UCH37. EMBO J. 25, 5742–53 (2006).
15. Hamazaki, J. et al. A novel proteasome interacting protein recruits the deubiquitinating enzyme UCH37 to 
26S proteasomes. EMBO J. 25, 4524–36 (2006).
16. Cohn, M. a, Kee, Y., Haas, W., Gygi, S. P. & D’Andrea, A. D. UAF1 is a subunit of multiple deubiquitinating 
enzyme complexes. J. Biol. Chem. 284, 5343–51 (2009).
17. Cohn, M. A. et al. A UAF1-containing multisubunit protein complex regulates the Fanconi anemia pathway. 
Mol. Cell 28, 786–97 (2007).
18. Kee, Y. et al. WDR20 regulates activity of the USP12 x UAF1 deubiquitinating enzyme complex. J. Biol. Chem. 
285, 11252–7 (2010).
19. Cooper, E. M. et al. K63-specific deubiquitination by two JAMM/MPN+ complexes: BRISC-associated Brcc36 
and proteasomal Poh1. EMBO J. 28, 621–31 (2009).
20. Sobhian, B. et al. RAP80 targets BRCA1 to specific ubiquitin structures at DNA damage sites. Science 316, 
1198–1202 (2007).
21. Cope, G. A. et al. Role of Predicted Metalloprotease Motif of Jab1 / Csn5 in Cleavage of Nedd8 from Cul1. 
Science (80-. ). 298, 608–611 (2002).
22. Worden, E. J., Padovani, C. & Martin, A. Structure of the Rpn11-Rpn8 dimer reveals mechanisms of substrate 
deubiquitination during proteasomal degradation. Nat. Struct. Mol. Biol. 21, 220–7 (2014).
23. Enchev, R. I., Schreiber, A., Beuron, F. & Morris, E. P. Structural insights into the COP9 signalosome and its 
common architecture with the 26S proteasome lid and eIF3. Structure 18, 518–27 (2010).
24. Lounnas, V. et al. Current progress in Structure-Based Rational Drug Design marks a new mindset in drug 
discovery. Computational and Structural Biotechnology Journal 5, (2013).
25. Faesen, A. C. et al. The differential modulation of USP activity by internal regulatory domains, interactors 
and eight ubiquitin chain types. Chem. Biol. 18, 1550–61 (2011).
26. Bar-Even, A. et al. The moderately efficient enzyme: Evolutionary and physicochemical trends shaping 
enzyme parameters. Biochemistry 50, 4402–4410 (2011).
27. Thornton, J. W., Need, E. & Crews, D. Resurrecting the ancestral steroid receptor: ancient origin of estrogen 
signaling. Science 301, 1714–1717 (2003).
28. Harms, M. J. & Thornton, J. W. Evolutionary biochemistry: revealing the historical and physical causes of 
protein properties. Nat. Rev. Genet. 14, 559–71 (2013). 

135
&Addendum
Summary 
Samenvatting 
Curriculum Vitae 
PhD portfolio 
List of publications 
Dankwoord
136
&
Summary
The covalent attachment of the small protein ubiquitin to target proteins, ubiquitination, 
is a major type of modification in cells. This modification can have a vast array of outcomes 
that allow cells to tightly control processes. Ubiquitination is reversed by deubiquitinating 
enzymes (DUBs) allowing these enzymes to regulate all processes affected by ubiquiti-
nation. Because of this powerful property, they themselves need to be kept in check by a 
variety of regulatory mechanisms that exist in cells.
In chapter 2 we describe the currently known mechanisms of DUB regulation. These 
mechanisms are diverse and can be exerted from outside the DUB, by external factors or 
post-translational modifications, or from within DUBs by domains specialized in recruit-
ing targets or activating the catalysis. The different types of regulation do not stand on 
their own though, but instead cooperate. This is exemplified by the fact that many DUBs 
are subject to multiple types of regulation simultaneously.
A particular type of DUBs that are regulated are ubiquitin C-terminal hydrolases (UCH) 
family. These enzymes are all characterized by an catalytic UCH domain responsible for 
the catalytic activity. The family members UCH-L5 and BAP1 also contain an additional 
ULD domain at their C-termini that is thought to be important for their regulation. For 
both proteins, the regulation is thought to be performed by proteins containing DEUBiq-
uitinase ADaptor (DEUBAD) domains. BAP1 and UCH-L5 play important roles in basic 
cellular processes such as DNA repair and gene regulation and are mutated in several 
cancers. 
UCH-L5 presents a remarkable case of DUB regulation since it can be activated by the 
DEUBAD domain of RPN13 but inhibited by the DEUBAD domain of INO80G. In chapter 
3 we show how this regulation works. Using crystal structure and functional analyses 
we demonstrate that RPN13 activates UCH-L5 by increasing the affinity for substrates 
through correct positioning of the ULD domain and active site cross over loop. Converse-
ly, INO80G inhibits UCH-L5 by dramatically decreasing the affinity for substrates and 
achieves this by blocking the ubiquitin binding site via large conformational changes.
In chapter 4 we investigate the mechanism of H2A deubiquitination by the BAP1/ASXL1 
complex, a complex homologous to the UCH-L5/RPN13 complex. We show that the BAP1/
ASXL1 complex specifically deubiquitinates the Polycomb site (K119) and is inactive on 
the DNA damage site (K13/15). Like RPN13, the DEUBAD domain of ASXL1 activates 
BAP1 H2A deubiquitination by increasing the affinity for the ubiquitinated substrate. Ac-
tivation of BAP1 by the DEUBAD domain of ASXL1 is however not the only requirement 
to deubiquitinate nucleosomal H2A. This also requires the C-terminal extension of BAP1 
that binds to nucleosomes. 
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An interesting feature of the BAP1/ASXL1 complex is that it is an asymmetric complex 
consisting of two molecules of BAP1 and one molecule of ASXL1. Moreover BAP1 itself 
forms homo-oligomers. In chapter 5 we characterize the oligomeric state of BAP1 and the 
BAP1/ASXL1DEU complex and examine the consequence of different oligomerization states 
on the enzymatic activity. We find that the C-terminal two helices of BAP1 promote higher 
order oligomerization and that ASXL1DEU prevents this by promoting a 2:1 BAP1/ASXL1DEU 
complex. We further show that in this complex both BAP1 molecule can be activated to 
deubiquitinate H2A despite the presence of only one ASXL1DEU molecule.
We end with a general discussion presented in chapter 6 where we place our findings in 
a broader context.
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Samenvatting
De covalente modificatie van eiwitten met het kleine eiwit ubiquitine, genaamd ubiqui-
tinering, is één van de meest voorkomende types modificaties in cellen. Ubiquitinering 
heeft een breed scala aan gevolgen en wordt door cellen gebruikt om processen te regu-
leren. Ubiquitinering wordt ongedaan gemaakt door de-ubiquitineringsenzymen (DUB’s). 
Hierdoor zijn deze enzymen in staat om alle processen die betrokken zijn bij ubiquitine-
ring te reguleren. Vanwege deze belangrijke functie, worden DUB’s zelf ook streng gecon-
troleerd door talloze regulatiemechanismen die in cellen voorkomen.
In hoofdstuk 2 beschrijven we de huidig bekende mechanismen van DUB-regulatie. 
Deze mechanismen zijn divers en kunnen uitgeoefend worden op DUB’s van buiten het 
enzym door post-translationele modificatie, of vanuit het enzym zelf door bijvoorbeeld 
domeinen die gespecialiseerd zijn in het rekruteren van substraten, of door domeinen die 
katalyse direct kunnen stimuleren. De verschillende typen regulaties werken echter niet 
afzonderlijk van elkaar, maar kunnen samenwerken. Dit principe komt tot uiting door het 
feit dat veel DUB’s gelijktijdig onderhevig zijn aan meerdere regulatietypes
Een bepaalde familie van DUB’s die gereguleerd wordt is de ubiquitine C-terminale hy-
drolase familie. De aanwezigheid van een UCH-domein die verantwoordelijk is voor de 
katalytische activiteit karakteriseert deze enzymen, Familieleden UCH-L5 en BAP1 bevat-
ten daarnaast ook nog een ULD-domein aan hun C-termini die als belangrijk wordt geacht 
voor hun regulering. Van beide enzymen wordt vermoed dat ze worden gereguleerd door 
eiwitten die DEUBiquitinase ADaptor (DEUBAD) domeinen bevatten. BAP1 en UCH-L5 
zijn vaak gemuteerd in kanker en hebben belangrijke rollen in basale cellulaire processen 
zoals het herstellen van DNA-schade en genregulatie.
UCH-L5 is een speciaal geval van DUB-regulatie omdat het zowel geactiveerd kan worden, 
door het DEUBAD-domein van RPN13, als geremd kan worden, door het DEUBAD-domein 
van INO80G. In hoofdstuk 3 laten we zien hoe deze regulering werkt. Met behulp van 
kristalstructuur en functionele analyses tonen we aan dat RPN13 UCH-L5 enerzijds acti-
veert door de substraataffiniteit te verhogen via het correct positioneren van het ULD-do-
mein en de active-site cross-over loop. INO80G remt UCH-L5 anderzijds, door de affiniteit 
voor substraten drastisch te verlagen en bereikt dit door het blokkeren van ubiquitine 
binding via grote, conformatie veranderingen.
In hoofdstuk 4 onderzoeken we het mechanisme van H2A de-ubiquitinering door het 
BAP1/ASXL1-complex, een complex dat homoloog is aan het UCH-L5/RPN13-complex. 
We tonen aan dat het BAP1/ASXL1-complex specifiek de Polycomblocatie de-ubiquiti-
neert (K119), en niet actief is op de DNA-schadelocatie (K13/15). Het DEUBAD-domein 
van ASXL1 activeert BAP1, net zoals bij RPN13, door de affiniteit voor substraten te ver-
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hogen. Activatie van BAP1 door het DEUBAD-domein van ASXL1 is echter niet de enige 
voorwaarde om nucleosomaal H2A te de-ubiquitineren. Hiervoor is ook de C-terminale 
extensie van BAP1 nodig die nucleosoombinding mogelijk maakt.
Een interessante eigenschap van het BAP1/ASXL1-complex is dat het een asymmetrisch 
complex is bestaande uit twee BAP1-moleculen en één ASXL1-molecuul. BAP1 is boven-
dien zelf ook in staat om homo-oligomeren te vormen. In hoofdstuk 5 karakteriseren we 
de oligomerische toestand van BAP1 en het BAP1/ASXL1-complex, en onderzoeken we 
de mogelijke gevolgen van de oligomerische toestand voor de enzymatische activiteit. We 
laten zien dat BAP1-oligomerisering wordt veroorzaakt door de twee C-terminale helixen 
van BAP1, en dat ASXL1 de neiging tot oligomerisering tegengaat door een 2:1 verhouding 
BAP1/ASXL1- complex te vormen. We laten verder zien dat in dat complex beide BAP 
moleculen geactiveerd kunnen worden om H2A te de-ubiquitineren ondanks de aanwe-
zigheid van slechts één ASXL1-molecuul.
We sluiten af met een algemene discussie in hoofdstuk 6, waar we onze bevindingen in 
een bredere context plaatsen.
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